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Background:   Over 200 million individuals worldwide are chronically exposed to arsenic (As) 
in drinking water at concentrations above the World Health Organization (WHO) guideline of 10 
µg/L.   Arsenic exposure is of particular concern in Bangladesh, where it is estimated that 35-77 
million people are exposed to As in well water at concentrations above the WHO guideline.  
Chronic As exposure is associated with neurological impairments, respiratory disease, 
cardiovascular disease, skin lesions, and cancers of the skin, liver, lung and bladder.  The 
mechanisms of As toxicity in humans are not well-characterized: there are considerable 
interspecies differences in As toxicokinetics, and until recently, there were no animal models to 
study As carcinogenesis.  However, two of several proposed pathways of As toxicity in humans 
involve DNA methylation and oxidative stress.  Arsenic metabolism, DNA methylation, and 
glutathione (GSH) are metabolically connected through the one-carbon metabolism and 
transsulfuration pathways, and their interactions are remarkably complex.  The epidemiologic 
studies in this dissertation are designed to address the overarching hypothesis that one-carbon 
metabolism and the transsulfuration pathway interact to influence susceptibility to As toxicity.  
Introduction:  Arsenic is methylated in the liver to monomethyl (MMA) and dimethyl (DMA) 
arsenical species by arsenic(III)-methyltransferase (AS3MT), which requires a methyl group 
from S-adenosylmethionine (SAM) and the presence of a reductant, such as glutathione (GSH).  
SAM is the universal methyl donor for transmethylation reactions, including DNA methylation, 
 
and is a product of folate-dependent one-carbon metabolism. GSH is the primary endogenous 
antioxidant and determinant of the intracellular redox state, and the rate-limiting precursor for 
GSH synthesis, cysteine (Cys), is a product of the transsulfuration pathway.  One-carbon 
metabolism and the transsulfuration pathway are connected through homocysteine (Hcys).  In 
humans, aberrant DNA methylation, oxidative stress, hyperhomocysteinemia (HHcys), and 
impaired As methylation capacity have been identified as risk factors for As-related conditions, 
including As-induced skin lesions.  However, there are knowledge gaps regarding the 
relationships among these risk factors in humans, namely (1) the dose-response relationship 
between chronic As exposure and global DNA methylation over a wide range of As 
concentrations, as well as the influence of As exposure on the newly-discovered epigenetic 
modification, 5-hydroxymethylcytosine (5hmC); (2) whether an oxidized GSH redox state 
impairs the capacity to methylate As and DNA; and (3) whether variants in one-carbon 
metabolism genes are associated with HHcys and susceptibility to As-induced skin lesions. 
Methods:   We addressed these questions in five self-contained epidemiological studies of As-
exposed Bangladeshi adults, which employed cross-sectional (Chapters 3-6) and nested case-
control (Chapter 7) designs.  First, we examined the dose-response relationship between As 
exposure and global methylation of peripheral blood mononuclear cell (PBMC) DNA (Chapter 
3).  Second, we optimized a high-throughput liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) assay to measure global 5-methylcytosine (5mC) and 5hmC content in human 
DNA samples, and we examined the associations of As exposure with global %mC and %hmC 
in two independent samples of As-exposed adults (Chapter 4).  Third, we measured GSH and its 
“oxidized” form, glutathione disulfide (GSSG) in plasma, and we examined the interaction of 
plasma GSH redox state and folate nutritional status on As methylation capacity (Chapter 5).  
 
Fourth, we examined the relationships between blood GSH redox, blood SAM, and global 
methylation of PBMC DNA (Chapter 6).  Fifth, we conducted a nested case-control study 
(Chapter 7) to determine whether nonsynonymous single nucleotide polymorphisms (SNPs) in 
methylene-tetrahydrofolate reductase (MTHFR) and other one-carbon metabolism genes were 
associated with HHcys and risk for As-induced precancerous skin lesions, and we conducted an 
exploratory genome-wide association study (GWAS) of Hcys in a subset of participants. 
Results:  Chronic As exposure was associated with increased global DNA methylation over a 
wide range of well water As concentrations (Chapter 3), but the relationship between As 
exposure and global %hmC was gender-specific, with a positive association in males and 
negative association in females (Chapter 4).  We found that an oxidized GSH redox state was 
associated with both decreased As methylation capacity (Chapter 5) and global DNA 
hypomethylation (Chapter 6).  Finally, in the nested-case control study, we confirmed previous 
findings that serum HHcys was a risk factor for As-induced skin lesions, and gene variants in 
MTHFR were found to explain a substantial proportion of the variance in serum Hcys 
concentrations (Chapter 7).  However, we did not find that one-carbon metabolism gene variants 
were risk factors for As-induced skin lesions.  The GWAS of serum Hcys identified one genome-
wide significant SNP in the pregnane X receptor (PXR) gene, along with other SNPs in genes 
involved in cell signaling and the establishment of epithelial cell polarity. 
 Taken together, our findings suggest that indices of one-carbon metabolism and the 
transsulfuration pathway—DNA methylation, GSH redox, and As methylation—interact with 
one another to influence susceptibility to As toxicity in humans.  In addition, to our knowledge, 
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Chapter 1:  Statement of hypotheses 
In Bangladesh, over 35 million people are chronically exposed to As in drinking water 
above the World Health Organization (WHO) guideline of 10 µg/L, which has been described as 
“the largest mass poisoning of a population in history.”  Chronic As exposure is associated with 
respiratory and cardiovascular diseases, neurological impairments, and cancers of the skin, liver, 
lung and bladder.  Although the mechanisms of As toxicity in humans are not well-characterized, 
two proposed pathways involve DNA methylation and oxidative stress.  Arsenic metabolism, 
DNA methylation, and glutathione (GSH) are metabolically connected through one-carbon 
metabolism and the transsulfuration pathway (Figure 1).  This dissertation is an epidemiologic 
investigation of the metabolic interplay between As metabolism, GSH, and DNA methylation to 
address the overarching hypothesis that one-carbon metabolism and the transsulfuration pathway 
interact to influence susceptibility to As toxicity in humans. 
 
Figure 1.  One-carbon metabolism and the transsulfuration pathway: metabolic 
interactions of arsenic metabolism, DNA methylation, and glutathione. 
2 
 
Hypothesis 1.   
We hypothesize that chronic As exposure is associated with alterations of global DNA 
methylation and hydroxymethylation. 
Specific Aim 1A: Arsenic exposure and global DNA methylation  
We will explore the dose-response relationship between As exposure and global 
methylation of peripheral blood mononuclear cell (PBMC) DNA, measured using the [
3
H]-
methyl incorporation assay, in the Folate and Oxidative Stress (FOX) study, a cross-sectional 
study of 378 Bangladeshi adults who were exposed to a wide range of As in well water.  
Additionally, we will examine whether there is evidence of a non-linear relationship. 
Specific Aim 1B: Arsenic exposure and global 5-hydroxymethylcytosine 
We will optimize a high-throughput liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) assay to measure global percent 5-methylcytosine (%5mC) and 5-
hydroxymethylcytosine (%5hmC) in human DNA samples.  We will then examine the cross-
sectional associations between As exposure and global %mC and %hmC in peripheral blood cell 
DNA in two independent samples of As-exposed Bangladeshi adults.  
 
Hypothesis 2.   
We hypothesize that an oxidized intracellular GSH redox state is associated with a 
reduced capacity to methylate DNA and As. 
Specific Aim 2A: Plasma GSH redox status, As methylation capacity, and folate 
We will examine the associations between plasma GSH redox status and urinary As 
metabolites (urinary %MMA and %DMA) in the FOX study, and test whether these associations 
are modified by plasma folate nutritional status. 
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Specific Aim 2B: Blood GSH redox status and global DNA methylation 
We will examine the association between whole blood glutathione (GSH) redox status 
and [
3
H]-methyl incorporation of PBMC DNA in the FOX study, and additionally, we will assess 
whether blood S-adenosylmethionine (SAM) is a mediator of this association. 
 
Hypothesis 3. 
 We predict that aberrant regulation of one-carbon metabolism contributes to increased 
susceptibility to As-induced skin lesions.   Specifically, we predict that nonsynonymous variants 
in one-carbon metabolism genes, specifically variants that are known to influence enzymatic 
activities, and elevated serum homocysteine (Hcys) are risk factors for As-induced skin lesion 
incidence.    
Specific Aim 3: One-carbon metabolism genes, serum Hcys, and As-induced skin lesions 
 We will conduct a nested case-control study within the Health Effects of Arsenic 
Longitudinal Study (HEALS) cohort of 876 incident skin lesions and matched controls, and we 
will measure single nucleotide polymorphisms (SNPs) in genes involved in one-carbon 
metabolism—with a focus on nonsynonymous SNPs in methylenetetrahydrofolate reductase 
(MTHFR)—and homocysteine (Hcys) concentrations in serum samples.  We will examine 
whether SNP genotypes are associated with serum Hcys concentrations separately in the case 
and control groups, and we will use conditional logistic regression to examine the associations 
between SNPs and risk of As-induced skin lesions.  In an exploratory analysis, we will conduct a 
genome-wide association study (GWAS) of serum Hcys in a subset of participants. 
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Chapter 2:  Background 
 
A.  One-carbon metabolism and the transsulfuration pathway. 
 
1.  One-carbon metabolism. 
 
Figure 1.  Mammalian one-carbon metabolism. 
 
a.  Overview of biochemistry. 
One-carbon metabolism is a folate- and cobalamin-dependent pathway involved in two 
major biologic processes: (1) the synthesis of thymidines and purine bases for DNA replication, 
synthesis, and repair; and (2) the generation of methyl groups for transmethylation reactions. The 
functions and biochemistry of mammalian one-carbon metabolism are outlined in several 
excellent review articles (Fox and Stover 2008; Tibbetts and Appling 2010).  The major 
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components of the pathway are shown in Figure 1.  Briefly, folate, in the forms of naturally-
occurring 5-methyltetrahydrofolate (5mTHF) and as folic acid (FA), is transported into the cell 
via a receptor-mediated (folate receptor alpha [FRα], beta [FRβ], or gamma [FRγ]) or carrier-
mediated (solute carrier family 19, member 1 [SLC19A1], also known as RFC1) transport 
mechanisms; FA is subsequently reduced to dihydrofolate (DHF) and tetrahydrofolate (THF).  
THF enters the one-carbon metabolic pathway and picks up a methyl group from serine, forming 
5,10-methylenetetrahydrofolate (5,10 methylene-THF).  5,10 methylene-THF can be used for 
synthesis of nucleotide bases (de novo thymidine synthesis) or reduced to 5mTHF via the 
enzyme methylenetetrahydrofolate reductase (MTHFR).  5mTHF derived from the metabolism 
of FA and that originating from naturally-occurring food folates are chemically 
indistinguishable.  The methyl group of 5mTHF is transferred to homocysteine (Hcys) via 
methionine synthetase (MTR), generating methionine (Met) and THF.  Met is activated by ATP 
to form S-adenosylmethionine (SAM), the universal methyl donor for transmethylation reactions.  
The donation of the methyl group yields the methylated product and S-adenosylhomocysteine 
(SAH), which is hydrolyzed by S-adenosylhomocysteine hydrolase (SAHH) to generate Hcys. 
 
b.  Folate and cobalamin. 
Folates.  Folates (Vitamin B9, pteroyl-L-glutamates) comprise a family of cofactors required for 
the transfer of methyl groups in one-carbon metabolism.  Naturally-occuring folates (generally 
the polyglutamated forms of 5mTHF and 5-formylTHF) are found in a variety of food sources, 
with high amounts found in beef liver, spinach, and green vegetables (USDA 2012).  Folic acid 
(pteroylmonoglutamic acid), a synthetic form of folate, does not occur in nature but is used for 
supplementation and food fortification (Wright et al. 2007).  Based on World Health 
6 
 
Organization (WHO) guidelines, the normal range of serum folate concentrations in humans is 
between 13.5 and 45.3 nmol/L, with marginal folate deficiency classified as concentrations 
between 6.8 to 13.4 nmol/L, and severe deficiency at concentrations <6.8 nmol/L (WHO 2012). 
 
Folate absorption and transport.  In the intestinal wall, dietary polyglutamates are deconjugated 
to their monoglutamate forms through the cleavage of their polyglutamate tails by 
folylpolyglutamate carboxypeptidase (Chandler et al. 1986).  Folic acid and reduced 
monoglutamyl folates are transported into enterocytes through a proton-coupled folate transport 
mechanism (SLC46A1, also known as PCFT), which has equal binding affinity for folic acid and 
reduced folates (Qiu et al. 2006).  Folate enters the hepatic portal vein and is transported to the 
liver, the primary site of one-carbon metabolism activity, folate storage (Rogers et al. 1997), and 
conversion of folic acid to reduced folates by dihydrofolate reductase (DHFR) (Wright et al. 
2007).  A portion of the folate pool is excreted in “first pass” hepatic metabolism, where folic 
acid is removed at a higher rate than other folates (Steinberg et al. 1979).  
Folate, predominately in the form of 5mTHF, can proceed into systemic circulation and 
taken into tissues through two mechanisms: (1) a bidirectional carrier-mediated system (RFC1), 
which has higher binding affinity for reduced folates compared to folic acid and is ubiquitously 
expressed in normal human tissues (Whetstine et al. 2002), or (2) a unidirectional receptor-
mediated system (FR), which has similar binding affinity for folic acid and reduced folates 
(Antony 1996).  The major FR isoforms in adult humans are FRα and FRβ:  FRα is expressed on 
the apical surface of polarized epithelial cells (Basal et al. 2009), whereas FRβ is primarily found 
on myeloid hematopoietic cells (Reddy et al. 1999).  Once folate enters the cell, 
folylpolyglutamate synthase (FPGS) converts monoglutamyl folates to polyglutamates forms, 
7 
 
which have longer intracellular retention than monoglutamates (McGuire et al. 1980).  The 
glutamate moiety can be removed by gamma-glutamyl hydrolase (GGH) to regulate the 
intracellular folate pool (Rhee et al. 1998).  Folate is exported from cells via ATP‐dependent 
efflux transporters called multidrug resistance proteins (MRP1-5) (Ifergan and Assaraf 2008).   
Cobalamin.   Cobalamin (Vitamin B12) is the cofactor for MTR, which catalyzes the regeneration 
of Met from Hcys (Banerjee and Matthews 1990).  The only naturally-occurring sources of 
Vitamin B12 (primarily in the forms of methylcobalamin, deoxyadenosylcobalamin and 
hydroxycobalamin) are in animal products, including clams, liver, various types of fish, beef, and 
dairy products; vegetarians and vegans must rely on supplementation or fortified foods, such as 
breakfast cereals, to meet their required intakes (USDA 2012).  In the circulation, cobalamin is 
bound to one of two carrier proteins, transcobalamin (TC) or haptocorrin (HC).  Approximately 
20% of total plasma cobalamin is bound to TC, which is normally 10% saturated with cobalamin 
(Obeid et al. 2006), while the majority of plasma cobalamin is bound to HC, a glycoprotein 
which is nearly 100% saturated with cobalamin, and whose biologic function is unclear 
(Seetharam and Li 2000).  Only cobalamin complexed to TC, known as holotranscobalamin 
(holoTC), can be transported into cells through a receptor-mediated endocytosis process 
mediated by the transcobalamin receptor (TCblR) (Quadros and Sequeira 2013).   
 
c.  Key functions of one-carbon metabolism.  
Synthesis of nucleotides.  Folate is involved in the de novo synthesis of purine and pyrimidine 
bases for DNA synthesis and repair.  Thymidine is synthesized through the methylation of 
deoxyuridine monophosphate (dUMP) by thymidylate synthase (TYMS), using 5,10 methylene-
THF as the methyl donor, yielding deoxythymidine monophosphate (dTMP) and DHF  (Longley 
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et al. 2003).  The synthesis of purine bases requires 10-formylTHF, which is produced from 5,10 
methylene-THF by methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) (Christensen et al. 
2013).  Due to the essential role of folate in DNA synthesis, folate deficiency impairs cell cycle 
progression (James et al. 1993) and increases uracil misincorporation (Blount et al. 1997; Duthie 
et al. 2000), leading to DNA strand breaks (Reidy 1988) and genomic instability (Melnyk et al. 
1999).  Folate for DNA synthesis is especially important during periods of rapid growth and 
development, such as the prenatal period (Antony 2007). 
Remethylation of Hcys.  The methylation of Hcys to Met can occur through the enzymatic 
transfer of a methyl group from one of two methyl donors: (1) 5mTHF via MTR, the primary 
route or (2) betaine via betaine-homocysteine S-methyltransferase (BHMT), an alternative route 
active during folate-deficient conditions (Reed et al. 2006).  MTHFR catalyzes the rate-limiting 
step in the synthesis of 5mTHF (irreversible reduction of 5,10 methylene-THF to 5mTHF), and 
its enzymatic activity is thus a major determinant of Hcys concentrations in humans (Ueland et 
al. 2001).  MTHFR activity is dependent upon riboflavin (vitamin B2), the precursor to the 
MTHFR cofactor flavin adenine dinucleotide (FAD) (Bates and Fuller 1986; Hustad et al. 2000; 
McNulty et al. 2002).  
The MTR-catalyzed methylation of Hcys to Met involves a two-step reaction, with 
cobalamin bound to MTR.  First, a methyl group is transferred from 5mTHF to cob(I)alamin, 
yielding methyl(III)cobalamin and THF; then, the methyl group from methyl(III)cobalamin is 
transferred to Hcys, yielding cob(I)alamin and Met (Matthews et al. 1998).  Occasionally, 
cob(I)alamin is oxidized to cob(II)alamin, rendering MTR inactive (Drummond et al. 1993).  
MTR activity can be restored through the regeneration of methyl(III)cobalamin, which occurs 
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via the reductive methylation of cob(II)alamin by the enzyme methionine synthase reductase 
(MTRR) and SAM (Wolthers and Scrutton 2007). 
 Deficiencies in folate and cobalamin result in elevated concentrations of Hcys, a 
condition known as hyperhomocysteinemia (HHcys) (Klee 2000).  Moderate HHcys is a well-
established risk factor for cardiovascular disease (Wald et al. 2002), cancer (Wu and Wu 2002), 
and neurodegeneration (Herrmann and Obeid 2011).  Hcys concentrations are sensitive to folate 
status and can be reduced with folic acid supplementation (Vermeulen et al. 2000).  However, 
under conditions of severe cobalamin deficiency, MTR cannot metabolize 5mTHF for Hcys 
methylation, resulting in a buildup of 5mTHF in a “methyl trap” (Scott and Weir 1981).   
Synthesis of S-adenosylmethionine.  SAM, the universal methyl donor for transmethylation 
reactions, is formed from the ATP-dependent activation of Met by a family of methionine 
adenosyltransferases (MATs); MAT1 is expressed in liver, while MAT2 is expressed in 
extrahepatic tissues (Roje 2006).  Although numerous enzymes use SAM, including DNA 
methyltransferases (DNMTs) and arsenic(III)-methyltransferase (AS3MT), two enzymes—
guanidinoacetate methyltransferase (GAMT) and phosphatidylethanolamine N-methyltransferase 
(PEMT)—consume over 70% of SAM-derived methyl groups (Williams and Schalinske 2007).  
GAMT regulates creatine synthesis from guanidinoacetate, and PEMT catalyzes the transfer of 
three SAM-derived methyl groups to phosphatidylethanolamine for the synthesis of the 
phospholipid phosphatidylcholine (PC), an important component of cell membranes (Williams 
and Schalinske 2007).  Upon donation of its methyl group, SAM is converted to SAH, a potent 
inhibitor of most methylation reactions (Chen et al. 2010).  SAH can be reversibly hydrolyzed to 
Hcys by SAH hydrolase (SAHH) in a reaction that favors SAH synthesis over Hcys synthesis 
(James et al. 2002).  Two long-range interactions—feedback inhibition of MTHFR by SAM and 
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GNMT by 5mTHF—ensure that intracellular SAM concentrations remain within a tight range 
(Reed et al. 2006).  SAM is also an allosteric activator of cystathionine-β-synthase (CBS), an 
enzyme catalyzing the conversion of Hcys to Cys in the first step of the transsulfuration pathway 
(Prudova et al. 2006).   
 
2.  The transsulfuration pathway. 
 
a.  Overview of biochemistry. 
 
Figure 2.  The transsulfuration pathway and glutathione synthesis in mammalian cells. 
 
The transsulfuration pathway involves the conversion of homocysteine (Hcys) to cysteine 
(Cys), the rate-limiting precursor for the synthesis of the primary endogenous antioxidant 
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glutathione (GSH) (reviewed in McBean 2012; Wu et al. 2004).  As shown in Figure 2, Hcys can 
be directed through the transsulfuration pathway via the vitamin B6-dependent enzyme CBS to 
form cystathionine, which is cleaved to Cys and α-ketobutyrate by cystathionine gamma-lyase 
(CSE).  Glutamate cysteine ligase (GCL) catalyzes the ATP-dependent condensation of Cys and 
glutamate (Glu) to form γ-glutamylcysteine (Glu-Cys).  Glycine (Gly) is then added to Glu-Cys 
by a condensation reaction catalyzed by glutathione synthase (GS), resulting in the formation of 
GSH.  Intracellular GSH can be used in antioxidant conjugation reactions, or can be exported out 
of the cell and catabolized via the cell membrane enzyme γ-glutamyltransferase (GGT).  GGT 
transfers the γ-glutamyl group to an amino acid, producing cysteinylglycine (Cys-Gly), which 
can be broken down to Cys and Gly via dipeptidase.   Cys is unstable extracellularly and rapidly 
oxidizes to cystine (CySS).  The xC
−
 antiporter can import CySS using a transmembrane Glu 
gradient, and the b
0+
 system can directly import CySS, which can be converted back to Cys to 
maintain the intracellular Cys pool.   
 
b.  Glutathione. 
Glutathione synthesis.  GSH, a low-molecular weight tripeptide thiol comprised of the amino 
acids Cys, Glu, and Gly, is the primary mammalian intracellular antioxidant, with concentrations 
between 0.5–10 mmol/L in cells (Dringen 2000; Wu et al. 2004).   Plasma GSH concentrations 
are markedly lower, with estimated concentrations between 2–20 μmol/L (Wu et al. 2004), and is 
believed to originate mainly from hepatic GSH synthesis (Griffith 1999).  The antioxidant 
activity of GSH results from the reducing activity of the thiol group of its Cys moiety (Dringen 
2000), and GSH depletion is a primary indicator of oxidative stress (Mytilineou et al. 2002). 
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Although the rate-limiting precursor in GSH synthesis—the semi-essential amino acid Cys—can 
be obtained from dietary sources, most of the Cys used for GSH production is derived from 
endogenous synthesis from Met via the transsulfuration pathway (Wu et al. 2004).  However, a 
functional transsulfuration pathway is not found in all tissues:  intact pathways are found in liver, 
kidney, small intestine and pancreas tissues (Finkelstein 1990) and were recently identified in 
brain (Vitvitsky et al. 2006) and T cells (Garg et al. 2011).  Under conditions of oxidative stress, 
Hcys flux through the transsulfuration pathway is enhanced 2-3 fold times its normal rate to 
increase Cys availability for GSH synthesis (Mosharov et al. 2000); this occurs through the 
upregulation of CBS, which contains a redox-sensitive heme domain (Taoka et al. 1998; Taoka 
et al. 2002).  In tissues lacking active transsulfuration pathways, CySS is imported into cells 
through membrane transport mechanisms and converted to Cys, as described in (a).  In addition 
to its role as an antioxidant, GSH also serves as a reservoir and transport mechanism for Cys 








B.  Biologic processes associated with one-carbon metabolism and transsulfuration. 
 
1.  DNA methylation. 
The term “epigenetics” refers to the study of modifications that influence gene expression 
without altering the underlying DNA sequence.  The most widely studied epigenetic 
modification is DNA methylation, a process involving the covalent addition of a methyl group to 
the 5’-position of cytosines to form 5-methylcytosine (5mC) (Smith and Meissner 2013).  5mC is 
generally found in the context of CpG dinucleotides, but non-CpG 5mC has been detected in low 
quantities in mammalian genomes (Ramsahoye et al. 2000; Ziller et al. 2011).  In mammals, 
methylation reactions are catalyzed by three conserved enzymes known as DNA 
methyltransferases (DNMT1, DNMT3A, and DNMT3B), and the methyl groups are donated 
from SAM, a product of one-carbon metabolism (Figure 3) (Smith and Meissner 2013).  Proper 
maintenance of genomic 5mC distribution is essential for normal mammalian development 
(Razin and Shemer 1995). 
 
 




a.  CpG methyltransferases. 
Dnmt1.  Riggs (1975) and Holliday and Pugh (1975) first proposed that DNA methylation is a 
heritable mechanism of gene regulation, but it was not until 1988 that Bestor and colleagues 
(Bestor 1988) cloned the first mammalian DNA methyltransferase enzyme, Dnmt1.  The Dnmt1 
enzyme preferentially methylates hemimethylated CpGs and is essential for the maintenance of 
DNA methylation patterns during DNA replication throughout S-phase (Leonhardt et al. 1992).  
The Dnmt1 protein is composed of two domains, the N-terminal regulatory domain and the C-
terminal catalytic domain, which are connected through a glycine-lysine (GlyLys)6 repeat 
(Margot et al. 2003) (Figure 4).  The N-terminus contains sequences that regulate interactions of 
DNMT1 with other proteins, including a zinc finger Cys-X-X-Cys (CXXC) domain that 
recognizes unmethylated CpG sites (Lee et al. 2001), while the C-terminus contains conserved 
amino acid methyltransferases motifs (e.g., I, IV and X), the catalytic center, and coenzyme 
binding site (Margot et al. 2003).  Dnmt1 is recruited by ubiquitin-like, containing PHD and 
RING finger domains, 1 (UHRF1), a protein that specifically binds hemimethylated CpGs (Arita 
et al. 2008).  
Dnmt3s.   In 1996, Lei et al. (1996) discovered that de novo CpG methylation occurred in 
Dnmt1-null mouse embryonic stem (ES) cells, suggesting the presence of other independently-
encoded Dnmt enzymes.  Two years later, colleagues from the same group cloned the de novo 
methyltransferases Dnmt3a and Dnmt3b and found that these enzymes catalyzed the methylation 
of unmethylated- and hemimethylated-CpG sites at equal rates (Okano et al. 1998).  The Dnmt3 
family contains the same conserved amino acid motifs at their C-termini as in Dnmt1, but the N-
termini of Dnmt1 and Dnmt3s do not share sequence similarity (Chen and Li 2004; Okano et al. 
1998) (Figure 4).  Their N-termini contain a Cys-rich domain and a PWWP domain; the latter 
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binds DNA in Dnmt3b (Qiu et al. 2002), but not in Dmnt3a (Chen et al. 2004), and is involved in 
directing the Dnmt3s to pericentric heterochromatin (Chen et al. 2004). 
 
Figure 4.  Organization of Dnmt1 and Dnmt3 family. (adapted from Margot et al. 2003) 
 
b.  Chromatin structure and gene expression. 
Histones and the nucleosome.  In eukaryotes, DNA is packed around eight histone core proteins 
(H2A, H2B, H3 and H4; two H2A-H2B dimers and one H3-H4 tetramer) in structural units 
called nucleosomes (Bartova et al. 2008).  DNA segments of 20-60 base pairs, known as “linker 
DNA,” connect the nucleosomes, and histone H1 “sits” on top of the DNA-core histone complex 
to stabilize the nucleosome and bind the linker DNA (Bartova et al. 2008) (Figure 5).  The core 
histones contain amino acid “tails” at their N-terminal domains that are subject to post-
translational epigenetic modifications such as acetylation (Ac), methylation (Me), and 




Figure 5.  Chromatin structure, DNA methylation, and histone tail modifications.  (A) Nucleosome structure.  (B) Chromatin 
structure.  Heterochromatin is associated with transcriptional silencing and is characterized by increased 5mC and decreased histone 







DNA methylation, chromatin structure, and gene expression.   Chromatin exists in two broad 
structural states that are associated with gene transcription: “euchromatin” refers to a relaxed, 
open structure that is associated with gene expression, while “heterochromatin” refers to a 
densely-packed structure linked to gene repression (Dillon 2004).  Heterochromatin can further 
be classified into constitutive and facultative heterochromatin, depending upon the reversibility 
of the state (Dillon 2004).   Constitutive heterochromatin is stable and associated with repetitive 
sequences, including telomeres and the transposable element sequences long interspersed 
element-1 (LINE-1) and Alu.  Conversely, facultative heterochromatin is reversible and 
generally localized to gene promoter regions, and the heterochromatic state is maintained by 
transcriptional repressors and epigenetic modifications associated with repression.   
DNA methylation is associated with gene repression through complex interactions with 
repressive proteins and histone modifications (Cedar and Bergman 2009).  CpG methylation is 
believed to block transcriptional machinery from accessing DNA (Curradi et al. 2002) and/or 
recruit methyl binding proteins (MBPs) that initiate chromatin remodeling (Klose and Bird 
2006).  Across the human genome, approximately 70% of all CpGs are methylated (Bird 1986), 
and the frequency of CpG dinucleotides is 25% lower than the expected frequency based upon 
GC content (Bird 1980).   CpG sites are more frequently found in exons, intronic regions, and 
gene promoters, with a particularly high enrichment of CpG sites around transcription start sites 
(TSS) (Saxonov et al. 2006).  These CpGs clusters, known as “CpG islands,” are around 1,000 
bp long and are less methylated than CpG sites in other regions (~3% in gene promoters) 
(Deaton and Bird 2011).  Although increased promoter CpG methylation is associated with gene 
repression, several in vitro studies have found that CpG methylation increases only after the 
initiation of gene silencing and the recruitment of other epigenetic silencing marks (including 
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H3K27me3), suggesting that enhanced CpG methylation may be a consequence, and not an 
initiator, of gene silencing (Deaton and Bird 2011).  CpGs outside of CpG islands tend to have 
high levels of methylation, which is associated with the silencing of constitutive heterochromatin 
and genome stabilization (Ma et al. 2005).   
 
c.  The “sixth base,” 5-hydroxymethylcytosine. 
 A new level of epigenetic complexity was unveiled by the recent discovery of 5-
hydroxymethylcytosine (5hmC), dubbed the “sixth base” in the genome (Rusk 2012).  Tahiliani 
et al. (2009) first discovered that the ten-eleven translocation-1 (TET1) protein catalyzes the 
conversion of 5mC to 5-hydroxymethylcytosine (5hmC).  Follow-up studies by Ito et al. (2010) 
in mouse ES cells established that all three Tet family proteins (Tet1, Tet2 and Tet3) catalyze the 
same reaction.  TET enzymes depend upon the presence of iron (Fe
2+
) and alpha-ketoglutarate 
(α-ketoglutarate) as cofactors (Tahiliani et al. 2009); α-ketoglutarate is a product of the oxidative 
decarboxylation of isocitrate by isocitrate dehydrogenase (IDH) enzymes (Reitman and Yan 
2010) (Figure 6) and is an intermediate in the Krebs cycle (Tretter and Adam-Vizi 2005).   
 
 






Initial speculation following the discovery by Tahiliani et al. (2009) was that 5hmC is an 
intermediate in a DNA demethylation pathway (Ito et al. 2010).  The proposed mechanisms 
involve active and passive processes (Figure 7).  Since DMNT1 poorly recognizes 5hmC 
(Valinluck and Sowers 2007), the accumulation of 5hmC results in passive loss of 5mC through 
successive rounds of DNA replication.  Additionally, DNA repair pathways involving thymine 
DNA glycosylase (TDG) and base excision repair (BER) have been shown to actively remove 
5hmC (Guo et al. 2011) (Figure 7).  5hmC might also have independent regulatory roles in gene 
expression (C-X Song et al. 2011), embryogenesis (Wossidlo et al. 2011), and neurodevelopment 




Figure 7.  Mechanisms of DNA demethylation through 5-hydroxymethylcytosine.   DNMTs catalyze the conversion of cytosine 
(C) to 5-methylcytosine (5mC) and are responsible for the establishment and maintenance of genomic 5mC patterns.  TETs catalyze 
the stepwise oxidation of 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), which 
results in DNA demethylation through active and passive mechanisms.  Through active pathways, the oxidation products 5fC and 
5caC are removed by thymine DNA glycosylases (TDGs), generating abasic sites that are converted back to C through base excision 
repair (BER).  5hmC can also be actively converted to C by DNMT3s, which exhibit dehydroxymethylase activities in oxidized 
environments.  Additionally, since the maintenance DNA methyltransferase DNMT1 does not readily recognize 5hmC, passive 






2.  Oxidative stress, redox regulation, and glutathione. 
 
a.  Oxidative stress and redox environment. 
Oxidative stress and ROS.  “Oxidative stress” refers to an imbalance in the production of reactive 
oxygen species (ROS) and a biological system's ability to detoxify the reactive intermediates 
(Jones 2008).  Aptly-named, ROS are oxygen-containing molecules that are highly damaging to 
sensitive targets.   Certain types of ROS, known as “free radicals,” contain unpaired electrons in 





), and hydroxyl radical (•OH) (Halliwell 1989).   Free radicals can induce 
macromolecular oxidative damage, such as protein oxidation (e.g., carbonyls), lipid peroxidation 
(e.g., malondealdyhyde), and oxidative DNA damage (e.g., 8-oxo-2'-deoxyguanosine) (Parman 
et al. 1999).  Nonradical oxidants (e.g., hydrogen peroxide, or H2O2) are less reactive than free 
radicals, but they have strong oxidizing capabilities and are prone to decomposing to free radical 
species (Campos-Martin et al. 2006).   
Redox couples and redox state.  Antioxidants are compounds that inhibit or remove ROS (Jones 
2008).  Many antioxidants are reducing agents, which are compounds that donate electrons to 
ROS and as a result, become oxidized themselves.  A pair of reduced and oxidized species is 
known as a redox couple (Schafer and Buettner 2001).  The term redox state refers to the ratio of 
reduced and oxidized species, as well as the concentrations of the reduced and oxidized species, 
within a particular redox couple; thus, the redox state reflects a redox couple’s reducing capacity 
(Schafer and Buettner 2001).  The reduction potential of a redox couple can be calculated using 
the Nernst equation, Eh(mV) = E0(-RT/nF) * ln([reductant]/[oxidant]), where E0 = standard 
reduction state at pH 7.0, R = gas constant, T = temperature in Kelvin, n = number of transferred 
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electrons, and F = Faraday’s constant.  There are several interconnected redox systems of 
biological importance: 
(1) Glutathione system (GSSG/2GSH).  The predominant redox couple within cells is GSH 
and glutathione disulfide (GSSG), with estimated cytosolic GSH concentrations between 
1–11 mM (Lu 2009).   Cellular GSH and GSSG concentrations can be used in the Nernst 
equation as an indicator of the intracellular redox environment: for the GSH/GSSG redox 
couple, the equation simplifies to Eh(mV) = -264 – 30 log([GSH]
2
/[GSSG])  (Jones et al. 
2000).  Since two free radical GSH molecules react to form GSSG, the redox state is 
dependent both on the concentrations and ratio of the GSH/GSSG couple, reflected in the 
Nernst equation by the squared GSH term.   
(2) Thioredoxin system (TrxSS/Trx(SH)2).  Thioredoxins (Trx) are small redox proteins that 
are found at intracellular concentrations 100- to 1000-fold lower than GSH, with 
estimated concentrations between 1 to 10 μM (Mari et al. 2009).  The TrxSS/Trx(SH)2 
system is important for the reduction of CySS in intramolecular disulfide bonds and 
regulates transcription factor binding (e.g., NF-kappaB [NF-kB]) and cellular signaling 
(Schenk et al. 1994) 
(3) Nicotinamide adenine dinucleotide phosphate system (NADP+/NADPH).  The cofactor 
nicotinamide adenine dinucleotide phosphate (NADPH) provides a pool of reducing 
equivalents for reduction reactions, notably for the regeneration of reducing agents in the 
GSH and Trx redox systems (Watson et al. 2003).  Each molecule of NADPH donates 
two electrons upon its conversion to its oxidized form, NADP
+
.  NADPH is primarily 
synthesized in the liver via the pentose phosphate pathway, but it can also be generated in 
mitochondria by isocitrate dehydrogenase (IDH) and NADH kinase (Dang 2012).   
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Redox disruption vs. oxidative damage.   The redox environment of a cell or tissue refers to the 
reducing capacity of the systems of redox couples within the specified milieu (Schafer and 
Buettner 2001).  Although macromolecular damage caused by oxidative stress has long been 
implicated as the causative factor in aging and disease, Dean Jones proposed that the 
pathological impact of oxidative stress might instead result from disruption of the redox 
environment (Jones 2008).  Based upon antioxidant enzyme kinetics, he proposed a scenario of 
“oxidative stress” (Figure 8) where the initial rates of free radicals versus nonradical oxidant 
generation is 10% and 90%, respectively, with a rate of radical scavenging of >99%, resulting in 
a total rate of production of nonradical oxidants of > 99.9% and macromolecular oxidative 
damage of < 0.1% (Jones 2008).  Thus, the greater impact of oxidative stress would be seen 
through the disruption of redox control, and macromolecular damage would correlate with redox 
disruption but would not likely be the causative factor in oxidative stress-related pathology.   
 
Figure 8.  Relative impacts of macromolecular damage versus redox disruption during 
conditions of oxidative stress. (adapted from Jones et al. 2008) 
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b.  Antioxidant enzymes and systems. 
Glutathione enzymes.  GSH readily donates a reducing equivalent from the thiol group of its Cys 
moiety via the glutathione peroxidase (GPx) enzyme family, and the free radical GSH molecule 
quickly reacts with another free radical GSH to form GSSG; e.g., the conversion of H2O2 to two 
molecules of H2O is characterized by the reaction 2GSH + H2O2 → GSSG + 2H2O (Figure 9).  
There are eight isoforms of GPx in humans (GPx1 through 8).  Five of the eight GPx isforms 
(Gpx1-4, Gpx6) are selenoproteins and are dependent upon selenium (Se) for their enzymatic 
activities (Moghadaszadeh and Beggs 2006).  GSH can be regenerated from GSSG via 
glutathione reductase (GR), which requires NADPH and FAD as cofactors (Berkholz et al. 
2008).  
Superoxide dismutases.  Superoxide dismutases (SODs) are metalloprotein enzymes that catalyze 
the dismutation of O2
-·
 to H2O2 and O2 (2 O2
-·
 + 2 H
+
 → O2 + H2O2) (Figure 9).  There are three 
types of human SODs:  SOD1 and SOD3 bind copper (Cu) and zinc (Zn) ions (Cu/Zn) and are 
found in the cytoplasm and extracellular space, respectively, while SOD2 binds manganese (Mn) 
ions and is found in mitochondria (Noor et al. 2002).   
Catalases.  Catalase (CAT) is a heme-containing enzyme that converts two molecules of H2O2 
into O2 and two molecules of H2O (2 H2O2 → 2 H2O + O2) (Figure 9).  Catalases are contained 
within peroxisomes (Sies 1974) and are expressed in every organ, with the highest expression in 





Figure 9.  Detoxification of superoxide by antioxidant enzymes. 
Nrf2-mediated defense system.  Oxidative stress stimulates the nuclear factor (erythroid-derived 
2)-like 2 (Nrf2) antioxidant response pathway, the primary cellular defense against ROS 
(Nguyen et al. 2009).  Nrf2 is a leucine zipper transcription factor that is normally kept in the 
cytoplasm by a protein complex of Kelch like-ECH-associated protein 1 (Keap1) and Cullin-3, 
which quickly degrades Nrf2 by ubiquitination (Zhang et al. 2004).  Under conditions of 
oxidative stress, the formation of Keap1 intermolecular disulfide bonds (via Cys
151
) prevents the 
Keap1/Cullin-3 complex from degrading Nrf2, which allows Nrf2 to accumulate and enter the 
nucleus (Fourquet et al. 2010; Zhang and Hannink 2003).  Nrf2 heterodimerizes with small Maf 
proteins and binds antioxidant response elements (AREs), cis-acting enhancer sequences in 
promoter regions that regulate gene transcription (Itoh et al. 1997).  AREs are located in 
promoters of numerous antioxidant and Phase II detoxification genes, including CAT and SOD1 
(Itoh et al. 1997). 
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Nrf2 and GSH.   Nrf2 regulates the transcription of several GSH-associated genes (Chan and 
Kwong 2000).  The rate-limiting step in GSH production is the conjugation of Glu and Cys by 
GCL, a heterodimeric enzyme composed of a catalytic subunit (glutamate cysteine ligase 
catalytic subunit, or GCLC) and a modifier subunit that improves catalytic efficiency by 
lowering the Km for Glu (glutamate cysteine ligase modifier subunit, or GCLM); both subunits 
contain AREs in their promoter regions (Erickson et al. 2002), and the Nrf2 pathway upregulates 
GSH biosynthesis by inducing GCL expression (Wild et al. 1999).  Nrf2 also increases GR 
expression for the reduction of GSSG back to GSH (Harvey et al. 2009).   
 
c.  Sources of reactive oxygen species.   
Figure 10.  Sources of endogenous ROS.  Major sources of ROS include (A) mitochondrial 
oxidative phosphorylation, (B) endoplasmic reticulum stress, (C) NADPH oxidase enzyme 
activity, (D) nitric oxide synthase uncoupling, and (E) the Fenton reaction. 
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Endogenous ROS are normal byproducts of various cellular processes, illustrated in Figure 10.   
A.  Oxidative phosphorylation in mitochondria.  Mitochondrial ATP production (oxidative 
phosphorylation) involves a series of redox reactions at the mitochondrial inner membrane that 
release free energy for the pumping of protons (H+) into the intermembrane space, creating an 
electrochemical gradient for the synthesis of ATP (Brookes et al. 2004).   Electrons are donated 
from reduced nicotinamide adenine dinucleotide (NADH) and succinate, products of the Krebs 
cycle, and electron transport occurs at four protein membrane complexes, Complexes I through 
IV.  Occasionally, electrons leak from the chain and react with O2, resulting in the formation of 
O2
-· 
(Murphy 2009).  The “vicious cycle” theory of aging postulates that the accumulation of 
ROS-induced mutations in mitochondrial DNA (mtDNA) leads to increased leakage of electrons 
from the transport chain, thereby increasing ROS production and additional mtDNA mutations in 
a “vicious cycle” of ever-increasing oxidative stress (Cui et al. 2012). 
Complex I (NADH dehydrogenase).  NADH is oxidized to NAD+ through the reduction 
of riboflavin-5′-phosphate (FMN) to FMNH2.  Two electrons are transferred from 
FMNH2 to ubiquinone (Q) in a two-step process involving the formation of two 
semiquinone (free radical) intermediates.  Complex I is the primary source of 
mitochondrial O2
-· 
production in aging and neurological conditions. 
Complex II (succinate dehydrogenase).  Succinate is oxidized to fumarate through the 
reduction of Q to ubiquinol (QH2).  
Complex III (Cytochrome bc1 complex).  Two electrons are transferred from QH2 to two 
molecules of cytochrome c.  Complex III is the primary source of O2
-· 
production in heart 
and lung mitochondria. 
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Complex IV (Cytochrome c Oxidase).  Four electrons are transferred from cytochrome c 
to molecular oxygen (O2) to produce two molecules of H2O.  
B.  Endoplasmic reticulum stress.  The redox environment within the endoplasmic reticulum 
(ER) is oxidized relative to other cellular compartments due to its involvement in protein folding, 
which requires an oxidized environment for disulfide bond formation (Csala et al. 2010).  ROS 
can be produced as a byproduct of protein oxidation and folding (Malhotra and Kaufman 2007) 
and through alterations of intra-ER Ca
2+
 homeostasis (Bhandary et al. 2012). 
C.  NOX enzymes. The NADPH oxidase (NOX) family is comprised of seven membrane-bound 
enzymes (NOX1-5, DUOX1, and DUOX2) (Ajayi et al. 2013) that produce O2
-·
 from O2 and 
NADPH in the reaction NADPH + 2 O2 → NADP
+




 (Ago et al. 1999).  NOX 
enzymes catalyze the transfer of electrons across membranes for multiple functions, including 
first-line host defense against microbes in phagocytes and cell signaling regulation in various 
tissues (Suh et al. 1999).  The NOX–mediated generation of ROS is vital for redox signaling 
pathway regulation under normal conditions and during the cellular response to oxidants and 
exogenous stressors (Jiang et al. 2011).  For example, NOX-mediated ROS production plays an 
important role in the inhibition of enzymes in the protein tyrosine phosphatase (PTP) 
superfamily, which contain a conserved redox-sensitive Cys residue in their catalytic domains 
(Jiang et al. 2011).  PTPs, along with protein tyrosine kinases (PTKs), are essential for the 
regulation of tyrosine phosphorylation, a mechanism of signal transduction pathway activation 
(Alho et al. 2013; Alonso et al. 2004).  However, the overexpression of NOX leads to excessive 
generation of O2
-·
 (Hamilton et al. 2001), and NOX dysregulation is implicated in 
carcinogenesis, aging, and neurodegeneration (Nauseef 2008).  
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D.  Nitric oxide synthase uncoupling.  Nitric oxide synthase (NOS) enzymes catalyze the five-
electron oxidation of L-arginine to nitric oxide (NO), a free radical signaling molecule that is a 
potent vasodilator and is involved in the cardiovascular system, immunity, and neurologic 
function (Jiang et al. 2013).  NOS enzymes require five cofactors—FAD, FMN, heme, 
tetrahydrobiopterin (BH4), and Ca
2+
/calmodulin-—and the electron flow occurs as follows:  
NADPH → FAD → FMN → heme → O2, characterized by the reaction L-arginine + 3/2 
NADPH + H
+
 + 2 O2 → citrulline + nitric oxide + 3/2 NADP
+
.  There are three human isoforms 
of NOS (Forstermann and Kleinert 1995): 
(1) Neuronal NOS (nNOS), encoded by NOS, constitutively expressed in brain; 
(2) Inducible NOS (iNOS) is encoded by NOS2, expressed in liver, induced by 
lipopolysaccharides and cytokines, and involved in immunity; and  
(3) Endothelial NOS (eNOS) is encoded by NOS3, constitutively expressed in the 
endothelium, and involved in vasodilation and maintaining vascular tone.   
If BH4 is depleted, the NOS enzyme becomes “uncoupled,” and electron flow is diverted 
away from NO production and toward O2
-•
 generation (Verhaar et al. 2004).  O2
-•
 can react with 
NO to form peroxynitrite (ONOO
-
), a powerful oxidant that can oxidize BH4 to 7,8-dihydro-
biopterin (BH2), leading to further BH4 depletion and NOS uncoupling (Kuzkaya et al. 2003).   
E.  Fenton reaction.  Iron (Fe) and other transition metals react with H2O2 to produce •OH in a 
reaction known as the Fenton reaction, Fe
2+
 + H2O2 → Fe
3+
 + •OH + 
-
OH (Jozefczak et al. 2012).  
The production of •OH through the Fenton reaction is a key mechanism in the toxicity of 




Exogenous ROS are derived from many types of environmental exposures, including xenobiotics, 
pollution, and radiation (Waris and Ahsan 2006).  This section will briefly discuss the roles of 
GSH and ROS in xenobiotic metabolism, a hepatic detoxification pathway with three phases, (A) 
Phase I oxidation, (B) Phase II conjugation, and (C) Phase III transport (reviewed in Omiecinski 
et al. 2011; Xu et al. 2005).  
A. Phase I oxidation.  Phase I metabolism is catalyzed primarily by the cytochrome (CYP) P450 
superfamily of heme enzymes, which involves xenobiotic monooxidation in a reaction requiring 




 → SO + H2O (Meunier et al. 2004).   Certain 
P450 families (2, 4, 7, 11, 17, 19, 21, 24, 27, 46, and 51) are involved in metabolism of 
endogenous steroid hormones, cholesterol, vitamin D, and eicosanoids, in addition to the 
metabolism of exogenous compounds (Pikuleva and Waterman 2013).  Although there are 57 
total human P450 enzymes, over 95% of all drug metabolism reactions involve only five P450s 
enzymes, CYP3A4, 2C9, 2C19, 2D6, and 1A2 (Guengerich 2008).  The production of O2
-*
 and 
H2O2 can occur through the uncoupling of NADPH oxidation with substrate oxygenation 
(Cederbaum et al. 2001; Gillette et al. 1957; Imaoka et al. 2004; Nordblom and Coon 1977). 
B. Phase II conjugation.  Phase II metabolism involves the conjugation of activated xenobiotics 
to increase their solubility and reduce their reactivity (unlike Phase I metabolism, which often 
involves bioactivation) (Omiecinski et al. 2011).  One of the major Phase II enzyme families is 
the glutathione S-transferase (GST) superfamily, which is comprised of eight cytosolic families 
(alpha, mu, pi, sigma, theta, tau, omicron, and kappa GSTs) that catalyze the conjugation of GSH 
to xenobiotic substrates (Katoh et al. 2008).  Phase II xenobiotic detoxification can result in 
depletion of the hepatic GSH pool (Hayes and Pulford 1995).  GSTs are also involved in the 
detoxification of ROS (Hayes and Pulford 1995) and are important components of the cellular 
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oxidative stress defense system (Board and Menon 2013).  Activities of GSTs, like most Phase II 
enzymes, are upregulated by the Nrf2 pathway during oxidative stress (Xu et al. 2005). 
C.  Phase III transport.  In Phase III transport, GSH-xenobiotic conjugates are excreted through 
MRP-mediated cellular efflux (Zaman et al. 1995).  ATP-dependent MRPs mediate biliary 
excretion of most Phase II conjugates (Kullak-Ublick et al. 2002) and are also involved in 
cellular efflux of GSSG (Mueller et al. 2005) and folates (Ifergan and Assaraf 2008). 
 
d.  Redox signaling. 
In addition to GSH’s roles in ROS scavenging and xenobiotic detoxification, the 
intracellular GSH/GSSG redox state influences redox signaling pathways involved in various 
physiologic processes, including gene expression and cell cycle progression (Zhang and Forman 
2012).  The subcellular compartmentalization of redox states, which do not exist in equilibrium 
with one another, allows for organelle-specific control of redox signaling (Jones and Go 2010). 
Redox-sensitive enzymes.  Redox-sensitive enzymes contain Cys residues that are susceptible to 
oxidative post-translational modifications, which influence their catalytic activities in response to 
changes in the redox environment (Klomsiri et al. 2011).  The redox reactivity of a Cys residue is 
largely dependent upon its susceptibility to deprotonation at a physiologic pH (pH 7.0-7.4); thus, 
low pKa thiols are generally considered to be “redox-sensitive” Cys residues (Paulsen and 
Carroll 2013).  The sulfhydryl group (-SH) group of redox-sensitive Cys residues can undergo a 
number of reversible oxidative modifications, including disulfide bond formation and S-
glutathionylation (Guttmann and Powell 2012). 
Disulfide bonds.  Under conditions of oxidative stress, the reversible formation of 
intramolecular disulfide bonds between redox-sensitive Cys residues (Figure 11) induces 
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structural changes that act as “switches” to activate or inhibit the enzyme in response to 
the redox environment (Cumming et al. 2004).  The functions of the disulfide bridges are 
directly related to the distance between the Cys residues and their placement within the 
protein (Wu et al. 2012).  GSH can serve as a reducing agent for disulfide bond cleavage 
(Chakravarthi and Bulleid 2004), and intracellular GSH/GSSG status is an indicator of 








S-glutathionylation.  Protein S-glutathionylation involves the formation of a mixed 
disulfide between GSH and redox-sensitive Cys residues (Dalle-Donne et al. 2007), 
which can occur spontaneously or through a reaction catalyzed by glutathione S-
transferase pi (GSTP) (Grek et al. 2013).  The forward and reverse S-glutathionylation 
reactions can also be catalyzed by glutaredoxin (Grx) and Trx proteins (Beer et al. 2004; 
Kalinina et al. 2008; Starke et al. 2003).  S-glutathionylation occurs through the attack of 
the sulfhydryl group of GSSG by a deprotonated Cys thiol, or under conditions of 
oxidative or nitrosative stress, S-glutathionylation can occur through the interaction of the 
Cys thiol with the GSH-thiyl radical (GS
*
) and/or the interaction of a modified Cys thiol 
with GSH (Grek et al. 2013).  S-glutathionylation also occurs via a disulfide/thiol 
exchange reaction between GSSG and the Cys thiol (Grek et al. 2013).  However, for the 
majority of redox-sensitive Cys residues, the intracellular GSH/GSSG ratio would need 
to change 100-fold to induce S-glutathionylation through disulfide/thiol exchange, 
indicating that this mechanism is only applicable to a small group of Cys residues with 
very low pKa values (Dalle-Donne et al. 2007; Shelton et al. 2005).   
NF-κB signaling.  The nuclear factor-kappaB (NF-κB)-dependent signaling pathway is involved 
in the upregulation of target genes in response to cellular stressors (Li and Stark 2002) and is 
important for cytokine transcription in inflammation and immunity (Vallabhapurapu and Karin 
2009) and gene expression in cell cycle regulation and apoptosis (Morgan and Liu 2011).  The 
NF-κB pathway also upregulates the expression of many antioxidant enzymes, including CAT, 
SOD2, Trx1, Trx2, GSTP, and GPX (Morgan and Liu 2011).  The mammalian NF-κB family of 
transcription factors is comprised of five proteins (RelA [also known as p65], RelB, c-Rel, NF-
κB1 [p50], and NF-κB2 [p52], which contain a conserved Rel-homology domain (RHD) for 
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dimerization and DNA binding (Basak and Hoffmann 2008).  In the cytosol, the NF-κB protein 
is complexed with inhibitor of κB (IκB) protein, which keeps NF-κB inactivated (Sun and 
Andersson 2002).  In the canonical activation pathway, IκB kinase (IKK) phosphorylates two 
serine residues within IκB, which leads to lysine ubiquitination and proteasomal degradation of 
IκB; active NF-κB can then dimerize and translocate to the nucleus to bind κB enhancers in 
target genes (Gilmore 2006).  Certain stimuli activate NF-κB through a non-canonical pathway 
involving NF-κB inducing kinase (NIK), which triggers the processing of the NF-κB2 precursor 
protein into its mature p52 subunit through phosphorylation and degredation of p100, a subunit 
complexed with p52 in the NF-κB2 precursor (Sun 2011). 
The first study examining ROS and NF-κB by Schreck and colleagues (1991) found that 
H2O2 was a potent activator of NF-κB in human T cells, and pretreatment with N-acetyl-L-
cysteine (NAC) and GSH blocked H2O2-mediated NF-κB activation (Flohe et al. 1997; Li and 
Karin 1999).  However, subsequent studies of NF-κB redox regulation have produced mixed 
findings, which is explained by the fact that redox influences NF-κB through multiple, cell type-
specific mechanisms (Morgan and Liu 2011).   
First, oxidative stress influences IKK activity in a context-dependent manner.  For 
example, H2O2 can irreversibly inhibit IKK through the direct oxidation of Cys
179
 of its β-subunit 
(IKK-β) (Korn et al. 2001).  This oxidative inhibition of IKK was later found to correspond with 
S-glutathionylation of the same Cys residue, which could be reversed by GRX1; the authors 
postulated that redox-mediated S-glutathionylation might be a mechanism to protect IKK-β from 
irreversible oxidation by H2O2 and allow the rapid regulation of enzymatic activity (Reynaert et 
al. 2006).  Alternatively, H2O2 can increase IKK activity by inducing dimerization of its IKK-γ 







 (Herscovitch et al. 2008), and can also increase IKK activity by inducing phosphorylation 
of serines in the IKK activation loop (Kamata et al. 2002). 
Oxidative stress also regulates NF-κB through IKK-independent mechanisms.   During 
IL-1β induction of NFκB, H2O2 upregulates NIK activity at low concentrations (1–10 μM) but 
inhibits NIK at higher concentrations (Li and Engelhardt 2006).  Under hypoxic conditions, NF-
κB activation can occur through an atypical pathway in which IκB degradation is trigged by 
phosphorylation of Tyr
42
 in the IκBα subunit (Imbert et al. 1996; Koong et al. 1994; Siomek 
2012), which is dependent upon the H2O2-mediated activation of c-Src kinases (Fan et al. 2003).  
The IκBα subunit also contains a Cys residue (Cys
189
) that is a target for S-glutathionylation 
under oxidized conditions, which prevents IκBα degredation (Kil et al. 2008).  In addition, the 
redox state in the nucleus influences the ability of the NF-κB complex to bind DNA (Toledano 
and Leonard 1991).  This inhibition can occur through direct oxidation of a Cys residue (Cys
62
) 
in the RHD of NF-κB (Matthews et al. 1993).  When nuclear GSH/GSSG ratios are low, DNA 
binding inhibition occurs through S-glutathionylation of Cys
62 
(Pineda-Molina et al. 2001). 
Due to the intricate crosstalk between oxidative stress and NF-κB signaling, it is 
impossible to summarize the “general” influence of oxidative stress on NF-κB activation.   
However, the complex interplay among ROS, GSH, and NF-κB allows the cell to initiate finely-
tuned redox signaling cascades in response to a variety of stimuli, in a manner that is dependent 
upon the physiologic state of the cell (Flohe et al. 1997).  Given the key role of NF-κB in the 
regulation of cell cycle progression, aberrant regulation of NF-κB signaling and ROS crosstalk is 
believed to play a role in carcinogenesis (Ben-Neriah and Karin 2011). 
AP-1 signaling.  The activator protein 1 (AP-1) family of leucine zipper transcription factors 
(comprised of Jun, Fos, Fra, and ATF subfamilies) regulates the expression of genes involved in 
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cell cycle control, DNA repair, and oncogenesis (Karin and Shaulian 2001).  AP-1 activity can 
be induced by numerous stimuli, including growth factors, stress signals, bacterial and viral 
infections, and UV radiation (Angel and Karin 1991; Hess et al. 2004).  The AP-1 complex is 
formed by the dimerization of different AP-1 proteins (usually a c-Jun/c-Fos heterodimer), which 
have different DNA binding affinities based upon the components of the dimer (Halazonetis et 
al. 1988), and the dimer binds to TPA response elements in promoter regions to enhance gene 
expression (Zhou et al. 2005).   
 One of the most widely-studied mechanisms of redox-associated AP-1 upregulation is via 
the mitogen-activated protein kinase (MAPK) family, which is comprised of three subfamilies of 
serine/threonine protein kinases (extracellular signal-regulated protein kinase [ERK], c-Jun N-
terminal kinase/stress-activated protein kinase [JNK/SAPK], and p38) that phosphorylate c-Jun 
and c-Fos (Torres and Forman 2003; Wang et al. 1998).  Activation of MAPKs requires 
phosphorylation by mitogen-activated protein kinase kinases (MKKs), which can be reversed by 
MAPK phosphatases (MKPs) (Boutros et al. 2008).  The dual-specificity MKPs are PTPs and 
thus, contain a conserved redox-sensitive Cys residue; H2O2 oxidizes this Cys residue in JNK 
phosphatases, resulting in sustained JNK activation (Kamata et al. 2005).  ROS have also been 
shown to downregulate ERK phosphatases, which can be reversed by pretreatment with NAC 
(Traore et al. 2008).  In addition, ROS activates JNK via the inactivation of GSTP, which 
normally binds the c-terminal of JNK to suppress its activity (Shen and Liu 2006).  MAPK 
activation is postulated to be a primary mechanism of ROS-induced apoptotic initiation (Circu 
and Aw 2010).        
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C.  Inorganic arsenic. 
 
1.  Background. 
Arsenic (As), a naturally-occurring metalloid, is a ubiquitous environmental contaminant 
in food, water, soil, and air (Mandal and Suzuki 2002).  Over 200 million people worldwide are 





), at concentrations greater than the WHO guideline of 10 µg/L (2008).  Countries 
with As-exposed populations include, but are not limited to, Argentina, Bangladesh, Chile, 
China, Ghana, India, Mexico, Taiwan, the United States, and Vietnam  (Naujokas et al. 2013).  
Arsenic exposure is of particular concern in Bangladesh: in a well-intentioned effort to prevent 
waterborne diseases from the consumption of pathogen-contamined surface water, humanitarian 
organizations installed tube wells throughout the country during the 1960s and 1970s (Flanagan 
et al. 2012).   Unfortunately, it was not until the early 1990s that As was first detected in these 
wells (Flanagan et al. 2012).  It is estimated that 35 to 77 million people in Bangladesh are 
chronically-exposed to As through drinking water (Kinniburgh and Smedley 2001).   
The Agency for Toxic Substances and Disease Registry (ASTDR) calculates a ranking of 
toxic chemicals that pose the greatest hazards to public health; in 2011, arsenic had the highest 
ranking on the priority list (Naujokas et al. 2013).  The relative toxicities of As compounds are 
strongly tied to their valence states.  In general, trivalent arsenicals are more reactive than 
pentavalent arsenicals (Styblo et al. 2000), which can be attributed primarily to the binding 
affinity of trivalent arsenicals to sulhydryl groups in proteins and enzymes (Hughes et al. 2011).  
The toxicity of As
V
 stems from its structural similarity to phosphate and its ability to replace 
phosphate in chemical reactions (ter Welle and Slater 1967).   
38 
 
2.  Metabolism of ingested arsenic. 
 
a.  Absorption and tissue uptake.   
 Following ingestion, inorganic arsenic (InAs) is readily absorbed (>90%) by the 
gastrointestinal tract:  As
V
 is transported into enterocytes by the high-affinity phosphate 
transporter NaPiIIb (Villa-Bellosta and Sorribas 2008), while As
III
 uptake is mediated through a 
variety of transport mechanisms, including glucose transporters (GLUT2, GLUT5), organic 
anion transporting polypeptides (OATPB) and aquaporins (AQP3 and AQP10) (Calatayud et al. 
2012).  Arsenic exits the enterocyte via basolateral transporters (GLUT2, AQP3, AQP4, and 
MRPs, likely MRP3) and enters the circulation (Calatayud et al. 2012), where As
III
 can be 
transported into tissues via AQPs (Maciaszczyk-Dziubinska et al. 2012). 
 
b.  Methylation.   
 Within cells, As
III
 is metabolized through a series of methylation reactions, resulting in 
the formation of monomethyl (MMAs) and dimethyl arsenicals (DMAs) (Lin et al. 2002).  The 
reaction is catalyzed by the enzyme arsenic(III)-methyltransferase (AS3MT), which is absolutely 
dependent upon a methyl group from SAM and the presence of a reductant (Lin et al. 2002), 
such as GSH (Thomas 2009; Waters et al. 2004b) or the TR/Trx/NADPH system (Waters et al. 
2004a; Waters et al. 2004b).  Although the primary site of As methylation is the liver, AS3MT is 
also expressed in kidney, lung, heart, and bladder tissues (Lin et al. 2002).  Three distinct 
AS3MT-catalyzed methylation pathways have been proposed in the literature (Figure 10 A-C): 
A.  Oxidative methylation. In this pathway first proposed by Challenger (1945, 1951), AS3MT 
catalyzes the oxidative methylation of As
III
 and methylarsonous acid (MMA
III





) and dimethylarsinic acid (DMA
V
), respectively.  A reductant (such as GSH) is 









).   
B.  Successive methylation via As-GSH complexes.  Hayakawa et al. (2005) proposed a pathway 
in which As-GSH complexes are substrates for AS3MT.  Here, As
III
 nonenzymatically 
complexes with GSH to generate arsenic triglutathione (ATG), which is methylated by AS3MT 
to form monomethylarsonic diglutathione (MADG).  MADG can be further methylated to 
dimethylarsinic glutathione (DMAG).  As-GSH complexes (ATG, MADG, and DMAG) are in 






) based on the concentration of 









) by environmental oxygen. 
C.  Ordered methylation mechanism.  Wang et al. (2012) proposed a model in which a reductant 
(thiol or nonthiol) changes the conformation of AS3MT to influence enzyme activity.  In this 
scheme, SAM binds to AS3MT; then, a reductant (such as GSH) cleaves a disulfide bond in the 
enzyme, which exposes active-site cysteine (Cys) residues for As
III
 binding.  As
III 
binds the Cys 
residues, forming arsenic tricysteine (ATC
III
), and the methyl group from SAM is transferred to 
ATC
III 
















, respectively.  




Figure 12.  Proposed mechanisms of arsenic methylation.  (A)  Oxidative methylation pathway, first proposed by Challenger in 
1945; (B) Methylation via As-GSH complexes, first proposed by Hayakawa et al. 2005; (C) Ordered methylation mechanism, first 








There are twelve conserved Cys residues in the human AS3MT (hAS3MT) structure (X 
Song et al. 2011).  The hAS3MT binding site for As
III





) that serve as the catalytic binding sites, and another Cys residue (Cys
250
) in this site is 
involved in an intramolecular disulfide bond to maintain structural stability (Song et al. 2009), 
possibly with Cys
72
 (X Song et al. 2011).  The structure of the hAS3MT binding site for SAM is 
less defined, but models indicate that Asp
102
 forms hydrogen bonds with ribose hydroxyl groups 
of SAM (Li et al. 2013b) and Tyr
59
 forms a hydrogen bond with the carboxyl group (Li et al. 






binding site are also found in the SAM 
binding pocket, with Cys
156
 predicted to interact with the S
+
-CH3 of SAM to orient the methyl 
group for As
III
 binding (Li et al. 2013a). 
Arsenic methylation:  detoxification.or bioactivation? 
Studies of As3mt-knockout mice suggest that As methylation plays a key role in As 
excretion and detoxification (Drobna et al. 2009; Hughes et al. 2010).  Following an acute As 
exposure of 0.5 mg As
V
/kg, compared to wildtype mice at 24 h, As3mt knockouts had markedly 
higher proportions of MMA in liver and higher As retention in liver, kidneys, bladder, lungs, and 
heart; whole-body retention of the As dose at 24 h was 6% in wildtype mice and 50% in As3mt-
knockout mice (Drobna et al. 2009).  Further examination of this same As
V
 dose over 10 daily 
doses (to achieve steady-state exposures) found that the whole body burden of As was 16 to 20 
times greater in As3mt-knockout mice compared to wildtype (Hughes et al. 2010).   
The methyl donor for As methylation is SAM, a product of folate-dependent one-carbon 
metabolism.  Early animal studies found that folate deficiency increased As retention and 
decreased urinary As excretion (Spiegelstein et al. 2005; Tice et al. 1997; Vahter and Marafante 




Mthfr knockouts compared to wildtype (Wlodarczyk et al. 2012).  In humans, folate deficiency 
has been associated with impaired As methylation capacity in numerous cross-sectional studies 
(Basu et al. 2011; Gamble et al. 2005; Heck et al. 2007).  A randomized controlled trial (RCT) in 
a folate-deficient, As-exposed Bangaldeshi population examining the influence of folic acid 
supplementation on As methylation capacity found that compared to placebo, daily 
supplementation with 400 µg folic acid for 12 weeks decreased urinary %MMA, increased 
urinary %DMA, and decreased total blood As (Gamble et al. 2006; Gamble et al. 2007). 
  Despite the experimental evidence linking As methylation capacity with whole-body As 
excretion, it has been argued that As methylation involves bioactivation rather than 
detoxification (Thomas et al. 2001; Vahter and Concha 2001).  The first examination of the in 
vitro toxicities of the methylated arsenicals found that MMA
III
 was the most cytotoxic, with an 
LC50 of 6.3 µM, and was considerably more toxic than the second-most toxic species, As
III
, with 
an LC50 of 19.8 µM (Petrick et al. 2000).  Based on these findings and results from other in vitro 
and in vivo cytotoxicity studies (Petrick et al. 2001; Styblo et al. 2000), the relative toxicities of 













(reviewed in Hall and Gamble 2012).  Recent studies have also examined the toxicities of the 










 was extremely cytotoxic in human bladder cells, second only to DMA
III
 
(Naranmandura et al. 2011).  In sum, evidence suggests that As methylation increases As 
excretion; however, incomplete As methylation resulting in increased MMA production, and 
endogenous environments supporting the formation of trivalent and thiol methylated metabolites, 




c.  Excretion.   
  The primary route of As elimination in humans is through urinary excretion.  Two 
toxicokinetic studies in healthy human adults found that, in conditions of chronic exposure  to 
varying oral doses of sodium arsenite (NaAsO2) with steady-state excretion, approximately 60% 
of the NaAsO2 dose is excreted in urine within 24 h (Buchet et al. 1981b), while another 
experiment from the same group found that a single oral dose of 500 µg As
III
 is excreted in urine 
within 4 days (Buchet et al. 1981a).  Among individuals who are chronically-exposed to As in 
well water, the predominant urinary As metabolite is DMA (typically ranging from 45-85%), 
followed by InAs (10-30%) and MMA (5-25%) (Gamble et al. 2005; Meza et al. 2004; Vahter 
and Concha 2001).  Arsenic (as As-GSH and As-GSH-Se complexes) can also be excreted in bile 
via MRP-mediated transport mechanisms (Figure 13) (Carew and Leslie 2010; Kala et al. 2000). 
 










3.  Health effects of chronic arsenic exposure in adults. 
 
a.  Arsenic-induced skin lesions.   
 Arsenic tends to accumulate in keratin-rich peripheral tissues, such as the skin, nails, and 
hair (Yu et al. 2006).  As such, one of the most common As-associated health outcomes is the 
appearance of skin lesions (melanosis, keratosis, and/or leukomelanosis), which are often the 
first visible sign of arsenicosis (Chakraborty and Saha 1987; Tseng et al. 1968).  Melanosis, the 
most common and early-presenting manifestation, is characterized by hyperpigmentation of the 
chest, back, and limbs; keratosis is a sign of moderate-to-severe As toxicity and is characterized 
by rough, dark nodules on the palms and soles of the feet; and leukomelanosis, an uncommon 
manifestation, is characterized by hypopigmentation and is associated with advanced-stage 
toxicity (Saha et al. 1999).   
Multiple studies have confirmed that As exposure is associated with a dose-dependent 
increase in risk for skin lesions (Argos et al. 2011; Guo et al. 2001; Haque et al. 2003; Tondel et 
al. 1999), and skin lesions are considered to be a specific biomarker of long-term As exposure 
(Chen et al. 2005), as well as a biomarker of increased susceptibility to As toxicity (Hsu et al. 
2013).  A recent study in Taiwan found that the presence of skin lesions was associated with 
increased risk of lung and endothelial cancer, even years after the cessation of As exposure (Hsu 
et al. 2013).  In addition, the prevalence of skin lesions in As-exposed populations is fairly high 
compared to other health outcomes, allowing for large sample sizes in epidemiologic studies:  
For example, in 1968, a large study of an As-exposed population in Taiwan found that the 
prevalence (per 1,000 individuals) of melanosis was 183.5 and keratosis was 71.0, while the 




progress to skin cancer at a high rate, examining the risk factors that increase the risk of As-
induced skin lesions might provide insight into mechanisms of As toxicity and factors that 
influence susceptibility.  
 
b.  Health outcomes. 
 Chronic As exposure is associated with increased all-cause and chronic-disease mortality 
rates (Argos et al. 2010) and increased risks for numerous health outcomes (Table 1).   
 
Table 1.  Examples of health outcomes associated with chronic As exposure in adult 
humans.  (adapted from Hughes 2002; Naujokas et al. 2013, Yoshida et al. 2004)  
 
System Disease/condition 
Skin Skin lesions, squamous cell carcinoma 
Respiratory Asthma, chronic obstructive pulmonary disorder 
Cardiovascular Ischemic heart disease, hypertension 
Nervous Peripheral neuropathy, impaired motor function 
Hepatic Liver cancer 
Hematological Bone marrow depression 
Endocrine Diabetes, thyroid disruption, glucose tolerance 






c.  As methylation and disease risk. 
 In human studies, impaired As methylation capacity (as indicated by increased %MMA 
and/or decreased %DMA in urine) has been associated with increased susceptibility to a variety 
of As-related diseases, including skin lesions, atherosclerosis, cardiovascular disease (CVD), and 
cancers of the lung, bladder, and skin (reviewed in Steinmaus et al. 2010).  Although the studies 
included in Steinmaus et al. examined prevalent cases, raising the possibility that the relationship 
between As methylation capacity and disease might not be temporal, a recent prospective study 
in Bangladesh observed a significant association between increased %MMA and risk for CVD 
(Chen et al. 2013). 
 
 





).  Elevated urinary %MMA is associated with increased disease risks 
across 16 independent studies. Courtesy of Dr. Megan Hall, adapted from Steinmaus et al. 2010. 
Odds Ratio 




4.  Mechanisms of arsenic toxicity and carcinogenesis in humans. 
 The exact mechanism(s) of action of As toxicity are unknown, but several pathways have 
been proposed (Figure 15) (Hughes 2002).  Unlike the majority of known chemical carcinogens, 
As is a weak point mutagen (Kligerman et al. 2003; Rossman et al. 1980).  Despite its inability to 
induce DNA mutations, in a study published in Science in 1988, NaAsO2 was shown to be a 
strong inducer of gene amplification in vitro (Lee et al. 1988), and subsequent in vitro studies 
have confirmed that As exposure induces genomic instability (reviewed in Bhattacharjee et al. 
2013).  In humans, As exposure in drinking water has been significantly associated with 
chromosomal aberrations and micronuclei formation in numerous studies (Ghosh et al. 2006; 
Gonsebatt et al. 1997; Lerda 1994; Mahata et al. 2003), which are hypothesized to occur through 
the pathways presented in Figure 15. 
Elucidating mechanisms of As toxicity in humans has proven difficult due to substantial 
interspecies differences in AS3MT expression and As toxicokinetics (Drobna et al. 2010).  This 
is a particular concern in the study of As carcinogenesis. Although As is a known human 
carcinogen, there is a lack of evidence for As carcinogenicity from in vivo experimental models, 
and until recently, there were no animal models of As carcinogenesis (Huff et al. 2000; Tokar et 
al. 2010).  Additionally, recently-developed rodent models generally administer As at doses 
(drinking water As in the ppm range) that are orders of magnitude higher than environmentally-
relevant exposures (drinking water As in the ppb range) (Tokar et al. 2010).   Since As exposure 
is likely to exert its toxic effects through multiple, dose-dependent mechanisms (Singh et al. 
2011), it is uncertain whether findings from animal models can be directly translated to humans.  
It is thus essential to complement experimental studies of As toxicity with mechanistic studies in 





Figure 15.  Proposed mechanisms of arsenic toxicity.  Four of several proposed mechanisms 
of As toxicity include (A) decreased capacity to methylate DNA and/or arsenic; (B) impaired 
DNA repair capacity; (C) oxidative stress; and (D) aberrant cell signaling.  As outlined in 
sections A and B of the introduction, transmethylation reactions and DNA repair capacity are 
regulated, in part, by folate and one-carbon metabolism, and oxidative stress and cell signaling 





5.  Metabolic interactions and unanswered questions. 
 As outlined in Sections A and B of the introduction, these proposed mechanisms of As 
toxicity are not metabolically independent, and they are all influenced, in part, by one-carbon 
metabolism and the transsulfuration pathway (Figure 16).  Given the complex metabolic 
interactions between As metabolism, GSH redox regulation, and DNA methylation, it is 
important to understand how these factors might interact with one another to influence As 
toxicity.  In this dissertation, we examined the relationships and metabolic interactions among 
these factors in a human population that is chronically-exposed to As in drinking water. 
 
 
Figure 16.  Metabolic interactions between DNA methylation, glutathione redox regulation, 
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BACKGROUND:  Several studies employing cell culture and animal models suggest that arsenic 
(As) exposure induces global DNA hypomethylation.  However, As has been associated with 
global DNA hypermethylation in human study populations.  It has been hypothesized that this 
discrepancy may reflect a non-linear relationship between As dose and DNA methylation. 
OBJECTIVE:  The objective of this study was to examine the dose-response relationship 
between As and global methylation of peripheral blood mononuclear cell (PBMC) DNA in 
apparently healthy Bangladeshi adults chronically exposed to a wide range of As concentrations 
in drinking water.    
METHODS:  Global PBMC DNA methylation, plasma folate, blood S-adenosylmethionine 
(SAM), and concentrations of As in drinking water, blood, and urine were measured in 320 
adults.  DNA methylation was measured using the [
3
H]-methyl incorporation assay, which 
provides disintegration per minute (DPM) values that are negatively associated with global DNA 
methylation. 
RESULTS:  Water, blood, and urinary As were positively correlated with global PBMC DNA 
methylation (P < 0.05).  In multivariable adjusted models, 1-µg/L increases in water and urinary 
As were associated with 27.6 unit (95% CI, 6.3 to 49.0) and 22.1 unit (95% CI, 0.5 to 43.8) 
decreases in DPM per µg DNA, respectively. Categorical models indicated that estimated mean 
levels of PBMC DNA methylation were highest in participants with the highest As exposures. 
CONCLUSIONS:  These results suggest that As is positively associated with global methylation 
of PBMC DNA over a wide range of drinking water As concentrations.  Further research is 





An estimated 70 million people in Bangladesh are chronically exposed to arsenic (As)-
contaminated drinking water at levels over the World Health Organization (WHO) limit of 10 
µg/L (Loewenberg 2007).  Exposure to As has been associated with cancers of the skin, lung, 
bladder, liver, and kidney (Navarro Silvera and Rohan 2007), hypertension and cardiovascular 
disease (Chen et al. 1995; Chen et al. 2011; Tseng et al. 2003), respiratory outcomes 
(Chattopadhyay et al. 2010; Dauphine et al. 2011; Parvez et al. 2010), and reduced cognitive 
function in children (Hamadani et al. 2011; Wasserman et al. 2004).  The mechanism(s) 
responsible for the pleiotropic health effects of As are not completely understood. 
DNA methylation involves the covalent addition of a methyl group from S-
adenosylmethionine (SAM) to the 5’ position of cytosine bases in CpG dinucleotides (Zhao et al. 
1997).  SAM biosynthesis is regulated by one-carbon metabolism, a biochemical pathway for the 
methylation of numerous substrates that is dependent on folate for the recruitment of methyl 
groups from serine (Chiang et al. 1996).  Methylation of CpG dinucleotides is associated with 
gene silencing: CpGs in intergenic regions and repetitive elements are usually methylated 
(Robertson 2001), while CpGs in gene promoter regions of transcriptionally active genes are 
generally less methylated than in other regions (Razin and Kantor 2005).  Global DNA 
hypomethylation is associated with genomic instability, including loss of heterozygosity 
(Matsuzaki et al. 2005), aneuploidy (Dodge et al. 2005), and chromosomal alterations (Schulz et 
al. 2002), and is commonly observed in tumors and transformed cells (Gaudet et al. 2003).  In 
addition, recent work by the ENCODE project (Consortium 2004) has highlighted important 




genome (previously coined “junk DNA”) in cell-type dependent transcriptional regulation 
(Bernstein et al. 2012; Thurman et al. 2012). 
Evidence based on in vitro and in vivo models suggests that chronic As exposure induces 
global DNA hypomethylation, in conjunction with hypermethylation of promoter regions of 
tumor suppressor genes (Benbrahim-Tallaa et al. 2005; Chen et al. 2004; Reichard et al. 2007; 
Ren et al. 2011).   Based on this literature, we initially hypothesized that As exposure would be 
associated with a reduction in global methylation of DNA in a population chronically exposed to 
As-contaminated drinking water, providing a mechanistic link between As exposure and 
increased cancer risk.  We further hypothesized that this would be exacerbated by folate 
deficiency.  However, in our first population-based study on this subject, contrary to our a priori 
hypotheses, chronic As exposure was positively associated with global methylation of peripheral 
blood leukocyte (PBL) DNA among subjects with sufficient folate levels (Pilsner et al. 2007).  
While these findings were unanticipated, the positive association between As exposure and 
global DNA methylation in humans has been replicated by our group (Pilsner et al. 2012; Pilsner 
et al. 2009) and by others (Kile et al. 2012; Lambrou et al. 2012; Majumdar et al. 2010).  We 
hypothesized that the discrepancy between the experimental and human studies is related to the 
dose and duration of As exposure:  High acute As exposures might result in DNA 
hypomethylation, whereas a non-linear pattern of association might be observed within the range 
of As exposures in human populations, many of whom have been exposed to As for decades.      
The primary objective of this analysis was to evaluate the relationship between As 
exposure and global methylation of peripheral blood mononuclear cell (PBMC) DNA.  We used 
data from the Folate and Oxidative Stress (FOX) study (Hall et al. 2013), which selected study 




relationship between As exposure and oxidative stress.  This study provided a unique opportunity 
to examine the dose-response relationship between As exposure and global DNA methylation in 




SUBJECTS AND METHODS 
Eligibility criteria and study design 
For the FOX study, we recruited 379 men and women between the ages of 30 and 65 y 
between April 2007 and April 2008 in Araihazar, Bangladesh.  Participants were selected based 
on well water As (wAs) exposure such that the final study sample represented the full range of 
wAs concentrations in the region. We aimed to recruit 75 participants from each of 5 exposure 
categories (Group A, 0-10 µg/L; Group B, 10-100 µg/L; Group C, 100-200 µg/L; Group D, 200-
300 µg/L; and Group E, >300 µg/L) but had difficulty recruiting participants in the highest 
exposure categories because households using wells that tested positive for As (i.e., > 50 µg/L, 
the Bangladesh standard) were encouraged to switch to lower-As wells (Chen et al. 2007).  Thus, 
the final participant numbers for the 5 categories were Group A, N=76; Group B, N=104; Group 
C, N=86; Group D, N=67, and Group E, N=45.  Note that a random sample in this region would 
have likely yielded 40-50% of participants consuming wAs ≤ 50 µg/L.   Participants must have 
been drinking from the same well for a minimum of 3 months prior to recruitment.  Participants 
were excluded if they were pregnant; were currently taking nutritional supplements (or had done 
so within the past 3 months); or had known diabetes, cardiovascular, or renal disease. 
Oral informed consent was obtained by our Bangladeshi field staff physicians, who read 
an approved consent form to the study participants. This study was approved by the institutional 
review boards of the Bangladesh Medical Research Council and of Columbia University Medical 
Center.     
Analytic techniques 




Blood samples were drawn and processed immediately at our field clinic laboratory in 
Araihazar.   Blood samples were centrifuged at 3,000 × g for 10 min at 4°C, and buffy coat and 
plasma were separated from red cells.  Aliquots of blood and plasma were stored at –80°C.  
Urine samples were collected in 50 mL acid-washed polypropylene tubes and frozen at –20°C.  
Blood, plasma, and urine samples were transported to Dhaka on dry ice and stored at -80°C.  
Samples were then shipped, frozen on dry ice, to Columbia University for analysis.   
Water As 
Field sample collection and laboratory procedures have been described in detail (Cheng 
et al. 2004; Van Geen et al. 2005).  Briefly, at the recruitment visit of the FOX study, new water 
samples were collected in 20 mL polyethylene scintillation vials and acidified to 1% with high-
purity Optima HCl (Fisher Scientific, Pittsburg, PA, USA) at least 48 hr before analysis (van 
Geen et al. 2007). Water samples were analyzed by high-resolution inductively coupled plasma 
mass spectrometry (ICP-MS) after 1:10 dilution and addition of a Ge spike to correct fluctuations 
in instrument sensitivity. A standard with an As concentration of 51 µg/L was run multiple times 
in each batch; the intra- and inter-assay coefficients of variation (CVs) for this standard were 
6.0% and 3.8%, respectively.   
Total urinary As and urinary creatinine 
Urinary As (uAs) metabolites were speciated using high performance liquid 









), and DMA (DMA
V
), followed by detection using ICP-MS (Vela et al. 




, MMA, and DMA; 
AsC and AsB were not included in the sum. The limit of detection for each uAs metabolite was 




creatinine (uCr), which was analyzed by a colorimetric assay based on the Jaffe reaction (Slot 
1965).  The intra-assay CVs were 4.5% for As
V
, 3.8% for As
III
, 1.5% for MMA, and 0.6% for 
DMA; inter-assay CVs were 10.6% for As
V
, 9.6% for As
III
, 3.5% for MMA, and 2.8% for DMA. 
Total blood As 
Total blood As (bAs) was analyzed using Perkin-Elmer Elan DRC II ICP-MS equipped 
with an AS 93+ autosampler, with a limit of detection of 0.1 μg/L, as previously described (Hall 
et al. 2006).  The intra- and inter-assay CVs were 3.2% and 5.7%, respectively.   
PBMC DNA isolation 
PBMCs were isolated from fresh blood samples in the field clinic laboratory in 
Araihazar.  To isolate PBMCs, 4 mL Ficoll solution was added to a tube containing 4 mL blood 
(with serum removed) and 11 mL PBS.  Tubes were centrifuged at 400 x g for 30 min, and the 
mononuclear cell layer was extracted and washed with PBS.  Cells were sedimented by 
centrifuging at 200 x g for 10 min.   The cell pellet was resuspended with 4 mL lysis solution and 
50 μl Proteinase K solution.  PBMC lysates were stored at 4°C until shipment to Columbia 
University.  PBMC DNA was isolated from 4 mL PBMC lysate using 1 mL Protein Precipitation 
Solution (5-Prime, New York, NY) and standard isopropanol extraction following the 
manufacturer’s protocol.  DNA was stored at -20°C until further analysis. 
Global DNA methylation 
Global DNA methylation was measured using the [
3
H]-methyl incorporation assay 
developed by Balaghi and Wagner (Balaghi and Wagner 1993), as previously described (Pilsner 
et al. 2007).  The assay employs 
3
H-labeled SAM and SssI methylase to add 
3
H-labeled methyl 
groups to unmethylated CpG sequences.  Thus, disintegration per minute (DPM) values are 




run included a blank (mixture including all reaction components except SssI enzyme), 
hypomethylated control (HeLa cell DNA), and positive control (DNA extracted from whole 
blood sample).  PicoGreen dsDNA Quantitation Reagent (Molecular Probes, Eugene, OR) was 
used to quantify the exact amount of double-stranded DNA (dsDNA) used in each reaction.  The 
mean DPM values from the duplicate samples were expressed per µg DNA, as determined by 
PicoGreen.  The intra- and inter-assay CVs were 3.4% and 10.4%, respectively.   
Plasma folate  
Plasma folate was analyzed by radioproteinbinding assay (SimulTRAC-S, MP 
Biomedicals, Orangeburg, NY).  This method requires heating plasma to 100°C to denature 
endogenous binding substances.  For folate concentration determination, folic acid as 
pteroylglutamic acid was used for calibration, and its 
125
I-labeled analog was used as the tracer.  
The intra- and inter-assay CVs were 6% and 14%, respectively.   
Blood S-adenosylmethionine 
SAM was measured in whole blood as described previously (Poirier et al. 2001).  SAM 
was detected at 254 nm using a 996 Photodiode Array ultraviolet absorbance detector (Waters 
Inc, Milford MA) and quantified relative to standard curves (Sigma, St. Louis, MO).  The inter-
assay CV was 9.6%.    
Statistical methods 
Descriptive statistics (means and standard deviations) were calculated for the overall 
sample.  Spearman correlations (for continuous variables) and the Wilcoxon rank-sum test (for 
dichotomous variables) were used to examine bivariate associations between As variables and 
other covariates with [
3
H]-methyl incorporation.  Certain confounders (sex, age, and ever versus 




(Pilsner et al. 2007).  Other potential confounders (BMI, years of education, plasma folate, 
plasma vitamin B12, ever betelnut use, and television ownership) were selected based on 
bivariate associations with markers of As exposure and [
3
H]-methyl incorporation in this dataset, 
but none met our criteria for inclusion in the final models (P > 0.20 for associations of the 
potential confounder with both the exposure and the outcome).  
Urinary As was adjusted for urinary Cr using the residual method.  To estimate these 
adjusted values, linear regression models were constructed with log-transformed uCr as the 
predictor of log-transformed uAs.  The residuals from this model were added back to the mean 
log-transformed uAs and exponentiated to get the final uCr-adjusted urinary As values.  The 
uCr-adjusted urinary As variable was used for all analyses involving urinary As.      
We used locally estimated scatterplot smoothing (LOESS) curves of unadjusted 
associations between As exposure variables and [
3
H]-methyl incorporation to visually identify 
potential nonlinear or nonmonotonic relationships.  A SAS macro for restricted cubic splines 
(RCS) was used to estimate associations between markers of As exposure and [
3
H]-methyl 
incorporation adjusted for sex, age, and smoking (Desquilbet and Mariotti 2010).  An RCS 
function represents the sum of piecewise cubic polynomial splines with continuity and 
constraints at 3 to 5 specified knots on the continuous exposure variables (Desquilbet and 
Mariotti 2010).  A Wald chi-square test with K-2 degrees of freedom, where K = number of 
knots and K-2 = number of spline variables, was used to test the null hypothesis of linear 
relationship between the exposure and outcome variables. Failure to reject the null hypothesis of 
linearity would support the use of linear regression to estimate associations between markers of 
As exposure (modeled as untransformed continuous variables) and [
3




Associations were also estimated by modeling As exposure using categorical variables.  
Water As categories were created with the reference category reflecting the Bangladeshi drinking 
water standard for As of 50 µg/L: 0-50 µg/L, 50-100 µg/L, 100-200 µg/L, 200-300 µg/L, and 
300-700 µg/L.  Urinary As was first adjusted for urinary Cr using the residual method; quintiles 
of uAs exposures were then constructed based on these adjusted values.  Blood As was 
categorized based on quintiles.  General linear models with categorized exposure variables were 
used to estimate covariate-adjusted least squares means for [
3




H]-methyl incorporation values were excluded from the analysis if duplicate assays had 
coefficients of variation > 15% (N=48), if less than 10 µg/mL of DNA was used in the assay 
(N=8), or if DPM values were extreme outliers, defined as values that exceeded the boxplot of 
the DPM values by more than three interquartile ranges (N=2).  Additionally, we were unable to 
extract DNA from 1 lysate, leaving a final dataset of N=320 for the analyses.  All statistical 
analyses were conducted using SAS (version 9.2; SAS Institute Inc., Cary, NC); statistical tests 





The characteristics of the study population are shown in Table 1.  The mean age was 43.2 
years, and there were roughly equal numbers of males and females.  Water As concentrations 
ranged from 0.4 to 700 µg/L, with a mean of 145 µg/L.  By design, wells that exceeded the 
Bangladeshi standard of 50 µg/L were the primary drinking water source for 70.9% of 
participants.   
Table 1.  Demographic and clinical data for current study (N=320). 
 
Baseline variables Mean ± SD (range) or N(%) 
Age (yrs) 43.2 ± 8.3 (30 - 63) 
Male 159 (49.7) 
BMI (kg/m
2
) 20.3 ± 3.5 (13.8 - 35.3) 
Underweight  




Ever cigarette smoking 123 (38.4) 
Ever betel nut use 142 (44.4) 




 145 ± 123 (0.4 - 700) 
Water As > 50 µg/L
a
 226 (70.9) 
Urinary As (µg/L) 213 ± 242 (2 - 1800) 
Urinary creatinine (mg/dL) 54.5 ± 43.7 (4.3 - 223.5) 
Urinary As adj. for urinary creatinine 
(µg/L) 
167 ± 122 (10 - 548) 












 1.29 ± 0.50 (0.44 - 3.38) 










All As variables (wAs, bAs, and uAs adjusted for uCr) were negatively correlated with 
[
3
H]-methyl incorporation (Table 2), indicating that As exposure was positively correlated with 
PBMC DNA methylation. Spearman correlation coefficients were similar between groups when 
stratified by folate deficiency (plasma folate < 9.0 nmol/L) (data not shown), suggesting that 
folate status did not modify associations between As exposure markers and [
3
H]-methyl 
incorporation in this sample.  Correlations also were similar between groups defined using more 
stringent definitions of folate deficiency (plasma levels < 8.0 nmol/L, N=69; or < 7.0 nmol/L, 
N=38) (data not shown). We also examined correlations of As and [
3
H]-methyl incorporation 
with blood SAM, which has been hypothesized to mediate the relationship between As exposure 
and DNA methylation (Mass and Wang 1997).  While blood SAM was negatively correlated 
with [
3
H]-methyl incorporation, As was not correlated with blood SAM (Table 2).  In addition, 
methylated metabolites of As were not correlated with [
3
H]-methyl incorporation (data not 
shown).  We did not observe significant correlations between plasma folate and [
3
H]-methyl 
incorporation or blood SAM, or between age and [
3
H]-methyl incorporation (Table 2). 
The shapes of the LOESS curves suggested that [
3
H]-methyl incorporation decreased 
linearly with increasing levels of wAs, bAs, and uAs (data not shown).   Using RCS functions 
with 5 knots, we similarly observed a decrease in [
3
H]-methyl incorporation as As levels 
increased (data not shown).  Tests of departures from the null hypothesis of linear dose-response 




Table 2.  Spearman correlation coefficients for arsenic variables, blood S-adenosylmethionine, plasma folate, and [
3
H]-methyl 




















































 0.75*** 0.63*** 0.75*** -0.14* -0.03 -0.04 -0.01 
Blood As - 0.67*** 0.93*** -0.13* -0.03 -0.06 0.00 




-  - -0.12* -0.04 0.00 0.01 
DPM per 
µg DNA 

















Unadjusted linear regression models of wAs, uAs, or bAs as predictors of [
3
H]-methyl 
incorporation indicated negative associations between As exposure and [
3
H]-methyl 
incorporation that were statistically significant for wAs (B = -28.2; 95% CI: -49.5, -6.8, P = 
0.01) and borderline significant for uAs (B = -20.2; 95% CI: -41.9, 1.4, P = 0.07) and bAs (B = -
254.5; 95% CI: -523.5, 14.6, P = 0.06)  (Table 3).  Estimates for the difference in mean DPM 
estimates associated with a 1-unit increase in As exposure adjusted for sex, age, ever smoking, 
and uCr (for uAs), were similar to unadjusted estimates for wAs (B = -27.6; 95% CI: -49.0, -6.3, 
P = 0.01) and uAs (B = -22.1; 95% CI: -43.8, -0.5, P = 0.045), but the association for bAs was 
attenuated (B = -211.7; 95% CI: -483.9, 60.5, P = 0.13 compared with B =-254.5; 95% CI: -
523.5, 14.6 before adjustment). 
 
Table 3.  Estimated regression coefficients from linear regression models of associations 
between arsenic variables and [
3
H]-methyl incorporation in PBMC DNA (N=320). 
 
 













Unadjusted -20.2 (-41.9, 1.4) 0.07 
Adjusted
b
 -22.1 (-43.8, -0.5) 0.045 
Blood As 
Unadjusted -254.5 (-523.5, 14.6) 0.06 
Adjusted
b









Linear models were constructed to estimate covariate-adjusted mean [
3
H]-methyl 
incorporation levels by As category (Figure 1).  Adjusted mean [
3
H]-methyl incorporation levels 
were similar between the lowest two wAs categories (Figure 1A) and among the lowest three 
uAs quintiles (Figure 1B).  Higher wAs and uAs exposure categories were associated with lower 
estimated mean values for [
3
H]-methyl incorporation: adjusted mean [
3
H]-methyl incorporation 
was 7.0% lower (95% CI: 2.2, 11.8%) among participants in the highest wAs category (300-700 
µg/L) compared with the 0-50 µg/L wAs referent group (P = 0.02, Figure 1A) and was 6.4% 
lower (95% CI: 2.5, 10.3%) among those in the highest uAs quintile compared with the lowest 
uAs quintile (P = 0.02, Figure 1B).   While the pattern of association for [
3
H]-methyl 
incorporation by quintile of bAs was similar to the pattern for wAs and uAs (Figure 1C), the 









Figure 1.  Adjusted mean values of [
3
H]-methyl incorporation by category means of water (A), urinary (B), and blood (C) 
arsenic.  Data points represent estimated mean DPM values (with 95% CI) according to the mean As value for each As exposure 
category, adjusted for gender, age, and ever cigarette smoking.  Categories for blood and urinary As are quintiles, while categories for 



































The primary objective of this study was to assess the dose-response relationship between 
As exposure and global methylation of PBMC DNA in adults chronically exposed to a wide 
range of As in drinking water in Bangladesh.  In agreement with previous findings (Pilsner et al. 
2007, 2009), As exposure was positively associated with global DNA methylation of PBMC 
DNA.   Furthermore, within the range of As exposures in our study, we did not detect a 
statistically significant departure from linearity in the association between As and DNA 
methylation.  Adjusted mean DNA methylation levels were similar among the lower As exposure 
categories but increased in the higher As exposure categories, with the highest estimated mean 
DNA methylation levels in the highest As exposure categories (water As > 300 µg/L).   
However, we cannot rule out the possibility of non-linearity at extremely high doses often used 
in animal studies, e.g., As exposures ranging from 1 to 85 ppm (1,000 to 85,000 µg/L) (Reichard 
and Puga 2010). 
In the present study, we did not find a significant correlation between age and [
3
H]-
methyl incorporation.  It is possible that this is attributable to the demographics of the study 
population.  In our first study of As exposure and global DNA methylation (Pilsner et al. 2007), 
global DNA methylation decreased with age across the 18-29, 30-36, and 37-45 year age 
categories.  However, global DNA methylation levels did not differ significantly between the 37-
45 and 46-66 year age groups (Pilsner et al. 2007).  The narrower age range of the FOX study 
(30-65 years) may therefore have contributed to the lack of a significant association between 
global DNA methylation and age in our study population.   
 We also did not find a correlation between plasma folate and [
3
H]-methyl incorporation.  




As exposure and global DNA methylation (12.6 vs. 8.6 nmol/L, respectively), and a smaller 
proportion was folate deficient (31.3 vs. 64.6%).  Folate might only influence DNA methylation 
under conditions in which folate is limiting. In support of this hypothesis, folic acid 
supplementation was not associated with higher global DNA methylation in study populations 
whose participants were folate sufficient at baseline (Basten et al. 2006; Jung et al. 2011).  In the 
present study population, associations between As and DNA methylation were similar between 
those with and without folate deficiency, even when more stringent definitions of folate 
deficiency were used. However, our ability to evaluate an interaction may have been limited by 
the small numbers of participants with severe folate deficiency. 
Other epidemiologic studies in adults have reported that associations between As 
exposure and global DNA methylation were modified by folate status.  In a study of elderly men 
in Massachusetts, toenail As concentrations were positively associated with Alu methylation 
only among men with plasma folate levels below the study median (Lambrou et al. 2012).  
Although this seemingly contradicts our previous finding of an association between As exposure 
and DNA methylation that was limited to participants with sufficient plasma folate levels 
(Pilsner et al. 2007), as noted by Lambrou et al. (2012), plasma folate levels in our folate-
sufficient group (> 9.0 nmol/L) overlapped with levels in their low folate group (< 32 nmol/L).  
In the present study, all but 6 participants had plasma folate levels < 32 nmol/L.   
Two studies of prenatal As exposure have reported positive associations between As 
exposure and global DNA methylation.  A study of 113 mother/newborn pairs in Bangladesh 
reported that As exposure was associated with higher methylation of LINE-1 in both umbilical 
cord blood and maternal leukocytes (Kile et al. 2012).  In a similar study of 101 mother/newborn 




methylation based on [
3
H]-methyl-incorporation in DNA extracted from umbilical cord blood 
leukocytes (Pilsner et al. 2012).  However, the direction of the associations between maternal As 
exposure and other markers of global DNA methylation (Alu, LINE-1, and LUMA) differed by 
sex: associations were positive in male newborns, but negative in female newborns (Pilsner et al. 
2012).   
Several mechanisms of As-induced epigenetic dysregulation have been proposed.  For 
example, because SAM is required for As metabolism, it has been hypothesized that As 
methylation may influence DNA methylation through competition for methyl groups (Mass and 
Wang 1997).  In an in vitro model, low-dose As exposure decreased SAM concentrations in 
keratinocytes cultured in folic acid-deficient medium (Reichard et al. 2007).  While blood SAM 
was positively correlated with DNA methylation in our study population, it was not correlated 
with markers of As exposure. In addition, in contrast with what one might expect if there were 
competition between DNA methyltransferases and arsenic methyltransferase for SAM, As 
metabolites also were not correlated with DNA methylation in our study population 
Quantitatively, methylation of As and DNA consumes only a very small proportion of total SAM 
(Gamble and Hall 2012).  
There is growing evidence that As exposure may alter post-translational modifications of 
lysine residues in histone tails.  For example, exposure to NaAsO2 led to increased global histone 
acetylation and more open chromatin formation in human HepG2 hepatocarcinoma cells 
(Ramirez et al. 2008), and exposure to InAs
III
 led to increased H3K9 dimethylation (H3K9me2) 
and decreased H3K27 trimethylation (H3K27me3) in human lung carcinoma A549 cells (Zhou et 
al. 2008).  Occupational exposure to inhalable As was significantly associated with H3K4me2 




Italy (Cantone et al. 2011).  In ongoing studies, we are evaluating associations of As exposure on 
global histone modifications in As-exposed Bangladeshis (Chervona et al. 2012) and whether 
these histone marks are additionally associated with global DNA methylation.     
The physiologic implications of increased global DNA methylation in apparently healthy 
adults are unclear, given that global DNA hypomethylation has been associated with multiple 
diseases, including As-induced skin lesions.   An increase in global DNA methylation might be 
associated with an increased spontaneous mutation rate:  methylated cytosines are more prone to 
deamination than unmethylated cytosines, which increases the likelihood of C→T transitions 
(Ehrlich et al. 1986).   Additionally, DNA methylation is associated with heterochromatic 
regions (Beisel and Paro 2011), and somatic mutation density in human cancer genomes were 
found to be highest in heterochromatin-like domains (Schuster-Bockler and Lehner 2012).   
Additionally, previous findings suggest that As-induced global DNA hypermethylation 
might be associated with concomitant increases in As-induced gene-specific promoter 
methylation of tumor suppressors or other disease-related genes.  Kile et al. reported that urinary 
As was associated with both increased LINE-1 methylation and increased P16 promoter 
methylation of leukocyte DNA from umbilical cord blood and maternal blood (Kile et al. 2012).  
Promoter methylation of P16 and P53 tumor suppressors was elevated in both As-exposed 
individuals and As-associated skin cancer cases in West Bengal, India (Chanda et al. 2006), and 
methylation of the tumor suppressors RASSF1A and PRSS3 was associated with toenail As 
concentrations and invasive tumor stage in bladder cancer cases in New Hampshire (Marsit et al. 
2006).  In women from the Argentinean Andes, urinary As concentrations were positively 
associated with promoter methylation of P16 and the DNA repair gene MLH1 (Hossain et al. 




We cannot dismiss the possibility that our findings may be explained by As-induced 
shifts in blood cell type distributions.  In our previous studies (Pilsner et al. 2007, 2009), DNA 
was isolated from PBLs, while our current study used PBMCs.   Because PBMCs are a subset of 
the cells present in PBLs, this would reduce cell type variability to some extent.  Arsenic 
exposure was not significantly associated with proportions of total T, Tc, B, or NK cells in 
PBMCs isolated from As-exposed children in Mexico (Soto-Pena et al. 2006).  Furthermore, 
average [
3
H]-methyl incorporation levels were not significantly different among DNA samples 
isolated from granulocytes, mononuclear cells, and white blood cells (Wu et al. 2011).   
In the present study population, the association of [
3
H]-methyl-incorporation with blood 
As was less statistically significant than associations with water or urine As.  Blood As is the 
most proximal marker of PBMC exposure, so one might expect that blood As would have the 
strongest and/or most significant association with PBMC DNA methylation.  While blood As 
was strongly correlated with water As (Spearman r = 0.75) and urinary As adjusted for urinary 
Cr (Spearman r = 0.93), the range of concentrations of As in blood (1.2 – 57.0 ug/L) was much 
smaller than in urine (10 – 548 ug/L) or water (0.4 – 700 ug/L), resulting in reduced statistical 
power to predict [
3
H]-methyl incorporation.  
This study has several limitations.  First, PBMCs are not known to be direct targets of 
As-induced carcinogenesis.  However, As trioxide is a highly effective therapeutic drug for the 
treatment of acute promyelocytic leukemia (Powell et al. 2010), demonstrating that As 
distributes to bone marrow progenitor cells and influences their cellular function (Petrie et al. 
2009; Soignet et al. 1998).  We do not know the extent to which methylation of PBMC DNA 
reflects the methylation of other target tissues.  Finally, it is possible that our results are 




contaminants in well water that may co-occur with As and potentially confound our observed 
associations.  However, mass spectrometry data for a panel of 33 elements from well water 
samples from our study area indicated that only As and Mn were elevated (Cheng et al. 2004), 
and Mn was not associated with DNA methylation (data not shown).   
In conclusion, As exposure was positively associated with global methylation of PBMC 
DNA in Bangladeshi adults with a wide range of As exposures, consistent with previous studies.  
Furthermore, we did not observe statistical evidence of non-linear relationships between As and 
global DNA methylation within the range of As exposures in our population.  Future studies, in 
addition to investigating the influence of As on histone modifications, should evaluate the 
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Chapter 4:  Arsenic exposure and age are associated with global hydroxymethylcytosine 
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BACKGROUND:  The ten-eleven translocation (TET) family of proteins catalyze the 
conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). 5hmC is believed to 
be an intermediate in DNA demethylation pathways, and changes in global 5hmC levels are 
independently associated with disease.  Arsenic (As) exposure is known to induce changes in 
global DNA methylation, but common methodologies used to assess global DNA methylation do 
not distinguish between 5mC and 5hmC. 
OBJECTIVE:  To assess the association between As exposure and global %hmC in blood cell 
DNA among As-exposed Bangaldeshi adults. 
METHODS:  We examined peripheral blood leukocyte (PBL) DNA from baseline in 200 folate-
deficient adults who were enrolled in a folic acid supplementation trial in Araihazar, Bangladesh 
and peripheral blood mononuclear cell (PBMC) DNA in 378 As-exposed adults in the Folate and 
Oxidative Stress (FOX) cross-sectional study.  Global %5mC and %5hmC of blood cell DNA 
was measured using LC-MS/MS.  Total As in plasma, urine, blood, and well water were 
measured by GFAA spectrometry and/or ICP-MS.   
RESULTS:  In adjusted models, water, blood, urinary, and plasma As were positively associated 
with global %hmC in males and negatively associated with global %hmC in females, and the 
magnitudes of association were consistent between the two study samples.  In addition, age was 
associated with a dose-dependent decrease in global %hmC in both study samples. 
CONCLUSIONS:  Arsenic exposure was positively associated with global %hmC of blood cell 
DNA in males and negatively associated with global %hmC in females.  Further research should 
examine the relevance of As-induced changes in global %hmC in As-related carcinogenesis and 





The most widely studied epigenetic process, DNA methylation, regulates gene expression 
through the covalent addition of a methyl group on cytosines, primarily in CpG dinucleotides, to 
form 5-methylcytosine (5mC) (Bird 1992).  Increased abundance of genomic 5mC is negatively 
associated with chromatin accessibility (Thurman et al. 2012) and gene activation (Siegfried et 
al. 1999), presumably through the recruitment of methyl-CpG-binding proteins (MBPs) and 
disruption of transcriptional machinery (Kass et al. 1997).  DNA methylation has important roles 
in cellular differentiation and mammalian development (Smith and Meissner 2013), and 
abnormal DNA methylation patterns are observed in human cancers (Bergman and Cedar 2013; 
Robertson 2005).   
Although DNA methylation is known to be a dynamic process, the mechanisms of DNA 
demethylation are not well-characterized.  Recently, the ten-eleven translocation (TET) enzymes 
(TET1, TET2, TET3) have been shown to catalyze the oxidation of 5mC to 5-
hydroxymethylcytosine (5hmC) (Tahiliani et al. 2009), which is believed to be an intermediate in 
cytosine demethylation (Ito et al. 2010).  The TET enzymes are dependent upon Fe
2+
 and alpha-
ketoglutarate (α-ketoglutarate) as cofactors (Tahiliani et al. 2009); the latter is generated from the 
oxidative decarboxylation of isocitrate by the isocitrate dehydrogenase (IDH) enzyme family 
(Reitman and Yan 2010).  The maintenance DNA methyltransferase DMNT1 poorly recognizes 
5hmC (Valinluck and Sowers 2007), which results in passive loss of DNA methylation through 
DNA replication.  5hmC is also actively removed through pathways involving thymine DNA 
glycosylase (TDG) and base excision repair (BER) (Guo et al. 2011).    
In addition, 5hmC might have independent regulatory roles in gene expression (Song et 




2009; K. E. Szulwach et al. 2011).  In general, enrichment of 5hmC is positively correlated with 
gene expression and is associated with enhancer regions and exon bodies (Stroud et al. 2011; 
Keith E. Szulwach et al. 2011).  TET1 was originally identified as a partner gene to the mixed 
lineage leukemia (MLL) gene translocation that is commonly found in acute myeloid leukemia 
(AML) cases (Lorsbach et al. 2003; Ono et al. 2002).  Mutations in TETs and IDHs have since 
been identified in myeloid malignant diseases, suggesting that 5hmC plays a role in 
hematopoietic differentiation and regulation (Murati et al. 2012).   
Arsenic (As), a Class I human carcinogen, is a ubiquitous environmental contaminant 
worldwide (Hughes et al. 2011).  Exposure to As is particularly high in Bangladesh, where over 
70 million people are chronically exposed to As in well water at concentrations above the World 
Health Organization standard of 10 µg/L (Loewenberg 2007).  While the mechanisms of As 
toxicity in humans are not fully understood, one proposed pathway is through epigenetic 
dysregulation (Ren et al. 2011).  Chronic As exposure has been associated with changes in global 
and gene-specific methylation of human peripheral blood cell DNA in numerous population-
based studies (Kile et al. 2012; Lambrou et al. 2012; Majumdar et al. 2010; Pilsner et al. 2009; 
Pilsner et al. 2012).  Paradoxically, arsenic trioxide (As2O3), in combination with all-trans 
retinoic acid (ATRA), is a highly effective treatment for acute promyelocytic leukemia (APL) 
(Lo-Coco et al. 2013), a subtype of AML that is believed to occur, in part, through epigenetic 
dysregulation of myeloid cell differentiation (Uribesalgo and Di Croce 2011).   However, the 
relationship between As exposure and 5hmC in human blood cell DNA is unknown. 
To our knowledge, global %hmC has not been measured in white blood cell DNA in a 
population-based human study.  In this study, we used liquid chromatography-tandem mass 




independent samples of Bangladeshi adults, and we examined the associations of gender, age, 
and As exposure with global %mC and %hmC.  The first sample examined peripheral blood 
leukocyte (PBL) DNA from baseline samples from the Nutritional Influences of Arsenic 
Toxicity (NIAT) randomized controlled trial (Gamble et al. 2006), which examined the influence 
of folic acid supplementation on As metabolism.  Our second sample examined peripheral blood 
mononuclear cell (PBMC) DNA from subjects in the Folate and Oxidative Stress (FOX) study 
(Hall et al. 2013), a cross-sectional study designed to assess the relationship between chronic As 




SUBJECTS AND METHODS 
Eligibility criteria and study design 
The NIAT folic acid intervention study design has described previously (Gamble et al. 
2006).  Briefly, NIAT participants were selected from the Health Effects of Arsenic Longitudinal 
Study (HEALS) cohort, which at the time of NIAT recruitment, included 11,746 men and 
women between the ages of 18 and 65 years in Araihazar, Bangladesh (Ahsan et al. 2006).   
NIAT participants were drawn from a cross-sectional study of 1,650 HEALS participants 
designed to assess the prevalence of folate and cobalamin deficiencies in Bangladesh; we 
randomly selected 200 NIAT participants from the 550 subjects in the lowest tertile of plasma 
folate (Gamble et al. 2005).   Participants were excluded if they were pregnant or cobalamin 
deficient (plasma cobalamin ≤ 185 pmol/L) or were taking nutritional supplements.  As 
described elsewhere (Pilsner et al. 2007), high-quality DNA samples were obtained from 195 
whole blood samples drawn from participants at baseline.  For the purposes of the current study, 
only baseline samples were included in the analysis. 
The details of the FOX study design are described in Chapter 3.  Unlike in the NIAT 
study, participants in FOX were not selected based on folate or cobalamin nutritional status. 
Oral informed consent was obtained by our Bangladeshi field staff physicians, who read 
an approved consent form to the FOX and NIAT study participants. The FOX and NIAT studies 
were approved by the institutional review boards of the Bangladesh Medical Research Council 
and of Columbia University Medical Center.     
Analytic techniques 
 Methods for water As, urinary As, urinary Cr, blood As, PBMC DNA isolation, plasma 




Chapter 3.  Analytic methods for the NIAT study, brief descriptions of any discrepancies in 
methodology between the NIAT and FOX studies, and methods for global %mC and %hmC in 
NIAT and FOX are outlined in this chapter. 
Sample collection and handling 
For the NIAT study, blood samples were drawn in the field, as described previously 
(Pilsner et al. 2007).  Blood was collected in heparin-containing evaporated tubes, placed in 
IsoRack cool packs (Brinkmann Instruments, Westbury, NY) in hand-carried coolers, and 
transported to the field clinic in Araihazar within 4 h of collection.  For the FOX study, blood 
samples were drawn at the field clinic laboratory in Araihazar and immediately processed.   All 
blood samples were centrifuged at 3,000 × g for 10 min at 4°C, and buffy coat and plasma were 
separated from red cells.  Aliquots of blood and plasma were stored at –80°C, and urine samples 
were stored at –20°C in acid-washed polypropylene tubes.  Blood, plasma, and urine samples 
were then shipped on dry ice to Columbia University.    
Water As 
  In NIAT, well water As concentrations were measured in a survey of all tube wells in the 
NIAT study region from January to May 2000.  Water samples were analyzed using graphite 
furnace atomic absorption (GFAA) spectrometry, with a detection limit of 5 µg/L; water samples 
with non-detectable As using GFAA were analyzed with inductively coupled mass spectrometry 
(ICP-MS), with a detection limit of 0.1 µg/L.   
In FOX, well water samples were collected at the time of the FOX recruitment visit, and 
all water samples were analyzed using ICP-MS.  The intra- and inter-assay coefficients of 
variation (CVs) were 6.0% and 3.8%, respectively.   













), and DMA (DMA
V
)—were separated using HPLC, 
and metabolite concentrations were measured using ICP-MS, with a limit of detection of 0.1 





MMA, and DMA, excluding the concentrations of AsC and AsB.  Urinary creatinine (uCr) was 
analyzed by a colorimetric assay based on the Jaffe reaction (Slot 1965) and used to adjust for 
urine concentration.  For FOX, the intra-assay CVs were 4.5% for As
V
, 3.8% for As
III
, 1.5% for 
MMA, and 0.6% for DMA, and the inter-assay CVs were 10.6% for As
V
, 9.6% for As
III
, 3.5% 
for MMA, and 2.8% for DMA.   
Total blood As 
Total blood As (bAs) was analyzed using Perkin-Elmer Elan DRC II ICP-MS equipped 
with an AS 93+ autosampler, with a limit of detection of 0.1 μg/L, as previously described (Hall 
et al. 2006).  The intra- and inter-assay CVs were 3.2% and 5.7%, respectively.   
Total plasma As 
In NIAT, total plasma As was analyzed using dynamic reaction cell (DRC) technology 
(Elan DRC II ICP-MS; Perkin- Elmer) equipped with an AS 93+ autosampler, as previously 
described (Pilsner et al. 2007).  The intra-assay CV was 10.4%.   Plasma As was not measured in 
the FOX study. 
PBL DNA isolation 
In NIAT, to isolate DNA from PBLs, 1 mL red blood cell solution (GenomicPrep Blood 
DNA Isolation Kit; Amersham Biosciences, Piscataway, NJ)  was added to the buffy coat, and 




shipment to Columbia University.  DNA was isolated from PBL lysates using silica membrane 
spin columns according to the manufacturer’s protocol.   
PBMC DNA isolation 
In FOX, the protocol for DNA isolation from PBMCs was outlined in Chapter 2.  Briefly, 
PBMCs were isolated from whole blood using Ficoll solution, and DNA was isolated from 
PBMC lysates with Protein Precipitation Solution (5-Prime, New York, NY) and isopropanol 
extraction according to the manufacturer’s protocol.   
Global %mC and %hmC 
 Global %mC and %hmC was analyzed using liquid chromatography-tandem mass 




N]methyldeoxycytidine internal standards, with methods adapted from the protocols of 
Quinlivan and Gregory (Quinlivan and Gregory 2008).  The LC-MS/MS method allows for the 
sensitive quantitation of mC and hmC concentrations in digested genomic DNA. 
DNA samples were hydrolyzed into nucleosides according to the protocol of Quinlivan 
and Gregory (Quinlivan and Gregory 2008).  A Digest Mix (per 100 samples) was prepared 
containing 250 U Benzonase (Sigma-Aldrich, St. Louis, MO), 300 mU phosphdiesterase (Sigma-
Aldrich), and 200 U alkaline phosphatase (Sigma-Aldrich), made up to 5 mL with buffer [10 
mM Tris–HCl, 50 mM NaCl, 10 mM MgCl2 (pH 7.9)].  DNA samples were hydrolyzed by 
adding 50 μL Digest Mix to 50 μL DNA sample (1 μg DNA in 50 μL water) and incubating at 
37°C for 6 h.  All samples within each study were digested in one day, using one batch of Digest 
Mix.    











Gregory 2008).  Cryopreserved Escherichia coli K12 grown in minimal medium (New England 
Biolabs, Ipswich, MA) was inoculated into 10 ml [
15
N]-labeled growth medium containing 50 
mM NaCl, 25 mM KH2PO5, 70 μM CaCl, 2.1 mM MgSO4, 10 mM glucose, and 50 mM 
[
15
N]NH4Cl (Cambridge Isotopes, Andover, MA), pH 7.2, and incubated while shaking at 37°C.  
After log-phase growth was reached, 10 μL of culture was transferred to 50 mL of fresh [
15
N]-
labeled growth medium and grown to lag-phase.  [U-
15
N]DNA was isolated using the 
ArchivePure DNA Extraction Kit (5-Prime) according to the manufacturer’s protocol for gram-
negative bacterial culture and reconstituted in buffer containing 10 mM Tris–HCl, 50 mM NaCl, 
1 mM dithiothreitol, and 10 mM MgCl2 (pH 7.9).  [U-
15
N]DNA concentrations were measured 
using NanoDrop and adjusted to ~50 μg/mL.  To increase the abundance of [
15
N3]-mdC, 100 U 
SssI (CpG) methyltransferase (New England Biolabs) and 20 μl SAM (32 mM) were added to 
[U-
15
N]DNA (per 100 ug DNA) and incubated at 37°C for 4 h.  Hypermethylated [U-
15
N]DNA 
samples were digested by adding 250 U Benzonase (Sigma), 300 mU phosphdiesterase (Sigma) 
and 200 U alkaline phosphatase (Sigma) (per 100 μg DNA), and incubating at 37°C for 12 h.  
Two separate batches of [U-
15
N]DNA internal standard were synthesized (one batch for FOX, 
one batch for NIAT), but all experimental samples within the same study received [U-
15
N]DNA 
internal standard from the same batch. 
Hydrolyzed DNA samples (100 μL) were transferred to vials (Agilent Technologies, 
Santa Clara, CA) with 4 μL [U-
15
N]DNA internal standard and analyzed in the Biomarkers Core 
Lab at Columbia University with the Agilent 6430 Triple Quadrupole LC-MS (Agilent 
Technologies, Santa Clara, CA).  10 μL of sample was injected onto a reverse phase UPLC 
column (Eclipse C18 2.1 × 50 mm, 1.8 µ particle size, Agilent) equilibrated and eluted (100 




enrichment scanning was performed in positive ionization mode using selected reaction 
monitoring (SRM) mode, monitoring the mass to charge (m/z) transitions of dC: 228.1→112.0; 
[
15
N3]dC: 231.1→115.0; mdC: 242.1→126.0; [
15
N3]mdC 245.1→129.0; and hmdC: 
258.1→142.1.  
A standard curve was run with each batch of experimental samples.  Stock mixtures of 
dC, mC, and hmC were created with known concentrations and proportions of mC and hmC to 
dC, and a standard curve was prepared using serial dilutions.  To correct for recovery, 4 ul of [U-
15
N]DNA internal standard was added to 50 ul of each dilution.  Standard curves were 
constructed by plotting the analyte/internal standard ratio (M+0/M+3) against the known 
concentrations of dC, mC, and hmC for each dilution.  The concentrations of dC, mC, and hmC 
in each experimental sample were calculated from the standard curves using the analyte/internal 
standard ratio (M+0/M+3) by reverse prediction, and %mC and %hmC were calculated by 
dividing the concentrations of mC and hmC, respectively, by the total dC sum (dC + mC + 
hmC).   
In the FOX study, one large aliquot (10 μg) of a DNA control sample was hydrolyzed, 
and aliquots of this control sample were run in duplicate with each batch of experimental 
samples; for this sample, the intra- and inter-assay CVs for %mC were 0.5 and 2.0%, 
respectively, and for %hmC, the intra- and inter-assay CVs were 7.0 and 14.4%, respectively.  In 
the NIAT study, we selected a subset of 48 subjects for which different aliquots of their original 
DNA samples were hydrolyzed and analyzed in a different batch than the overall samples, using 
a different batch of [U-
15
N]DNA internal standard; for these samples, the inter-assay CVs for 




was randomized in each study, and the LC-MS/MS operators were blinded to the identities of the 
samples.   
Plasma folate and cobalamin 
Plasma folate and cobalamin were analyzed by radioproteinbinding assay (NIAT:  
Quantaphase II, Bio-Rad Laboratories, Hercules, CA; FOX: SimulTRAC-S, MP Biomedicals, 
Orangeburg, NY).  In NIAT, the intra- and inter-assay CVs for folate were 3% and 11%, 
respectively, and the intra- and inter-assay CVs for cobalamin were 4% and 8%, respectively.  In 
FOX, the intra- and inter-assay CVs for folate were 6% and 14%, respectively, and the intra- and 
inter-assay CVs for cobalamin were 4% and 9%, respectively. 
Plasma total homocysteine 
Plasma total Hcys was assayed using the protocol of Pfieffer et al. (Pfeiffer et al. 1999), 
as previously described (Gamble et al. 2005)  In NIAT, the intra- and inter-assay CVs for plasma 
total Hcys were x and x%, respectively; in FOX, the intra- and inter-assay CVs for plasma total 
Hcys were 4 and 9%, respectively.    
Statistical methods 
Descriptive statistics (means and standard deviations for continuous variables, 
proportions for dichotomous variables) were calculated for the FOX and NIAT samples.  
Spearman correlations were used to examine bivariate associations between continuous study 
characteristics and global %mC and %hmC, overall and stratified by gender.  Since the global 
%mC and %hmC variables were normally distributed in the datasets, we used t-tests to compare 





Linear regression models were constructed with As exposure variables (wAs, uAs, bAs, 
and pAs) as predictors and global %mC and %hmC as outcomes, with and without adjusting for 
confounders.  Since the directions of the bivariate associations between As variables and global 
%mC and %hmC differed by gender, we built linear regression models separately by gender.  
Confounders (age, BMI, cigarette smoking, and betelnut use) were selected based on biologic 
plausibility and their bivariate associations with As exposure variables and global %mC and 
%hmC in each dataset.  Differences in parameter estimates by gender were examined using Wald 
tests.   
Urinary As was adjusted for urinary Cr using the residual method.  To estimate these 
adjusted values, linear regression models were constructed with log-transformed uCr as the 
predictor of log-transformed uAs.  The residuals from this model were added back to the mean 
log-transformed uAs and exponentiated to get the final uCr-adjusted uAs values.  The uCr-
adjusted urinary As variable was used for all analyses involving uAs.      
All statistical analyses were conducted using SAS (version 9.3; SAS Institute Inc., Cary, 






NIAT and FOX study characteristics  
 
The demographic and clinical characteristics of the NIAT and FOX study populations are 
presented in Table 1.  Both studies had equal numbers of males and females, and there were 
similar proportions of participants who reported ever smoking cigarettes or chewing betelnut.  
Since the minimum inclusion age differed between the FOX and NIAT studies (30 y vs. 18 y), 
the mean age was higher in FOX than in NIAT.  Also due to differences in sampling designs 
between the studies, the mean wAs concentration was higher in FOX.  Participants in NIAT were 
randomly selected from a subset of individuals who had previously been identified as having low 
folate (plasma folate ≤ 9 nmol/L) and sufficient cobalamin (plasma cobalamin > 185 pmol/L), 
whereas FOX participants were not selected based on folate or cobalamin status; as such, mean 
plasma cobalamin was higher in NIAT than in FOX, while mean plasma folate was lower. 
 
Global %mC and %hmC in NIAT and FOX studies  
 
We isolated DNA from two different subpopulations of peripheral blood cells:  in NIAT, 
DNA was isolated from PBLs, while in FOX, DNA was isolated from PBMCs, a subset of PBLs 
comprised mainly of lymphocytes (Table 1).  Mean global %mC was higher in NIAT (4.61%) 
than in FOX (4.57%) (Table 1).  Mean global %hmC was two orders of magnitude lower than 
global %mC; mean global %hmC was slightly higher in NIAT (0.0325%) than FOX (0.0307%), 
but the range of global %hmC values in FOX (0.0147 – 0.0505%) was wider than in NIAT 
(0.0245 – 0.0443%) (Table 1).  In NIAT, global %mC and %hmC were not correlated with one 
another (Spearman r = 0.02, P = 0.82), while in FOX, global %mC and %hmC were positively 















NIAT (N=190) FOX (N=376) 
Mean ± SD (range) 
or N(%) 
Mean ± SD (range)  
or N(%) 
Demographic   
Age (years) 38.4 ± 10.2 (19 - 66) 43.1 ± 8.3 (30 - 63) 
Male 92 (48.4) 183 (48.7) 
BMI (kg/m
2
) 19.9 ± 3.1 (13.4- 32.5) 20.4 ± 3.5 (13.8 - 35.3) 
Ever smoked cigarettes  76 (40.0) 137 (36.4) 
Ever chewed betel nut 72 (37.9) 160 (42.6) 
Education (years)   
0 years 78 (39.0) 150 (39.8) 
1-5 years 75 (37.5) 134 (35.5) 
> 5 years 47 (23.5) 92 (24.4) 
Arsenic exposure   
Water As (µg/L) 105 ± 103 (0.1 - 435) 139 ± 124 (0.4 - 700) 
Water As > 50 µg/L 118 (62.1) 226 (70.9) 
Urinary As (µg/L) 136 ± 125 (7 - 741) 206 ± 236 (2 - 1800) 
Urinary As adj. for uCr 
(µg/L) 
121 ± 99 (12 - 543) 160 ± 120 (10 - 548) 
Blood As (µg/L) 9.8 ± 5.1 (3.3 – 28.8)
c
 13.4 ± 9.8 (1.2 - 57.0) 
Plasma As (µg/L) 6.9 ± 3.3 (2.2 – 19.4) N/A 
Nutritional status   
Plasma folate (nmol/L) 8.1 ± 4.0 (3.0 – 44.7) 12.9 ± 7.2 (2.4 - 60.6)
c
 





285 ± 128 (118 - 920) 203 ± 113 (44 - 1183)
d
 
DNA methylation   
Cell type for DNA 
extraction 
Peripheral blood  
leukocytes 
Peripheral blood  
mononuclear cells 
Global %mC 4.61 ± 0.10 (4.36 – 4.99) 4.57 ± 0.12 (4.24 – 4.85) 
Global %hmC 
0.0325 ± 0.0038  
(0.0245 – 0.0443) 







We examined the correlations between global %mC and %hmC and values from the 
[
3
H]-methyl incorporation assay, which assesses global DNA methylation by measuring 
incorporation of tritiated methyl groups into unmethylated CpG sites (thus, values are negatively 
related to global DNA methylation).  We found that global %mC was negatively correlated with 
[
3
H]-methyl incorporation in both NIAT (Spearman r = -0.16, P = 0.03) and FOX (Spearman r = 
-0.24, P < 0.0001), demonstrating agreement between the two methods.  Interestingly, global 
%hmC was also negatively correlated with [
3
H]-methyl incorporation in NIAT (Spearman r = -
0.21, P = 0.004) and FOX (Spearman r = -0.24, P < 0.0001).  
 
Figure 1.  Spearman correlations between global %mC and global %hmC in human DNA 
from two different subpopulations of WBCs.  Global %mC (x-axis) and global %hmC (y-axis) 
are plotted for each subject in the NIAT (Figure 1A) and FOX (Figure 1B) samples. 
 
Global %mC is higher in males 
Mean global %mC was 6% higher in males than females in both FOX (males vs. females, 
4.60 vs. 4.54%, P < 0.0001) and NIAT (males vs. females, 4.64 vs. 4.58%, P < 0.0001).  To 




groups, we plotted mean global %mC in NIAT and FOX, stratified by gender and age group 
(Figures 2A and 2B).   Males had higher mean global %mC than females across all age groups in 
both studies (Figures 2A and 2B).  In NIAT, we did not observe a decline in global %mC with 
age in males, although in females, there was a borderline significant 0.05% decrease (P = 0.06) 
in mean global %mC in the 48-63 y age group compared to the 18-29 y group (Figure 2A).  In 
FOX, mean global %mC decreased with increasing age in both genders, with a 0.05-0.06% 
decrease in in the 48-63 y age groups compared to the 30-35 y groups (Figure 2B).   
To explore whether global %mC was associated with other demographic characteristics, 
we constructed regression models with demographic variables as predictors of global %mC and 
global %hmC, shown in Table 2.   Based on results from bivariate analyses, we included gender, 
cigarette smoking, betelnut use, years of education, age, BMI, and wAs variables in the models 
simultaneously.  The R
2
 values for these models were 11.9 and 11.7% for NIAT and FOX, 
respectively (Table 2).  The negative association between female gender and global %mC 
persisted after adjustment for covariates, with an estimated decrease in global %mC of 0.064% in 
NIAT (95% CI, -0.103, -0.024) and 0.042% in FOX (95% CI, -0.074, -0.011) compared to males 
(Table 2).  Gender explained a large proportion of the variance in global %mC (Δ in R
2 
= 4.9% 
in NIAT, 1.7% in FOX).  Other predictors were not associated with global %mC consistently 
between the two study samples.  In FOX, ever cigarette smoking was associated with a 0.034% 
increase (95% CI, 0.002, 0.067) and age (10-year unit increase) was associated with a 0.029% 
decrease (95% CI, -0.045, -0.045) in global %mC, but these associations were not observed in 






Global %hmC declines with age 
No gender differences were observed for mean global %hmC (NIAT, males vs. females, 
0.032 vs. 0.033%, P = 0.63; FOX, males vs. females, 0.031 vs. 0.031%, P = 0.71).  When mean 
global %hmC was assessed by gender and age range (Figures 2C and 2D), a steady decrease in 
mean global %hmC was observed with increasing age groups in both genders (Figures 2C and 
2D).  Parameter estimates for global %hmC from regression models adjusting for gender, 
cigarette smoking, betelnut use, years of education, age, BMI, and wAs are presented in Table 3.  
The R
2
 values for the global %hmC models were 9.1 and 7.6% for NIAT and FOX, respectively 
(Table 2), indicating that these demographic variables explained a smaller proportion of the 
variance in global %hmC, compared to global %mC.   
Consistent with the observations in Figure 1, a 10-year increase in age was associated 
with a 0.0011% decrease in global %hmC in NIAT (95% CI: -0.0017, -0.0004) and 0.0015% 
decrease in FOX (95% CI: -0.0023, -0.0007) (Table 3).  Age explained the largest proportion of 
the variance in global %hmC by a wide margin (Δ in R
2 
= 5.6% in NIAT, 3.3% in FOX).  BMI 
(5-kg/m
2
 unit increase) was associated with a decrease in global %hmC of 0.0006% in NIAT 
(95% CI: -0.0015, 0.0003) and 0.0009% in FOX (95% CI: -0.0018, -0.0001) and explained 
approximately 1% of the variance in global %hmC in both samples (Table 3).  In FOX, females 
had an estimated 0.0017% increase in global %hmC compared to males (95% CI: 0.0001, 
0.0033), but no difference in global %hmC by gender was found in NIAT (Table 3).  Similarly, 
cigarette smoking and increased years of education were positively associated with global %hmC 





Figure 2.  Global %mC and %hmC, by gender and age range, in NIAT and FOX samples.  Plots represent mean ± SD values for 








Table 2.  Regression coefficients for associations between study characteristics and global 












Predictor Level or unit B (95% CI) 
Δ in R2 
(%) 
B (95% CI) 
Δ in R2 
(%) 
Gender   4.9  1.7 
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Betel chewing    0.3  0.0 








Education   0.2  0.7 
 0 years ref.  ref.  










































 Table 3.  Regression coefficients for associations between study characteristics and global 













Predictor Level/unit B (95% CI) 
Δ in R2 
(%) 
B (95% CI) 
Δ in R2 
(%) 
Gender   0.2  1.1 
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Betel chewing   0.6  0.0 








Education   1.0  2.0 
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†





Arsenic is associated with increased global %mC in males  
 
We next examined the relationships between As exposure and global %mC.  As shown in 
Table 2, water As was not associated with global %mC in the overall study samples in NIAT and 
FOX, and other As variables were not correlated with global %mC in bivariate analyses 
(Appendix, Table E1).  Based on previous studies from our group (Pilsner et al. 2012) and others 
(Nohara et al. 2011) that reported associations between As exposure and DNA methylation that 
were modified by gender, we additionally examined the relationships between As exposure and 
global %mC separately in males and females.  In bivariate analyses, As exposure was positively 
correlated with global %mC in males, but no consistent correlations between As exposure and 
global %mC was observed in females (Appendix, Table E1).  We built regression models with 
As exposure variables predicting global %mC, adjusted for age, BMI, cigarette smoking, and 
years of education, stratified by gender (Figure 3).  In males, As exposure was positively 
associated with global %mC at marginal statistical significance (P < 0.10 for wAs, uAs, and bAs 
in NIAT and FOX) (Figure 3).  In females, no consistent associations between the As exposure 
variables and global %mC were observed (Figure 3). 
 
Arsenic is associated with increased global %hmC in males, decreased global %hmC in females    
We also examined the relationship between As exposure and global %hmC.  In bivariate 
analyses, the As exposure variables were not correlated with global %hmC in the overall samples 
(Appendix, Table E1).  Upon stratification by gender, As exposure was positively correlated with 
global %hmC in males and negatively correlated with global %hmC in females (Appendix, Table 
E1).  Regression models for As exposure variables predicting global %hmC, stratified by gender 




Although the parameter estimates for the As variables predicting global %hmC were not all 
significant at P < 0.05, the estimates were consistently positive in males and negative in females, 
and the magnitudes of the estimates were similar between the two samples (Figure 4).  The 
associations for the As exposure variables (wAs, uAs, bAs, and pAs) predicting global %hmC 
were significantly different by gender, as determined by Wald tests (P < 0.05 for all As exposure 





Figure 3.  Adjusted regression coefficients for As exposure variables predicting global 
%mC, stratified by gender, in NIAT and FOX samples.  Plots represent B ± 95% CI for each 
As variable predicting global %mC from regression models adjusting for age, BMI, ever 





Figure 4.  Adjusted regression coefficients for As exposure variables predicting global 
%hmC, stratified by gender, in NIAT and FOX samples.  Plots represent B ± 95% CIs for 
each As variable predicting global %hmC from regression models adjusting for age, BMI, ever 







 In this study, we examined the associations of gender, age, and As exposure with global 
%mC and %hmC in different subtypes of WBC DNA from two independent samples of 
Bangladeshi adults.  We observed that global %mC was higher in males, and global %hmC 
decreased with age.  Arsenic exposure was associated with global %hmC differentially by 
gender:  In males, As exposure was positively associated with global %hmC, while in females, 
As exposure was negatively associated with global %hmC.  The directions and magnitudes of the 
parameter estimates for age and As exposure variables were consistent between the two samples.  
Our results suggest that in DNA isolated from human PBLs and PBMCs, age is associated with a 
dose-dependent decrease in global %hmC, and chronic As exposure is associated with gender-
specific changes in global %hmC.   
Few studies have examined global 5hmC content in human blood cell DNA.  While 
Nestor et al. (2012) found barely-detectable levels of 5hmC in human PBL DNA using an 
immuno dot-blot method (N=2 biological samples), Pronier et al. (2011) detected measurable 
5hmC in PBLs using HPLC-MS-MS in myeloproliferative neoplasm patients and healthy 
controls.  The range of global %hmC in PBL and PBMC DNA in our study (0.0147-0.0505% of 
total cytosine) was markedly lower than the global %hmC content in human brain (0.67% of 
total DNA, or 0.13% of total cytosines, assuming a cytosine proportion of 20% in human DNA) 
and liver (0.46% of total DNA, or 0.092% of total cytosines) and similar to global %hmC in lung 
(0.14% of total DNA, or 0.028% of total cytosines) and breast (0.05% of total DNA, or 0.010% 
of total cytosines), as reported by Li and  Liu (2011).  We found no correlation between global 
%mC and %hmC in DNA isolated from PBLs, consistent with a previous report that global 5mC 




%mC and %hmC were strongly correlated in DNA isolated from PBMCs, suggesting that global 
%mC and %hmC content might be correlated within a specific tissue or cell type. 
Most of the current literature on the aging process and 5hmC dynamics has examined 
5hmC in murine brain tissue.  In mouse models, 5hmC content in the hippocampus increases 
from birth through 12 months (Song et al. 2011) and is preferentially acquired in 
developmentally-activated genes (K. E. Szulwach et al. 2011); through 24 months, 5hmC content 
has been shown to increase in hippocampal tissues (Chen et al. 2012; Chouliaras et al. 2012), as 
well as decrease in mitochrondrial DNA (mtDNA) in the frontal cortex (Dzitoyeva et al. 2012).  
Little has been reported on the relationship between age and 5hmC in other tissues.  Age was 
positively correlated with global 5mC and 5hmC (measured by enzyme-linked immunosorbent 
assay) in a small study of human sperm DNA samples from 15 fertile donors (Jenkins et al. 
2013), but to our knowledge, no other studies have examined the relationship between age and 
5hmC in samples from non-diseased animals or humans. 
We found that age was strongly associated with global %hmC depletion in blood cell 
DNA from healthy adults.  Aging is associated with hematopoietic and immunological decline 
and increased risk of leukemias (Henry et al. 2011), which might result, in part, from a decline in 
hematopoietic stem cell integrity (Geiger et al. 2013).  Busque et al. (2012) found a marked 
increase in the presence of Tet2 somatic mutations in granulocyte DNA from elderly patients 
with age-associated skewing (AAS) of X-inactivation ratios in blood cells compared with age-
matched healthy individuals, as well as a decrease in 5hmC levels in myeloid cells with age; the 
authors speculated that TET2-mediated 5hmC depletion may play an important role in the aging 
hematopoietic system (Busque et al. 2012).  Our findings support the concept that global %5hmC 




decline.  We found that age was similarly associated with global %hmC decline in DNA isolated 
from both PBLs (primarily granulocytes) and PBMCs (primarily lymphocytes), suggesting that 
the age-related decrease in 5hmC occurs in both myeloid and lymphoid blood cells.  Global loss 
of 5hmC is observed in numerous human cancers (Haffner et al. 2011); if aging is found to have 
a causal effect on 5hmC decline, it is possible that therapies to prevent 5hmC loss might reduce 
the risk of age-related leukemias and other malignancies. 
Arsenic exposure was associated with gender-specific changes in global %hmC of PBL 
and PBMC DNA.  The implications of this finding are unclear.  As stated earlier, As2O3 in 
combination with ATRA is a successful treatment in APL, an AML subtype characterized by the 
fusion of the promyelocytic leukaemia (PML) gene to retinoic acid receptor alpha (RARα) 
(Goddard et al. 1991).  One proposed mechanism of PML–RARα-induced leukaemogenesis is 
through its interaction with polycomb repressive complexes (PRC2) and subsequent 
transcriptional repression via tri-methylation of histone H3 lysine 27 (H3K27me3), which 
interferes with myeloid differentiation (Shih et al. 2012).  Interestingly, in AML subtypes that 
are normally ATRA-resistant, lysine-specific demethylase 1 (LSD1) inhibitors “unlock” ATRA’s 
pro-differentiation functionality:  in both ATRA-responsive and insensitive cells, the co-
treatment of LSD1 inhibitors with ATRA enhances the expression of genes associated with 
myeloid differentiation by increasing gene-specific dimethylation of histone H3 lysine 4 
(H3K4me2) (Schenk et al. 2012), a mark associated with gene activation (Pekowska et al. 2010).  
This suggests that in APL, As2O3 induces epigenetic modifications that potentiate ATRA-driven 
myeloid differentiation.  Since increased 5hmC content is associated with accessible chromatin 




plausible that the treatment effects of As2O3 occur through increases in global hmC levels, 
consistent with our observations in males. 
Arsenic exposure might influence several key components involved in 5hmC dynamics.    
In cell culture, arsenite and its methylated metabolites have been shown to decrease BER activity 
(Ebert et al. 2011), which would interfere with active 5hmC demethylation.  Arsenic is a known 
inhibitor of pyruvate dehydrogenase (PDH), an enzyme that transforms pyruvate into acetyl-
CoA, a molecule involved in the Krebs cycle (Schiller et al. 1977).  The TET cofactor α-
ketoglutarate is a critical intermediate in the Krebs cycle, and deficiencies in the Krebs cycle 
enzyme succinate dehydrogenase (SDH) are associated with decreased 5hmC levels in mice 
(Letouzé et al. 2013) and humans (Mason and Hornick 2013), suggesting that aberrant Krebs 
cycle metabolism might contribute to epigenetic dyregulation during carcinogenesis (Garraway 
and Lander 2013).  Arsenic exposure has also been linked with alterations of histone 
modifications in animal models (Cronican et al. 2013) and human studies (Cantone et al. 2011; 
Chervona et al. 2012), which could induce downstream effects on 5hmC.  However, it is still not 
clear why we observed gender-specific associations of As exposure and global %hmC.  Future 
research in experimental models should examine the potential mechanisms through which As 
exposure might induce changes in 5hmC content in blood cells and the biologic basis for a 
gender-specific effect. 
Similar magnitudes of association for age and As exposure were observed in DNA 
isolated from different subtypes of WBCs in two independent samples of adults, which reduces 
the possibility that our findings were observed by chance and/or are explained by shifts in blood 
cell subtypes or counts.  Nevertheless, given the observational nature of our study, we cannot 




also cannot determine the precise mechanisms through which the aging process and/or As 
exposure might induce global 5hmC changes, but our findings are useful for hypothesis 
generation for future experimental studies.   
In conclusion, in two independent samples of Bangladeshi adults, we observed that age 
was associated with decreased global %hmC of PBL and PBMC DNA and that As exposure was 
associated with gender-specific changes in global %hmC.  Future studies should examine the 
relevance of global 5hmC as a marker of age-related decline and disease risk, in addition to the 
potential causative role of aging on global 5hmC levels.  Studies should also examine the 
mechanisms through which As exposure might induce changes in 5hmC content in human blood 
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Appendix, Table E1.  Spearman correlations between As exposure variables and age with 
global %mC and %hmC, overall and stratified by gender, in NIAT and FOX samples. 
 
†
p<0.10; *p<0.05; **p<0.01 
 
a.  Global %mC       







 NIAT -0.03 -0.07 0.20* -0.01 0.03 
 FOX 0.01 0.04 0.09 --- -0.12* 







 NIAT 0.09 -0.04 0.22 0.01 -0.01 
 FOX 0.11 0.13
†
 0.15* --- -0.18* 







 NIAT -0.14 -0.03 0.10 -0.03 -0.13 
 FOX -0.12
†
 -0.04 -0.03 --- -0.16* 
b.  Global %hmC       







 NIAT 0.05 0.15* 0.02 0.15* -0.23** 
 FOX 0.05 0.00 -0.02 --- -0.16** 







 NIAT 0.16 0.26* 0.05 0.31** -0.19
†
 




 --- -0.17* 







 NIAT -0.05 0.05 -0.02 0.01 -0.29** 
 FOX -0.23** -0.14
*




Chapter 5:  Interactions of plasma glutathione redox and folate deficiency on arsenic 
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BACKGROUND:  Inorganic arsenic (InAs) is metabolized through a series of methylation 
reactions catalyzed by arsenic(III)-methyltransferase (AS3MT), resulting in the generation of 
monomethylarsonic (MMAs) and dimethylarsinic acids (DMAs).  AS3MT activity requires the 
presence of the methyl donor S-adenosylmethionine (SAM), a product of folate-dependent one-
carbon metabolism, and a reductant.  Redox-sensitive cysteine residues have been identified in 
the AS3MT active site, suggesting that AS3MT activity might be particularly sensitive to redox 
conditions.  Although glutathione (GSH), the primary endogenous antioxidant, is not required for 
As methylation, GSH stimulates As methylation rates in vitro.  However, the relationship 
between GSH redox and As methylation capacity in humans is unknown. 
OBJECTIVE:   To test the hypothesis that a more oxidized plasma GSH redox status is 
associated with decreased As methylation capacity, and examine whether these associations are 
modified by folate nutritional status.   
METHODS:  Concentrations of plasma GSH and GSSG, plasma folate, total blood As, total 
urinary As, and urinary As metabolites were assessed in 376 Bangladeshi adults who were 
chronically exposed to As in drinking water. 
RESULTS:  A decreased plasma GSH/GSSG ratio (reflecting a more oxidized redox state) was 
associated with increased urinary %MMA, decreased urinary %DMA, and increased total blood 
As among folate-deficient individuals (plasma folate ≤ 9.0 nmol/L).  Concentrations of plasma 
GSH and GSSG were independently associated with increased and decreased As methylation 
capacity, respectively.  No significant associations were observed in folate-sufficient individuals, 
and interactions by folate status were statistically significant.  
CONCLUSIONS:  An oxidized plasma GSH/GSSG redox state was associated with decreased 




redox might contribute to the large interindividual variation in As methylation capacity observed 





 Over 140 million people throughout Bangladesh, India, Vietnam, Nepal, and Cambodia 
are chronically exposed to arsenic (As) in drinking water at concentrations over 10 μg/L, the 
World Health Organization guideline (Ahmed et al. 2006).  As a Class I human carcinogen 
(IARC 1987), As is associated with increased risk for cancers of the skin, lung, bladder, liver, 
and kidney (Navarro Silvera and Rohan 2007), although the carcinogenic mechanism of As is 
incompletely understood (Rossman 2003). 
Inorganic arsenic (InAs) is metabolized, primarily in the liver, through a series of 
methylation reactions catalyzed by arsenic(III)-methyltransferase (AS3MT), resulting in the 
formation of monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA) (Lin et al. 2002).  
The methyl group for the reaction is donated from S-adenosylmethionine (SAM) (Lin et al. 
2002), a product of folate-dependent one-carbon metabolism (Chiang et al. 1996).  Since 
methylation increases As excretion and reduces As body burden (Hughes et al. 2010), it is 
believed to be a detoxification process (Gebel 2002).   However, in vitro and in vivo studies have 
identified MMA
III
 as the most toxic As form (Petrick et al. 2001; Styblo et al. 2000), suggesting 
that As methylation also involves bioactivation (Vahter and Concha 2001).  Epidemiologic 
studies consistently find that a reduced capacity to fully methylate InAs, as indicated by higher 
%MMA
(III+V)
 and lower %DMA
(III+V)
  in urine, is associated with increased risk for As-induced 
skin lesions and cancers of the skin, lung, and bladder (Smith and Steinmaus 2009).  As such, the 
identification of factors that facilitate complete methylation of InAs to DMA might provide 
insight into interventions to reduce risk for As-related diseases (Tseng 2007).   
Although the proposed As methylation pathways presented in Figure 1 are distinct, they 




primary endogenous antioxidant, GSH readily donates an electron for reduction reactions, 
forming its oxidized form, glutathione disulfide (GSSG), in the process (Jones 2008).  A lower 
ratio of GSH to GSSG reflects a more oxidized intracellular redox state (Jones 2008).  While 
GSH is not required for As methylation to proceed, GSH can serve as the reducing agent 
necessary for AS3MT activity (Song et al. 2010; Thomas et al. 2007; Waters et al. 2004a; Waters 
et al. 2004b).  The addition of GSH can stimulate AS3MT-catalyzed methylation rates in 
experimental systems already containing another reductant (Ding et al. 2012).   
GSH might facilitate As methylation by donating electrons for the reduction of 
pentavalent arsenate (As
V
) to trivalent arsenite (As
III
), shown in the oxidative methylation 
pathway first proposed by Challenger (Challenger 1945, 1951), or by forming As-GSH 
complexes that are substrates for AS3MT, as proposed by Hayakawa et al. (Hayakawa et al. 
2005).  Recent work by Wang et al. found that a reductant (such as GSH) is needed to cleave a 
disulfide bond within AS3MT, which allows As
III
 to bind the enzyme (Wang et al. 2012).  
Additionally, active-site cysteine (Cys) residues that are potentially redox-sensitive have been 
identified in AS3MT (Fomenko et al. 2007).  Redox-sensitive Cys residues are prone to 
oxidative modifications such as S-glutathionylation—the reversible formation of a mixed 
disulfide between a Cys residue and GSH or GSSG—which might also regulate AS3MT activity 
(Dalle-Donne et al. 2007).   
We wished to test the hypothesis that a more reduced GSH redox state is associated with 
increased As methylation capacity, as indicated by a decrease in urinary %MMA, increase in 
urinary %DMA, and increase in the urinary secondary methylation index (SMI, defined as the 
ratio of DMA to MMA).  We measured the GSH/GSSG ratio in plasma and in blood; the plasma 




of As methylation, and was therefore chosen for our focus in the present analyses.  We also 
examined whether the associations were modified by plasma folate status.  We used data from 
the Folate and Oxidative Stress (FOX) study (Hall et al. 2013), which was originally designed to 





SUBJECTS AND METHODS 
Eligibility criteria and study design 
The FOX study design is described in detail in Chapter 3.   
Analytic techniques 
Methods for sample collection and analysis of water As, urinary As, urinary Cr, blood As 
and plasma folate and cobalamin are described in detail in Chapter 3.   
Blood and plasma glutathione and glutathione disulfide 
Whole blood and plasma GSH and GSSG were assayed based on the protocol by Jones et 
al (Jones et al. 1998), as previously described (Hall et al. 2013).  Briefly, blood was collected in 
the field laboratory in Bangladesh and immediately transferred into Eppendorf tubes containing 
5% perchloric acid (PCA), 0.1 M boric acid, and γ-glutamyl glutamate (internal standard).  
Samples were derivatized in Bangladesh, and the derivatized samples were stored at -80°C until 
delivered to Columbia University on dry ice for HPLC analysis.  Metabolites were detected 
using a Waters 474 scanning fluorescence detector, with 335 nm excitation and 515 nm emission 
(Waters Corp., Milford, MA).  Intra-assay CVs were all between 5 and 10%, and inter-assay CVs 
were between 11 and 18%. 
Calculation of the Reduction Potential  
The reduction potential of the thiol/disulfide plasma GSH/GSSG redox pair (Eh) was 
calculated using the Nernst equation (Eh= Eo + RT/nF ln [disulfide]/[thiol]
2
 where Eo= standard 
potential for the redox couple, R= gas constant, T= absolute temperature, n=2 for the number of 
electrons transferred, and F= Faraday’s constant) (Jones et al. 2002).  A more positive Eh value 





Descriptive statistics were calculated for the overall sample.  Chi-square test and the 
Wilcoxon rank-sum test were used to detect group difference in categorical and continuous 
variables, respectively. Spearman correlations were used to examine bivariate associations 
between quantitative variables including covariates with urinary As metabolite percentages and 
plasma GSH and GSSG concentrations. Certain covariates (gender, age, ever cigarette smoking, 
and water As) were selected based on biologic plausibility and previous studies in the literature.  
Other biologically-plausible confounders (BMI, plasma cobalamin, ever betelnut use, television 
ownership, and uCr) were considered by examining their bivariate associations with plasma GSH 
variables and As exposure variables in this dataset; covariates were included in the regression 
models if they were associated with both exposure and outcome at significance level of 0.2.  To 
reduce extraneous variation in plasma GSH and GSSG, we adjusted these variables for 
laboratory batch using the residual method using batch (day of run) as a categorical variable and 
used the batch-adjusted plasma GSH and GSSG variables in all analyses. 
Linear regression models were constructed with plasma GSH variables as predictors and 
urinary As metabolite variables as the outcomes.  Variables with skewed distributions were log-
transformed to normalize the distributions of the variables and/or improve the linearity of the 
relationships between the predictors and outcomes; transformed variables included uAs, bAs, 
wAs, urinary SMI, plasma GSH, plasma GSSG, and plasma GSH/GSSG.  Relationships were 
also examined by using plasma GSH/GSSG variables categorized at tertiles in the overall study 
sample, and linear models with categorized plasma GSH/GSSG variables to calculate gender and 
well water As adjusted mean urinary %MMA and %DMA within the categories, for the plasma 
folate strata.  Differences in the associations between predictor (GSH, GSSG, GSH/GSSG ratio) 




detected by Wald tests.  Of the total N=378 participants in the study sample, two participants 
were excluded for missing data (N=1 participant with missing plasma folate, N=1 participant 
with missing plasma GSH), leaving N=376 participants in the analysis.  All statistical analyses 






 Demographic and clinical characteristics of the study participants, overall and by plasma 
folate status, are shown in Table 1.  In the overall sample, the average age was 43 y, and there 
were roughly equal numbers of males and females.  Folate-deficient individuals (plasma folate 
concentrations < 9.0 nmol/L) comprised approximately 29% of the sample.  The folate-deficient 
group had a higher proportion of males, ever cigarette smokers, and betel nut chewers; higher 
mean age; and lower mean BMI.  The folate-deficient group also had higher %InAs and %MMA 
and lower %DMA in urine.  
Males had significantly higher mean urinary %MMA (16.0% vs. 12.0%, P < 0.0001) and 
lower mean urinary %DMA (66.6% vs. 69.9%, P < 0.0001) and plasma GSH/GSSG ratio (1.25 
vs. 1.34, P = 0.04).  As shown in Table 2, the plasma GSH/GSSG ratio was negatively correlated 
with age in both folate groups.  In support of previous findings from our group (Hall et al. 2009), 
plasma cobalamin was positively correlated with urinary %MMA.  Total As exposures in well 
water, urine, and blood were positively correlated with %InAs and %MMA and negatively 
correlated with urinary %DMA, consistent with inhibition or saturation of AS3MT by InAs and 










Table 1.  Descriptive characteristics for study sample by plasma folate status.  
 
a.
 Mean ± SD (all such values); 
b. 

















(30 to 63) 
44.4 ± 8.0 
(30 to 62) 
42.6 ± 8.3 








20.4 ± 3.5 
 (13.8 to 35.3) 
19.7 ± 3.0  
(13.8 to 31.7) 
20.7 ± 3.6 
 (14.5 to 35.3) 
0.02 
Ever cigarette smoking 136 (36.2) 59 (53.6) 77 (29.0) <0.0001 
Ever betel nut use 160 (42.6) 59 (53.6) 101 (38.0) 0.003 
Television ownership 219 (58.2) 57 (51.8) 162 (60.9) 0.07 
Plasma folate (nmol/L) 
12.9 ± 7.2 
(2.4 to 60.6) 
7.1 ± 1.4 
(2.4 to 8.9) 
15.3 ± 7.2 
(9.1 to 60.6) 
<0.0001 
Plasma cobalamin (µM) 
204 ± 113 
(44 to 1183) 
191 ± 93 
(59 to 557) 
209 ± 119 
(44 to 1183) 
0.20 
Plasma GSH (µmol/L) 
2.6 ± 0.7 
(1.0 – 5.8) 
2.5 ± 0.7 
(1.2 – 4.8) 
2.7 ± 0.8 
(1.0 to 5.8) 
0.25 
Plasma GSSG (µmol/L) 
2.1 ± 0.6 
(0.8 – 4.8) 
2.0 ± 0.7 
(0.9 – 4.8) 
2.2 ± 0.6 
(0.8 to 4.0) 
0.02 
Plasma GSH/GSSG  
1.3 ± 0.4 
(0.4 to 2.9) 
1.3 ± 0.4 
(0.6 to 2.6) 
1.3 ± 0.5 
(0.4 to 2.9) 
0.38 
Plasma GSH Eh (mV) 
-98.7 ± 7.3 
(-118.0 to -73.4) 
-98.6 ± 6.8 
(-112.6 to -83.6) 
-98.7 ± 7.5 
(-118.0 to -73.4) 
0.92 
Water As (µg/L) 
138 ± 124 
(0.4  to 700) 
164 ± 143 
(0.4  to 700) 
128 ± 114 
(0.4 to 447) 
0.04 
Blood As, total (µg/L) 
13.4 ± 9.8 
(1.2 to 57.0) 
15.4 ± 10.9 
(1.3 to 51.3) 
12.5 ± 9.1 
(1.2 to 57.0) 
0.03 
Urinary As, total (µg/L) 
202 ± 226 
(3 to 1990) 
209 ± 207 
(7 to 992) 
119 ± 223 
(3 to 1990) 
0.43 
Urinary Cr (mg/dL) 
53 ± 44 
(4 to 224) 
53 ± 42 
(4 to 212) 
55 ± 44 
(6 to 224) 
0.83 
Urinary As/Cr (µg/g 
Cr) 
417 ± 329 
(16 to 1832) 
464 ± 361 
(16 to 1743) 
397 ± 312 
(18 to 1832) 
0.14 
    Urinary %InAs 
17.7 ± 5.5 
(6.7 to 51.8) 
18.6 ± 5.9 
(8.3 to 42.9) 
17.4 ± 5.3 
(6.7 to 51.8) 
0.05 
    Urinary %MMA 
13.9 ± 5.0 
(3.6 to 30.0) 
15.3 ± 5.5 
(3.6 to 30.0) 
13.4 ± 4.7 
(4.2 to 28.5) 
0.002 
    Urinary %DMA 
68.3 ± 7.9 
(38.3 to 88.0) 
66.1 ± 8.5 
(39.5 to 88.0) 
69.3 ± 7.4 





Table 2.  Spearman correlations of continuous sample characteristics with plasma 
glutathione variables and urinary As metabolite percentages. 
 
 
     










Age -0.23*** -0.17** 0.15** 0.01 
BMI -0.12* -0.05 -0.18** 0.14** 
Plasma cobalamin -0.15** -0.08 0.13* -0.04 
Water As 0.05 0.21*** 0.21*** -0.26*** 
Urinary As/Cr 0.04 0.19** 0.22*** -0.25*** 
Blood As 0.01 0.25*** 0.30*** -0.35*** 











Age -0.29*** -0.24** 0.23** -0.01 
BMI -0.19* -0.08 -0.22** 0.20** 
Plasma cobalamin -0.18 0.05 0.13 -0.10 
Water As 0.16 0.21* 0.29** -0.27** 
Urinary As/Cr 0.11 0.25** 0.22* -0.28** 
Blood As 0.03 0.29** 0.36** -0.38*** 











Age -0.22*** -0.17** 0.09 0.05 
BMI -0.08 -0.03 -0.14* 0.10 
Plasma cobalamin
a
 -0.14* -0.13* 0.14* -0.02 
Water As 0.00 0.20** 0.14** -0.22** 
Urinary As/Cr 0.01 0.16** 0.19** -0.22** 
Blood As -0.01 0.22** 0.25*** -0.31*** 




In multiple linear regression models stratified by plasma folate status (Table 3), the 
plasma GSH/GSSG ratio was negatively associated with urinary %MMA (B ± SE, -4.7 ± 1.6, P 
= 0.004) and positively associated with urinary %DMA (B ± SE, 5.7 ± 2.7, P = 0.04) in the 
folate-deficient stratum, indicating that a more reduced plasma GSH/GSSG ratio is associated 
with increased As methylation capacity.  No significant associations were observed in the folate-
sufficient stratum, and the interactions by folate status were significant for %MMA (P = 0.01) 
and %DMA (P = 0.04).  The plasma GSH/GSSG ratio was not associated with urinary %InAs in 
adjusted models in either folate stratum (folate-deficient, P = 0.62; folate-sufficient, P = 0.47).  
Additionally, the plasma GSH/GSSG ratio was positively associated with urinary SMI in the 
folate-deficient group (folate-deficient, B ± SE, 0.44 ± 0.14, P = 0.002; folate-sufficient, B ± SE, 
0.00 ± 0.08, P = 0.98; P interaction = 0.01).  The change in R
2
 values for urinary SMI models 
were 6.1% in the folate-deficient group and 0.0% in the folate-sufficient group; the change in R
2
 
represents the percentage of the variance in urinary SMI explained by the plasma GSH/GSSG 
ratio after adjustment for covariates.  Additionally, in the folate-deficient group, the plasma 
GSH/GSSG ratio was negatively associated with total bAs concentrations (B ± SE, -0.43 ± 0.17, 
P = 0.02).  Similar patterns of association were observed when plasma GSH Eh, as calculated by 
the Nernst equation, was used as the predictor: in adjusted models, a more oxidized plasma GSH 
Eh was associated with decreased urinary SMI (P = 0.03), increased urinary %MMA (P = 0.03), 









Table 3.  Regression coefficients for associations between log-transformed plasma GSH/GSSG ratio and arsenic methylation 




Adjusted for gender, log-transformed water As, age, cigarette smoking (ever/never), betelnut chewing (ever/never), television 
ownership, plasma cobalamin, and BMI; N=110 in folate deficient, N=259 in folate sufficient 
 
b















































-0.81 ± 0.71 -5.21 ± 1.58** 36.3 7.1 0.17 ± 0.78 24.8 0.0 0.002 
Urinary 
%DMA 




0.09 ± 1.16 4.93 ± 2.56
†









   































To examine whether concentrations of plasma GSH or GSSG were independently 
associated with As methylation capacity, we built regression models with GSH and GSSG 
concentrations as predictors of urinary As metabolites, shown in Table 4.  Since plasma GSH 
and GSSG were positively correlated with one another (Spearman r = 0.29, P < 0.0001), we 
included both variables in the models simultaneously.  After adjustment, in the folate-deficient 
stratum, plasma GSH was positively associated with urinary SMI (B ± SE, 0.37 ± 0.18, P = 
0.04), while plasma GSSG was negatively associated with urinary SMI (B ± SE, -0.49 ± 0.15, P 
= 0.002).  Again, no significant associations were observed in the folate-sufficient stratum.  
Least squares mean urinary %MMA and %DMA by plasma GSH/GSSG tertiles, 
stratified by plasma folate status, are presented in Figure 1.  In the folate-deficient stratum, the 
most oxidized plasma GSH/GSSG category (Category 1, ratios of 0.39-1.06) had a 4.4% higher 
adjusted mean urinary %MMA compared to the least oxidized plasma GSH/GSSG category 
(Category 3, ratios of 1.42-2.92) (P = 0.0001) (Figure 1A).  Category 2 (ratios of 1.07-1.41) had 
a 2.7% increase in mean urinary %MMA compared to Category 3 (P = 0.01) (Figure 1A).  
Adjusted mean urinary %MMA did not differ by plasma GSH/GSSG category in the folate-
sufficient stratum (Figure 1B).  Similarly, Category 1 had a 3.5% lower mean urinary %DMA 
compared to Category 3 in the folate-deficient (P = 0.07) (Figure 1C), but no differences by 












Table 4.  Regression coefficients for associations between log-transformed plasma GSH and plasma GSSG concentrations and 

















 -0.02 ± 0.88 -4.75 ± 2.00* 1.16 ± 0.98 0.008 
Plasma GSSG
a
 1.59 ± 0.87
†




 -0.60 ± 1.50 4.93 ± 3.37 -1.24 ± 1.68 0.10 
Plasma GSSG
a
 -1.13 ± 1.48 -7.40 ± 2.90* 0.50 ± 1.76 0.02 
Urinary SMI
 c
    
Plasma GSH
a
 -0.04 ± 0.08 0.41 ± 0.18* -0.14 ± 0.09 0.006 
Plasma GSSG
a
 -0.15 ± 0.08
†






 -0.10 ± 0.10 -0.34 ± 0.22 -0.05 ± 0.12 0.25 
Plasma GSSG
a






Adjusted for gender, log-transformed water As, age, cigarette smoking (ever/never), betelnut chewing (ever/never), television 






















Figure 1.  Adjusted mean urinary %MMA and %DMA by plasma GSH/GSSG category, stratified by plasma folate status. 









The primary objective of this study was to examine the associations of the plasma 
GSH/GSSG ratio with indicators of As methylation capacity (urinary %MMA, %DMA, and 
SMI) and to further examine whether these associations were modified by plasma folate status.  
In the folate-deficient stratum, we observed that the plasma GSH/GSSG ratio was negatively 
associated with urinary %MMA and positively associated with urinary %DMA and urinary SMI.  
No significant associations were observed in the folate-sufficient stratum, and the interaction by 
folate status was statistically significant.  Additionally, the plasma GSH/GSSG ratio was 
negatively associated with total bAs concentrations in the folate-deficient stratum.  Our findings 
suggest that a more reduced plasma GSH redox state is associated with increased As methylation 
capacity and decreased bAs concentrations, and plasma folate status is a modifier of these 
associations. 
We found that an oxidized plasma GSH redox state was negatively associated with As 
methylation capacity, with concentrations of plasma GSH and GSSG having independent—and 
opposite—associations with urinary As metabolite percentages.  We speculate that these 
observations might be explained by S-glutathionylation, i.e., direct binding of GSH and GSSG to 
AS3MT (Dalle-Donne et al. 2007).  Unpublished in vitro results from David Thomas’s group 
using biotinylated GSH and GSSG found that both molecules bind to the AS3MT protein, with 
GSH and GSSG leading to an increase and decrease in catalytic activity, respectively (David 
Thomas, personal communication).  Furthermore, GSH and GSSG are antagonists: binding of 
GSH is reduced by the addition of GSSG (David Thomas, personal communication).  These in 




AS3MT activity and might be one of several mechanisms that determines As methylation 
capacity. 
Since the association between plasma GSH/GSSG and As methylation capacity was only 
observed in the folate-deficient group, it is possible that S-glutathionylation of AS3MT, if 
present, might have a regulatory purpose.  For example, GSSG inhibits the Na,K-ATPase 
enzyme through S-glutathionylation of Cys residues in its ATP binding site, but this inhibition 
does not occur when ATP concentrations are above a certain threshold (Petrushanko et al. 2012).  
The authors spectulated that S-glutathionylation of Na,K-ATPase is a regulatory mechanism to 
prevent irreversible loss of ATP under ATP-deficient conditions  (Petrushanko et al. 2012).  It is 
possible that an analogous mechanism occurs with AS3MT, where exposure to GSSG under 
folate-deficient conditions increases S-glutathionylation of redox-sensitive Cys residues near the 
SAM binding site, thereby conserving SAM.  Interestingly, the AS3MT Cys residues that were 




, are located in the SAM binding 
pocket (Li et al. 2013a; Li et al. 2013b) .  While we cannot definitively establish that this 
mechanism explains our observations, it would be of interest to explore this potential regulatory 
mechanism in experimental models. 
It is also possible that our observed associations might be explained by differential biliary 




 from hepatocytes to 
the bile via multidrug resistance protein 2 (Mrp2) requires the formation of As-GSH conjugates 
(Leslie 2012).  If plasma GSH redox state indeed influences biliary As excretion, we would 
expect that plasma GSH redox would be associated with urinary As concentrations.  However, 
we found no significant associations between plasma GSH, GSSG, or GSH/GSSG ratio with 




shown).  This suggests that the plasma GSH redox state is only associated with the distribution 
of urinary As metabolites for a given As exposure.  The absence of associations between plasma 
GSH redox and urinary As concentrations also suggests that our observations are less likely to be 
explained by reverse causality, e.g., inhibition of glutathione reductase (GR) by As metabolites 
seen at very high As concentrations in vitro (Chouchane and Snow 2001; Styblo and Thomas 
1995; Styblo et al. 1997) and in vivo (Rodríguez et al. 2005). 
We are aware of only one other study that examined the associations between GSH and 
urinary As metabolites in humans (Xu et al. 2008).  Xu et al. found that total non-protein 
sulfhydryls (primarily GSH + GSSG) measured in whole blood was strongly associated with 
increased urinary %MMA and decreased urinary %DMA in children and adults in Inner 
Mongolia, China (Xu et al. 2008).  In our study, we did not observe any significant associations 
between whole blood GSH or the sum of whole blood GSH and GSSG and urinary As metabolite 
percentages, either in the overall sample or within the folate strata (data not shown).  The reason 
for this discrepancy is unclear, but it might be related to differing laboratory methodologies used 
to measure GSH or differences in the study populations.   Conversely, numerous studies have 
examined the associations of genetic variants in the glutathione S-transferase (GST) family of 
enzymes with urinary As metabolite profiles, although no consistent associations have been 
observed (Agusa et al. 2012; Ahsan et al. 2007; Caceres et al. 2010; Chiou et al. 1997; Chung et 
al. 2010; Hwang et al. 2010; Lindberg et al. 2007; Marnell et al. 2003; Paiva et al. 2010; 
Schlawicke Engstrom et al. 2007; Steinmaus et al. 2007).  It is possible that the inconsistent 
findings might be due to differences in folate nutritional status among the populations included 




Our study has several limitations.  First, we used plasma measurements of GSH, GSSG, 
and folate as proxies for liver measurements of GSH, GSSG, and SAM.  Since the liver is the 
primary site of As methylation in the body, we would ideally measure GSH, GSSG, and SAM 
concentrations in hepatic tissue.  However, mathematical models of hepatic folate and GSH 
metabolism indicate that plasma biomarkers might be informative: Based on model predictions, 
plasma folate is strongly related to liver SAM (Duncan et al. 2013), and plasma GSH/GSSG 
tracks liver GSH/GSSG over a range of steady-state oxidative stress (H2O2) concentrations (Reed 
et al. 2008).  Second, evidence from Currier et al. suggests that our method for measuring urinary 
As metabolites, HPLC-ICP-MS, might underestimate the concentrations of the trivalent 




 (Currier et al. 2013).  Finally, due to the 
cross-sectional nature of our study, we are unable to establish the directionality of the 
relationship between plasma GSH redox status and As methylation capacity. 
 In conclusion, we found that an oxidized plasma GSH/GSSG redox state was associated 
with decreased As methylation capacity (increased urinary %MMA, decreased urinary %DMA, 
and decreased urinary SMI) and increased total bAs among folate-deficient Bangladeshi adults.  
GSH/GSSG redox might be one of several mechanisms controlling intracellular AS3MT activity 
and might contribute to the large interindividual variation in As methylation capacity observed in 





 This work was supported by grants RO1 CA133595, RO1 ES017875, P42 ES10349, P30 
ES009089, and T32 CA009529-24 from the National Institutes of Health.  The content is solely 
the responsibility of the authors and does not necessarily represent the official views of the 
National Institute of Environmental Health Sciences, the National Cancer Institute, or the 








Agusa T, Kunito T, Tue NM, Lan VT, Fujihara J, Takeshita H, et al. 2012. Individual variations 
in arsenic metabolism in vietnamese: The association with arsenic exposure and gstp1 genetic 
polymorphism. Metallomics 4:91-100. 
Ahmed MF, Ahuja S, Alauddin M, Hug SJ, Lloyd JR, Pfaff A, et al. 2006. Epidemiology. 
Ensuring safe drinking water in bangladesh. Science 314:1687-1688. 
Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F, et al. 2007. Arsenic 
metabolism, genetic susceptibility, and risk of premalignant skin lesions in bangladesh. Cancer 
Epidemiology Biomarkers & Prevention 16:1270-1278. 
Caceres DD, Werlinger F, Orellana M, Jara M, Rocha R, Alvarado SA, et al. 2010. 
Polymorphism of glutathione s-transferase (gst) variants and its effect on distribution of urinary 
arsenic species in people exposed to low inorganic arsenic in tap water: An exploratory study. 
Arch Environ Occup Health 65:140-147. 
Challenger F. 1945. Biological methylation. Chemical Reviews 36:315–361. 
Challenger F. 1951. Biological methylation. Advances in enzymology and related subjects of 
biochemistry 12:429-491. 
Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, et al. 1996. S-
adenosylmethionine and methylation. FASEB J 10:471-480. 
Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH, Hsieh FI, et al. 1997. Arsenic methylation 
capacity, body retention, and null genotypes of glutathione s-transferase m1 and t1 among 
current arsenic-exposed residents in taiwan. Mutat Res 386:197-207. 
Chouchane S, Snow ET. 2001. In vitro effect of arsenical compounds on glutathione-related 
enzymes. Chem Res Toxicol 14:517-522. 
Chung CJ, Pu YS, Su CT, Chen HW, Huang YK, Shiue HS, et al. 2010. Polymorphisms in one-
carbon metabolism pathway genes, urinary arsenic profile, and urothelial carcinoma. Cancer 
Causes Control 21:1605-1613. 
Currier J, Saunders RJ, Ding L, Bodnar W, Cable P, Matousek T, et al. 2013. Comparative 
oxidation state specific analysis of arsenic species by high-performance liquid chromatography-
inductively coupled plasma-mass spectrometry and hydride generation-cryotrapping-atomic 
absorption spectrometry. J Anal At Spectrom 28:843-852. 
Dalle-Donne I, Rossi R, Giustarini D, Colombo R, Milzani A. 2007. S-glutathionylation in 
protein redox regulation. Free Radic Biol Med 43:883-898. 
Ding L, Saunders RJ, Drobna Z, Walton FS, Xun P, Thomas DJ, et al. 2012. Methylation of 




methionine 287 threonine (m287t) polymorph: Role of glutathione. Toxicol Appl Pharmacol 
264:121-130. 
Duncan TM, Reed MC, Nijhout HF. 2013. The relationship between intracellular and plasma 
levels of folate and metabolites in the methionine cycle: A model. Mol Nutr Food Res 57:628-
636. 
Fomenko DE, Xing W, Adair BM, Thomas DJ, Gladyshev VN. 2007. High-throughput 
identification of catalytic redox-active cysteine residues. Science 315:387-389. 
Gebel TW. 2002. Arsenic methylation is a process of detoxification through accelerated 
excretion. International Journal of Hygiene and Environmental Health 205:505-508. 
Hall MN, Liu X, Slavkovich V, Ilievski V, Mi Z, Alam S, et al. 2009. Influence of cobalamin on 
arsenic metabolism in bangladesh. Environ Health Perspect 117:1724-1729. 
Hall MN, Niedzwiecki M, Liu X, Harper KN, Alam S, Slavkovich V, et al. 2013. Chronic 
arsenic exposure and blood glutathione and glutathione disulfide concentrations in bangladeshi 
adults. Environ Health Perspect 121:1068-74. 
Hayakawa T, Kobayashi Y, Cui X, Hirano S. 2005. A new metabolic pathway of arsenite: 
Arsenic-glutathione complexes are substrates for human arsenic methyltransferase cyt19. Arch 
Toxicol 79:183-191. 
Hughes MF, Edwards BC, Herbin-Davis KM, Saunders J, Styblo M, Thomas DJ. 2010. Arsenic 
(+3 oxidation state) methyltransferase genotype affects steady-state distribution and clearance of 
arsenic in arsenate-treated mice. Toxicol Appl Pharmacol 249:217-223. 
Hwang YH, Chen YH, Su YN, Hsu CC, Yuan TH. 2010. Genetic polymorphism of as3mt and 
delayed urinary dma excretion after organic arsenic intake from oyster ingestion. J Environ 
Monit 12:1247-1254. 
IARC. 1987. Overall evaluations of carcinogenicity: An updating of iarc monographs volumes 1 
to 42. IARC monographs on the evaluation of carcinogenic risks to humans Supplement / World 
Health Organization, International Agency for Research on Cancer 7:1-440. 
Jones DP, Carlson JL, Samiec PS, Sternberg P, Jr., Mody VC, Jr., Reed RL, et al. 1998. 
Glutathione measurement in human plasma. Evaluation of sample collection, storage and 
derivatization conditions for analysis of dansyl derivatives by hplc. Clin Chim Acta 275:175-
184. 
Jones DP, Mody VC, Jr., Carlson JL, Lynn MJ, Sternberg P, Jr. 2002. Redox analysis of human 
plasma allows separation of pro-oxidant events of aging from decline in antioxidant defenses. 
Free Radic Biol Med 33:1290-1300. 





Kombu RS, Zhang G-F, Abbas R, Mieyal JJ, Anderson VE, Kelleher JK, et al. 2009. Dynamics 
of glutathione and ophthalmate traced with 2h-enriched body water in rats and humans. 
American Journal of Physiology - Endocrinology And Metabolism 297:E260-E269. 
Leslie EM. 2012. Arsenic–glutathione conjugate transport by the human multidrug resistance 
proteins (mrps/abccs). Journal of Inorganic Biochemistry 108:141-149. 
Li X, Cao J, Wang S, Geng Z, Song X, Hu X, et al. 2013a. Residues in human arsenic (+3 
oxidation state) methyltransferase forming potential hydrogen bond network around s-
adenosylmethionine. PLoS ONE 8:e76709. 
Li X, Geng Z, Wang S, Song X, Hu X, Wang Z. 2013b. Functional evaluation of asp76, 84, 102 
and 150 in human arsenic(iii) methyltransferase (has3mt) interacting with s-adenosylmethionine. 
FEBS Letters 587:2232-2240. 
Lin S, Shi Q, Nix FB, Styblo M, Beck MA, Herbin-Davis KM, et al. 2002. A novel s-adenosyl-l-
methionine:Arsenic(iii) methyltransferase from rat liver cytosol. J Biol Chem 277:10795-10803. 
Lindberg AL, Kumar R, Goessler W, Thirumaran R, Gurzau E, Koppova K, et al. 2007. 
Metabolism of low-dose inorganic arsenic in a central european population: Influence of sex and 
genetic polymorphisms. Environ Health Perspect 115:1081-1086. 
Marnell LL, Garcia-Vargas GG, Chowdhury UK, Zakharyan RA, Walsh B, Avram MD, et al. 
2003. Polymorphisms in the human monomethylarsonic acid (mma v) reductase/hgsto1 gene and 
changes in urinary arsenic profiles. Chem Res Toxicol 16:1507-1513. 
Navarro Silvera SA, Rohan TE. 2007. Trace elements and cancer risk: A review of the 
epidemiologic evidence. Cancer Causes Control 18:7-27. 
Paiva L, Hernandez A, Martinez V, Creus A, Quinteros D, Marcos R. 2010. Association between 
gsto2 polymorphism and the urinary arsenic profile in copper industry workers. Environ Res 
110:463-468. 
Petrick JS, Jagadish B, Mash EA, Aposhian HV. 2001. Monomethylarsonous acid (mma(iii)) and 
arsenite: Ld(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res 
Toxicol 14:651-656. 
Petrushanko IY, Yakushev S, Mitkevich VA, Kamanina YV, Ziganshin RH, Meng X, et al. 
2012. S-glutathionylation of the na,k-atpase catalytic alpha subunit is a determinant of the 
enzyme redox sensitivity. J Biol Chem 287:32195-32205. 
Reed MC, Thomas RL, Pavisic J, James SJ, Ulrich CM, Nijhout HF. 2008. A mathematical 
model of glutathione metabolism. Theor Biol Med Model 5:8. 
Rodríguez VM, Del Razo LM, Limón-Pacheco JH, Giordano M, Sánchez-Peña LC, Uribe-
Querol E, et al. 2005. Glutathione reductase inhibition and methylated arsenic distribution in cd1 




Rossman TG. 2003. Mechanism of arsenic carcinogenesis: An integrated approach. Mutat Res 
533:37-65. 
Schlawicke Engstrom K, Broberg K, Concha G, Nermell B, Warholm M, Vahter M. 2007. 
Genetic polymorphisms influencing arsenic metabolism: Evidence from argentina. Environ 
Health Perspect 115:599-605. 
Smith AH, Steinmaus CM. 2009. Health effects of arsenic and chromium in drinking water: 
Recent human findings. Annu Rev Public Health 30:107-122. 
Song X, Geng Z, Li X, Hu X, Bian N, Zhang X, et al. 2010. New insights into the mechanism of 
arsenite methylation with the recombinant human arsenic (+3) methyltransferase (has3mt). 
Biochimie 92:1397-1406. 
Steinmaus C, Moore LE, Shipp M, Kalman D, Rey OA, Biggs ML, et al. 2007. Genetic 
polymorphisms in mthfr 677 and 1298, gstm1 and t1, and metabolism of arsenic. J Toxicol 
Environ Health A 70:159-170. 
Styblo M, Thomas DJ. 1995. In vitro inhibition of glutathione reductase by arsenotriglutathione. 
Biochemical pharmacology 49:971-977. 
Styblo M, Serves SV, Cullen WR, Thomas DJ. 1997. Comparative inhibition of yeast glutathione 
reductase by arsenicals and arsenothiols. Chem Res Toxicol 10:27-33. 
Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, et al. 2000. 
Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and 
human cells. Arch Toxicol 74:289-299. 
Thomas DJ, Li J, Waters SB, Xing W, Adair BM, Drobna Z, et al. 2007. Arsenic (+3 oxidation 
state) methyltransferase and the methylation of arsenicals. Experimental biology and medicine 
(Maywood, NJ) 232:3-13. 
Thomas DJ. 2009. Unraveling arsenic--glutathione connections. Toxicol Sci 107:309-311. 
Tseng CH. 2007. Arsenic methylation, urinary arsenic metabolites and human diseases: Current 
perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25:1-22. 
Vahter M, Concha G. 2001. Role of metabolism in arsenic toxicity. Pharmacol Toxicol 89:1-5. 
Wang S, Li X, Song X, Geng Z, Hu X, Wang Z. 2012. Rapid equilibrium kinetic analysis of 
arsenite methylation catalyzed by recombinant human arsenic (+3 oxidation state) 
methyltransferase (has3mt). J Biol Chem 287:38790-38799. 
Waters SB, Devesa V, Del Razo LM, Styblo M, Thomas DJ. 2004a. Endogenous reductants 





Waters SB, Devesa V, Fricke MW, Creed JT, Styblo M, Thomas DJ. 2004b. Glutathione 
modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of 
trimethylarsine oxide and trimethylarsine. Chem Res Toxicol 17:1621-1629. 
Xu Y, Wang Y, Zheng Q, Li X, Li B, Jin Y, et al. 2008. Association of oxidative stress with 












Chapter 6:  Blood glutathione redox status and global methylation of peripheral blood 



















, Alexander van Geen
4









, Joseph H. Graziano
1
, and  Mary V. Gamble
1




Department of Environmental Health Sciences, 
2
Department of Epidemiology, 
3
Department of Biostatistics, 
1-3
Mailman School of Public Health, Columbia University, New 
York NY,10032, USA; 
4
Lamont-Doherty Earth Observatory of Columbia University, Palisades, 
NY, USA; 
5
Columbia University Arsenic Project in Bangladesh, Dhaka, Bangladesh 
 
Published:  https://www.landesbioscience.com/journals/epigenetics/article/25012/ 
Niedzwiecki MM, Hall MN, Liu X, Oka J, Harper KN, Slavkovich V, Ilievski V, Levy D, van 
Geen A, Mey JL, Alam S, Siddique AB, Parvez F, Graziano JH, Gamble MV.  Blood 
glutathione redox status and global methylation of peripheral blood mononuclear cell DNA 





BACKGROUND:  Oxidative stress and DNA methylation are metabolically linked through the 
relationship between one-carbon metabolism and the transsulfuration pathway, but possible 
modulating effects of oxidative stress on DNA methylation have not been extensively studied in 
humans.  Enzymes involved in DNA methylation, including DNA methyltransferases and 
histone deacetylases, may show altered activity under oxidized cellular conditions.  Additionally, 
in vitro studies suggest that glutathione (GSH) depletion leads to global DNA hypomethylation, 
possibly through the depletion of S-adenosylmethionine (SAM). 
OBJECTIVE:  We tested the hypothesis that a more oxidized blood GSH redox status is 
associated with decreased global peripheral blood mononuclear cell (PBMC) DNA methylation 
in a sample of Bangladeshi adults. 
METHODS:  Global PBMC DNA methylation and whole blood GSH, glutathione disulfide 
(GSSG), and SAM concentrations were measured in 320 adults.  DNA methylation was 
measured by using the [
3
H]-methyl incorporation assay; values are inversely related to global 
DNA methylation.  Whole blood GSH redox status (Eh) was calculated using the Nernst 
equation. 
RESULTS:  We found that a more oxidized blood GSH Eh was associated with decreased global 
DNA methylation (B ± SE, 271 ± 103, P = 0.009).  Blood SAM and blood GSH were associated 
with global DNA methylation, but these relationships did not achieve statistical significance. 
CONCLUSIONS:  Our findings support the hypothesis that a more oxidized blood GSH redox 
status is associated with decreased global methylation of PBMC DNA.  Furthermore, blood 
SAM does not appear to mediate this association.  Future research should explore mechanisms 





Methylation of cytosines in CpG dinucleotides is an epigenetic mechanism involved in 
the regulation of gene expression and cellular differentiation (Jones and Taylor 1980; Razin and 
Riggs 1980).  The methyl donor for this reaction is S-adenosylmethionine (SAM), whose 
synthesis is regulated by folate-dependent one-carbon metabolism.  Decreased levels of global 
DNA methylation are associated with increased chromatin accessibility and gene transcriptional 
activity (Thurman et al. 2012), as well as genomic instability (Lengauer et al. 1997).  
Consequently, global DNA hypomethylation, along with site-specific DNA hypermethylation of 
tumor suppressor genes, is commonly found in tumor tissue and transformed cells (Das and 
Singal 2004) and is believed to play a role in carcinogenesis (Robertson and Jones 2000). 
Oxidative stress is a risk factor also commonly implicated in carcinogenesis (Klaunig and 
Kamendulis 2004).  The body’s primary antioxidant is glutathione (GSH), a thiol-containing tri-
peptide (γ-glutamyl-cysteinyl-glycine) that readily donates an electron to reactive oxygen species 
(ROS) via glutathione peroxidase (GPx) and quickly reacts with another free radical GSH 
molecule to form glutathione disulfide (GSSG) (Forman et al. 2009).  Reduced levels of GSH, 
increased levels of GSSG, and a decrease of the ratio of GSH to GSSG are indicative of a more 
oxidized intracellular environment (Jones 2008).  Since the GSH-GSSG couple is the most 
abundant intracellular redox pair, their absolute concentrations can be used in the Nernst 
equation to estimate the intracellular redox state, Eh (in mV) (Schafer and Buettner 2001).  
Approximately 50% of the cysteine (Cys) used in the production of GSH is derived from the 
conversion of homocysteine (Hcys) to cystathionine in the first step of the transsulfuration 




Increased oxidative stress and aberrant DNA methylation often co-occur in 
carcinogenesis (Franco et al. 2008).  Although DNA methylation and oxidative stress are 
metabolically linked through the relationship between one-carbon metabolism and the 
transsulfuration pathway, possible modulating effects of oxidative stress on DNA methylation 
have not been extensively studied in humans.  Two mechanisms have been proposed in the 
literature. 
 First, a more oxidized cellular redox state may lead to a decrease in genomic DNA 
methylation through redox regulation of related enzymes.  A BLAST analysis of gene sequences 
containing possible redox-sensitive cysteine residues identified the SAM-dependent 
methyltransferases as potentially redox-sensitive (Fomenko et al. 2007).   Additionally, the 
activity of methionine adenosyltransferase (MAT), which catalyzes the enzymatic addition of 
methionine to adenosine for the synthesis of SAM, is decreased in environments with a more 
oxidized GSH:GSSG ratio (Pajares et al. 1992). 
Second, it has been hypothesized by others that GSH depletion under conditions of 
chronic oxidative stress may lead to decreased global DNA methylation through the depletion of 
SAM (Hitchler and Domann 2007).   Under oxidizing conditions, cystathionine-β-synthase 
(CBS) activity increases to direct Hcys flux through the transsulfuration pathway for the 
generation of GSH (Mosharov et al. 2000).  Consequently, less Hcys is directed toward the 
regeneration of methionine, which may result in decreased SAM levels.  In support of this 
hypothesis, treatment with the GSH-depleting hepatotoxin bromobenzene led to extensive 
depletion of liver methionine pools and hypomethylation of genomic liver DNA in Syrian 




We tested the hypothesis that increased oxidative stress is associated with decreased 
global DNA methylation in a cohort of Bangladeshi adults by examining the associations of 
blood GSH concentrations and blood GSH redox state (Eh) with global methylation of peripheral 
blood mononuclear cell (PBMC) DNA.  To evaluate whether the association of blood GSH 
redox state with global PBMC DNA methylation might be due to depletion of SAM, we also 
examined the associations of blood SAM with the blood GSH redox variables and DNA 




SUBJECTS AND METHODS 
Eligibility criteria and study design 
The details of the FOX study design are described in Chapter 3.   
Analytic techniques 
Methods for sample collection and analysis of water As, PBMC DNA isolation, genomic 
DNA methylation, plasma folate, plasma homocysteine, and urinary Cr are described in detail in 
Chapter 3.  Analytic methods for whole blood GSH and GSSG, blood SAM and SAH, urinary 8-
oxodG, and the calculation of the whole blood GSH reduction potential (Eh) are outlined here. 
Whole blood and plasma glutathione and glutathione disulfide 
Whole blood and plasma GSH and GSSG were assayed by the method of Jones et al. 
(1998), as previously described (Hall et al. 2013).  Briefly, blood samples were collected in the 
field laboratory with a butterfly syringe, immediately processed for derivatization, and stored at -
80°C until delivered to Columbia University for analysis. 20 µl of each sample was injected onto 
the HPLC, and metabolites were detected using a Waters 474 scanning fluorescence detector 
with 335 nm excitation and 515 nm emission (Waters Corp., Milford, MA).  Intra-assay CVs 
were between 5 and 10%, and inter-assay CVs were between 11 and 18%.    
Blood S-adenosylmethionine and S-adenosylhomocysteine 
SAM and SAH were measured in whole blood, as previously described (Poirier et al. 
2001).  Briefly, blood was thawed, vortexed, and 400 µl were added to an equal volume of 0.1 M 
sodium acetate, pH 6.0, plus 40% TCA.  SAM and SAH were detected at 254 nm using a 996 
Photodiode Array ultraviolet absorbance detector (Waters Inc, Milford, MA) and quantified 
relative to standard curves generated using purified compounds (Sigma, St. Louis, MO).  The 





Urinary 8-oxodG was measured using the ‘New 8-OHdG Check’ ELISA kit at the Genox 
Corporation’s laboratory (Baltimore, MD).  Samples were measured in triplicate. The detection 
level for this assay was 0.64 ng/mL urine. A significant proportion of the study sample (N=56 
individuals, or 18%) had urinary 8-oxodG levels below the detection limit; levels for these 
individuals were set to one-half of the detection limit, or 0.32 ng/mL. The intra- and inter-assay 
coefficients of variation were 7.5% and 7.7%, respectively. Urinary Cr was analyzed with a 
colorimetric assay based on the Jaffe reaction (Slot 1965) to adjust for urine concentration. 
Calculation of the reduction potential (Eh) 
The reduction potentials of the blood GSH/GSSG redox pair was calculated using the 
Nernst equation, Eh = Eo + (RT/nF)ln([acceptor]/[donor]), where Eo is the standard potential for 
the redox couple at the defined pH, R is the gas constant, T is the absolute temperature, F is 
Faraday's constant, and n is the number of electrons transferred (Jones 2002).  For GSH and 
GSSG, the equation simplifies to Eh (mV) = -264 – 30 log([GSH]
2
/[GSSG]), where [GSH] and 
[GSSG] are molar concentrations and the Eo value assumes a physiologic pH of 7.4 (Jones 
2002).  A more positive Eh value reflects a more oxidized state.  
Statistical methods 
Descriptive statistics (means and standard deviations) were calculated for the 
characteristics of the sample.  Spearman correlations were used to examine bivariate associations 
between blood GSH variables, [
3
H]-methyl incorporation, and other continuous covariates.  
Wilcoxon rank-sum test was used to detect differences in continuous measures between 




Linear regression analyses were constructed with blood GSH redox variables and blood 
SAM as predictors and [
3
H]-methyl incorporation as the outcome, with and without controlling 
for confounding factors. Proper transformations were applied to the continuous independent 
variables with skewed distribution to reduce the impact of extreme values. Certain confounders 
(gender, age, cigarette smoking, and water As) were selected a priori based on biologic 
plausibility and previous studies in the literature (Pilsner et al. 2007).  Other potential 
confounders (plasma folate, plasma Hcys, plasma vitamin B12, betel nut chewing, BMI, 
television ownership, education) were considered by examining their bivariate associations with 
blood GSH redox variables, blood SAM, and [
3
H]-methyl incorporation. The control variables in 
the final models were those that were related to the outcome and main predictors and resulted in 
an appreciable (>5%) change in the regression coefficient for the association between a predictor 
and the outcome.  Since cigarette smoking did not predict [
3
H]-methyl incorporation 
independently of gender, it was excluded from the final model.  The final regression models 
contained gender, age, and water As as covariates. 
Blood SAM was considered to be a partial mediator of the association between blood 
GSH and [
3
H]-methyl incorporation if it met the following criteria:  (I) Blood GSH (predictor) 
was significantly associated with blood SAM (mediator); (II) Blood GSH was significantly 
associated with [
3
H]-methyl incorporation (outcome); (III) Blood SAM was significantly 
associated with [
3
H]-methyl incorporation; (IV) inclusion of blood SAM in a model of blood 
GSH predicting [
3
H]-methyl incorporation resulted in attenuation of the regression coefficient. 
Values for [
3
H]-methyl incorporation were excluded from the analysis if duplicates had 
coefficients of variation > 15% (N=48), DNA assay inputs below 10 µg/ml (N=8), or values that 




than three interquartile ranges (N=2).  Additionally, we were unable to isolate DNA from N=1 
lysate, resulting in a final sample size of 320.  All statistical analyses were conducted using SAS 





Demographic and clinical characteristics of the study participants are shown in Table 1.  
The average age was 43 years, and there were roughly equal numbers of males and females.  
Approximately 35% of the population was classified as underweight (BMI < 18.5 kg/m
2
), and 
31.3% of the participants were folate deficient (plasma folate < 9 nmol/L).  Due to the Folate and 
Oxidative Stress (FOX) study sampling design, nearly 71% of the participants used wells with 
water arsenic (As) > 50 ug/L (the Bangladeshi standard) as their primary drinking source.  Mean 
blood GSH and GSSG concentrations were 491.0 and 37.3 µmol/L, respectively, and the mean 
blood GSH Eh was –198 mV. 
In our evaluation of potential covariates for inclusion in the regression models, we 
observed that water As was negatively correlated with blood GSH (Spearman r = -0.15, P = 
0.008), as reported in an earlier study from our group.(Hall et al. 2013)  Males had higher blood 
GSH concentrations, less oxidized blood GSH Eh values, and higher blood SAM levels than 
females (P < 0.0001).  Ever-smokers also had higher GSH concentrations, less oxidized blood 
GSH Eh values, and higher SAM levels than never-smokers.  Since most ever-smokers were 
male (113/123, 91.9%), we stratified the ever-smoking analyses by gender: no significant 
associations were found between GSH and smoking status after stratification, indicating that the 
observed differences in GSH, GSH Eh, and SAM by smoking status were due to the 







Table 1.  Descriptive characteristics for study sample (N=320). 
Baseline variables 
Mean ± SD (range)  
or N(%) 
Age (yrs) 43.2 ± 8.3 (30 – 63) 
Male 159 (49.7) 
BMI (kg/m
2
) 20.3 ± 3.5 (13.8 – 35.3) 
Underweight (BMI < 18.5 kg/m
2
) 112 (35.1) 
Ever cigarette smoking 123 (38.4) 
Ever betel nut use 142 (44.4) 
Television ownership 185 (57.8) 
Water As (µg/L) 144.9 ± 122.5 (0.4 – 699.9) 
Water As > 50 µg/L 226 (70.9) 
Plasma folate (nmol/L)
a 12.6 ± 7.0 (2.4 – 60.6) 
Folate deficiency (folate < 9.0 nmol/L)
 a
 100 (31.3) 
Plasma Hcys (µmol/L) 11.2 ± 12 (3.0 – 165.4) 
Hyperhomocystinemia (Hcys > 13 µmol/L ) 56 (17.5) 
DPM per µg DNA 149,123 ± 23,932 (61,398 – 215,666) 
Blood GSH (µmol/L) 491.0 ± 170.6 (104.6 – 1072.1) 
Plasma GSH (µmol/L) 2.6 ± 0.7 (1.0 – 5.8) 
Blood GSSG (µmol/L) 37.3 ± 18.8 (9.6 - 121.8) 
Plasma GSSG (µmol/L) 2.1 ± 0.6 (0.8 – 4.8) 
Blood GSH Eh (mV) -198.0 ± 13.0 (-227.9 to -144.4) 
Plasma GSH Eh (mV) -98.5 ± 7.2 (-118.0 to -73.4) 
Blood SAM
b
 (µM) 1.29 ± 0.50 (0.44 – 3.38) 
Blood SAH
b









To support the validity of whole blood GSH Eh as a marker of intracellular redox in blood 
cells, we examined relationships of blood GSH redox variables with plasma Hcys and blood S-
adenosylhomocysteine (SAH), shown in Table 2.  Cellular oxidative stress has been shown 
experimentally to decrease plasma Hcys in vitro (Hultberg and Hultberg 2007) and in vivo 
(Rogers et al. 2007).  As expected, a more oxidized blood GSH Eh was negatively correlated 
with both plasma Hcys (Spearman r = -0.27, P < 0.0001) and blood SAH (Spearman r = -0.42, P 
< 0.0001).  We did not find that plasma GSH Eh was correlated with plasma Hcys (Spearman r = 
0.07, P = 0.22) or blood SAH (Spearman r = 0.02, P = 0.74).  
 
Table 2.  Spearman correlation coefficients of blood and plasma glutathione redox 






































A more oxidized blood GSH Eh was significantly correlated with increased [
3
H]-methyl 
incorporation in bivariate analyses (Spearman r = 0.17, P = 0.002).  Since [
3
H]-methyl 
incorporation is inversely related to genomic DNA methylation, this indicated that a more 
oxidized blood GSH Eh is associated with reduced global DNA methylation.  In covariate-
adjusted linear regression models shown in Table 3, a 1 mV increase in blood GSH Eh was 
associated with an increase in [
3
H]-methyl incorporation of 271 disintegrations per minute 




an increase in [
3
H]-methyl incorporation of 12.7 DPM per µg DNA, but this association was not 
statistically significant (P = 0.11).   
For statistical evidence to support blood SAM as a mediator of the association between 
blood GSH redox and global DNA methylation, we examined associations of blood SAM with 
blood GSH, blood GSH Eh, and [
3
H]-methyl incorporation.  Blood SAM was negatively 
associated with [
3
H]-methyl incorporation at borderline significance (B ± SE = -4803 ± 2747, P 
= 0.08, Table 3).  Blood GSH concentration was a significant predictor of log-transformed blood 
SAM in a covariate-adjusted model (B ± SE = 0.026 ± 0.012 for a 100 µM increase in blood 
GSH, P = 0.04), but blood GSH Eh was not associated with blood SAM (P = 0.23). Since the 
association of blood GSH and [
3
H]-methyl incorporation did not reach statistical significance, 
and since blood GSH Eh and blood SAM were not associated, the result did not support the role 
of blood SAM as a mediator.   
In exploratory analyses, we also examined associations of other variables with [
3
H]-
methyl incorporation.  Neither blood SAH nor the blood SAM/SAH ratio were significantly 
associated with [
3
H]-methyl incorporation in adjusted models (P = 0.65 and P = 0.79, 
respectively).  An oxidized blood GSH Eh correlated positively with urinary 8-oxodG levels per 
g urinary creatinine (Cr) (Spearman r = 0.17, P = 0.004); since oxidative damage of guanines in 
CpG dinucleotides has been hypothesized to decrease global DNA methylation (Valinluck et al. 
2004; Weitzman et al. 1994), we also examined the association between urinary 8-oxodG/Cr 
levels and [
3
H]-methyl incorporation.  However, the covariate-adjusted association was not 







Table 3.  Unadjusted and adjusted regression coefficients for associations between 
predictors and [
3













Blood GSH Eh 
Unadjusted 303 ± 102 0.003 2.7  
Adjusted
a 271 ± 103 0.009 5.5 2.0 
Blood GSH 
Unadjusted -13.0 ± 7.8 0.10 0.9  
Adjusted
a -12.7 ± 8.0 0.11 4.2 0.7 
Blood SAM
b 
Unadjusted -4799 ± 2698 0.08 1.0  
Adjusted
a -4803 ± 2747 0.08 5.2 1.7 
 
a 







 The objective of this study was to examine whether oxidative stress is associated with 
decreased global methylation of PBMC DNA in a cross-sectional study of Bangladeshi adults.  
We tested this hypothesis by examining the associations of blood GSH and blood GSH Eh with 
PBMC DNA methylation, and we also examined whether these associations were mediated by 
blood SAM levels.  We observed that a more oxidized blood GSH Eh was associated with 
decreased DNA methylation.  Decreased blood GSH was not significantly associated with 
decreased DNA methylation, indicating that the association of blood GSH Eh with global DNA 
methylation depended on the concentrations and balance of blood GSH and GSSG and was not 
simply explained by the concentration of blood GSH.  Finally, although blood SAM was 
positively associated with PBMC DNA methylation at marginal significance, blood GSH Eh was 
not associated with blood SAM.  Taken together, our observations are consistent with the 
hypothesis that an oxidized intracellular redox state, as measured by blood GSH Eh, is associated 
with decreased global DNA methylation, but blood SAM does not appear to mediate this 
association.   
Only a few other epidemiologic studies have examined the association between oxidative 
stress and DNA methylation.  A study of 45 infertile men found that seminal ROS production 
was negatively correlated with sperm global DNA methylation, and three-month 
supplementation with antioxidants produced a significant decrease in seminal ROS and 
significant increase in sperm global DNA methylation (Tunc and Tremellen 2009).  Additionally, 
in a study of 61 bladder cancer patients and 45 healthy controls, total antioxidant status in urine 
was positively correlated with methylation of long interspersed nuclear element-1 (LINE-1) in 




knowledge, this is the first study to find an association between blood glutathione redox status 
and global DNA methylation in a generally healthy population. 
While methylation of DNA is known to be a dynamic process, a mechanism for 
demethylation has not been clearly established.  Recent work has shown that the ten-eleven 
translocation (Tet) family of proteins can convert 5-methylcytosine (5mC) into 5-
hydroxymethylcytosine (5hmC) (Ito et al. 2010; Tahiliani et al. 2009), which is believed to be an 
intermediary in passive and/or active DNA demethylation (Guo et al. 2011; Wu and Zhang 
2010).   Interestingly, Chen et al. found that the de novo methyltransferases DNMT3a and 
DNMT3b act as both DNA methyltransferases and DNA dehydroxymethylases, depending upon 
the redox environment: treatment with dithiothreitol (DTT) or hydrogen peroxide (H2O2) 
inhibited and enhanced the dehydroxymethylation activities of the enzymes, respectively (Chen 
et al. 2012).  Chen et al. speculated that the dual methylation and dehydroxymethylation 
activities of the DNMT3 enzymes might explain the paradoxical observation that DMNT3 
expression is up-regulated and gene-specific DNA methylation is increased in cancer cells, yet 
global DNA methylation is decreased (Chen et al. 2012). 
Histone deacetylase (HDAC) inhibition has been shown experimentally to induce DNA 
hypomethylation (Selker 1998), and it has been hypothesized that HDAC activities might also be 
influenced directly by cellular redox (Cyr and Domann 2011).   In human neuroblastoma cells, 
exposure to H2O2 induces global DNA hypomethylation, along with downregulation of HDAC3, 
DNMT1, and DNMT3a expression (Gu et al. 2013).  One potential mechanism of redox 
inhibition of HDACs might occur through alteration of cysteine residues:  reactive carbonyl 




and Fitzpatrick 2010), and exposure to ROS-producing compounds induces intramolecular 
disulfide bond formation in conserved cysteine residues in HDAC4 (Ago et al. 2008).   
We did not find that blood SAM was significantly associated with global DNA 
methylation or blood GSH Eh.  Mathematical modeling of one-carbon metabolism predicts that 
the DNMT methylation rate is remarkably stable over wide fluctuations of SAM concentrations, 
primarily due to the low Km for the DNMT reaction and long-range allosteric regulation of CBS 
and methylenetetrahydrofolate reductase (MTHFR) by SAM (Nijhout et al. 2006).  Furthermore, 
the hypothesis that increased demand for GSH production depletes SAM levels is complicated 
by the discovery that CBS is allosterically activated by SAM but destabilized under SAM-
deficient conditions (Prudova et al. 2006).  These findings, along with the observations in this 
study, do not lend strong support to the hypothesis that oxidative stress leads to DNA 
hypomethylation through SAM depletion. 
It is not clear whether whole blood concentrations of SAM and GSH reflect intracellular 
concentrations in other tissues.  Although in vitro evidence suggests that SAM is not easily 
transported across cell membranes (McMillan et al. 2005; Van Phi and Soling 1982), in a cohort 
of healthy adults, the plasma SAM/SAH ratio was strongly correlated with the intracellular 
lymphocyte SAM/SAH ratio (r = 0.73) (Melnyk et al. 2000).  A study in rats showed that an 
increase in reduced oxygen species in liver initiated changes in the erythrocytic GSH:GSSG 
ratio; the authors concluded that the erythrocytic GSH:GSSG ratio reflects oxidative stress in 
liver and other tissues (Siems et al. 1987).  Additionally, an intact transsulfuration pathway has 
been identified in blood cells, including macrophages (Garg et al. 2006) and T cells (Garg et al. 
2011), and transsulfuration pathway flux is upregulated in naïve and activated T cells after 




directly reflect the absolute concentrations in other tissues, the presence of intact one-carbon 
metabolism and transsulfuration pathways in blood cells suggests that blood biomarkers might be 
appropriate to study perturbations of these pathways by oxidative stress. 
We observed that an oxidized blood GSH Eh was correlated with decreased blood SAH 
and plasma Hcys, which is consistent with an increase in Hcys flux through the transsulfuration 
pathway under oxidized intracellular conditions (Mosharov et al. 2000).  Although some studies 
have used plasma GSH Eh as a marker of intracellular redox (Ashfaq et al. 2006; Mannery et al. 
2010), we did not observe significant correlations of Hcys or SAH with plasma GSH Eh, which 
suggests that whole blood GSH Eh might be a better indicator of the intracellular redox 
environment, at least within blood cells.  However, an oxidized plasma GSH Eh is thought to 
reflect oxidative stress in other tissues (Jones 2002) or systemic oxidative stress (Calabrese et al. 
2012) and is observed in aging (Samiec et al. 1998), obesity (Joao Cabrera et al. 2010), and 
disease states such as asthma (Fitzpatrick et al. 2011) and heart disease (Huang et al. 2006).  
Indeed, we found that plasma GSH Eh, but not blood GSH Eh, was positively correlated with age 
(Spearman r = 0.14, P = 0.01) and BMI (Spearman r = 0.11, P = 0.05).  As such, the 
measurements of GSH redox pairs in both plasma and whole blood might be informative to fully 
understand the influence of “oxidative stress” in an organism.  
Redox regulation is known to influence white blood cell cycle progression and 
proliferation (Iwata et al. 1994), and thus, it is possible that our observations are explained by 
redox-induced shifts in PBMC cell type distributions or counts.  However, the overall level of 
global DNA methylation across cell types would have to vary dramatically for cell distribution 
shifts to explain our observations.  While site-specific CpG methylation levels at certain loci 




methylation levels were not significantly different among DNA samples from granulocytes, 
mononuclear cells, and white blood cells in adult women (Wu et al. 2011).  Furthermore, since 
PBMCs are a subset of total WBCs, the influence of cell type variability is reduced to some 
extent in our study.   
Our study has several limitations.  First, the cross-sectional design precludes us from 
establishing the directionality of the relationship between blood GSH redox state and global 
DNA methylation.  Epigenetic alterations might induce changes in the cellular redox status: for 
example, mice exposed to d-β-hydroxybutyrate, an inhibitor of class I HDACs, exhibit an 
increase in global H3 acetylation, increase in expression of oxidative stress resistance genes, and 
a reduction in oxidative damage from ROS (Shimazu et al. 2013).  We also cannot establish 
whether the observed association with global DNA methylation is explained by an upstream 
factor (e.g., H2O2), the GSH redox state itself, or another redox-associated event, e.g., alterations 
of the citric acid cycle and/or the NAD
+
/NADH ratio (Cyr and Domann 2011).  Finally, we were 
unable to adjust for PBMC cell type counts or distributions in our regression models.     
In conclusion, we observed that a more oxidized intracellular redox state, as measured by 
blood GSH Eh, was associated with a decrease in global methylation of PBMC DNA.  
Furthermore, blood SAM was marginally associated with an increase in global DNA 
methylation, but it did not mediate the association between blood GSH Eh and global DNA 
methylation.  Future research should examine whether alteration of intracellular redox is a 
mechanism through which environmental exposures and other factors influence DNA 
methylation.  It might also be of interest to examine whether redox therapies might help to 
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Chapter 7:  Genetic variants associated with serum homocysteine concentrations and 
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BACKGROUND:  Elevated homocysteine (Hcys), a condition known as hyperhomocysteinemia 
(HHcys), is highly prevalent in Bangladesh.  HHcys is a risk factor for arsenic (As)-induced skin 
lesions in Bangladeshis, but the role of HHcys in skin lesion pathogenesis is unknown.  Single 
nucleotide polymorphisms (SNPs) in one-carbon metabolism genes, particularly MTHFR 677 
CT (rs1801133), are associated with Hcys in other populations, but the influences of gene 
variants on serum Hcys and skin lesion development in Bangladesh has not been examined 
previously. 
OBJECTIVE:  To identify gene variants associated with serum Hcys in Bangladesh and examine 
whether Hcys-associated gene variants are associated with risk for As-induced skin lesions. 
METHODS:  We conducted a nested case-control study in which 876 incident skin lesion cases 
were matched to controls on gender, age, and follow-up time.  Homocysteine was measured in 
701 cases and 703 controls with serum from baseline, and 64 SNPs in one-carbon metabolism 
genes were measured with OpenArray.  A genome-wide association study (GWAS) of serum 
Hcys was conducted in a subset of 358 cases and 149 controls. 
RESULTS:  Compared to subjects with serum Hcys < 10 µM, the odds ratios (ORs) and 95% 
confidence intervals (CIs) for skin lesion incidence for subjects with serum Hcys 10-15 µM, 15-
25 µM, and > 25 µM were 1.29 (0.94 to 1.79), 1.60 (1.12 to 2.27), and 1.83 (1.12 to 3.01), 
respectively.  MTHFR 677 CT was strongly associated with serum Hcys; in the overall 
sample, geometric mean (± standard deviation [SD]) serum Hcys in 677 CC, CT, and TT 
genotypes were 13.1 ± 1.5 µM, 16.7 ± 1.6 µM, and 34.4 ± 2.0 µM, respectively.  Diplotypes 
constructed from MTHFR SNPs (rs1801133, rs1801131, and rs1476413) explained 19.6% of the 




were not associated with skin lesion incidence (P > 0.05).  GWAS results identified one SNP in 
NR1I2 (rs6438549) associated with serum Hcys at genome-wide significance (P = 4.69 x 10
-8
).  
Top hits were in genes involved in epithelial cell polarity, cell adhesion, and squamous cell 
carcinoma.   
CONCLUSIONS:  Serum Hcys was associated with a dose-dependent increase in odds for 
incident skin lesions, and MTHFR variants were associated with serum Hcys.  However, 
MTHFR variants were not significantly associated with skin lesion risk.  The GWAS for serum 
Hcys identified genes relevant to skin cancer, suggesting that HHcys might not be causally-
related to skin lesion development but might instead reflect increased susceptibility to As-





Elevated homocysteine (Hcys) concentrations (often defined as plasma Hcys > 15 µM), a 
condition known as hyperhomocystenemia (HHcys), is a well-established risk factor for 
numerous diseases, including cardiovascular disease (CVD) (Refsum et al. 1998), neurologic 
conditions (Diaz-Arrastia 2000), and cancer (Wu and Wu 2002).  Homocysteine is endogenously 
synthesized via one-carbon metabolism (Figure 1):  the donation of a methyl group from the 
methyl donor S-adenosylmethionine (SAM) yields the byproduct S-adenosylhomocysteine 
(SAH), which is then hydrolyzed to form Hcys (Scott and Weir 1998).  Although Hcys induces 
oxidative stress and inflammation in experimental models (Dayal et al. 2004; Eberhardt et al. 
2000), whether HHcys is a causative factor in human disease, or merely a biomarker of disease 
risk, is under debate (Brattström and Wilcken 2000).  For example, numerous studies have found 
that HHcys is a risk factor for CVD, yet folic acid supplementation for Hcys lowering has failed 
to reduce the risk of secondary CVD events (Group 2010; Lonn et al. 2006).  Since Hcys is often 
examined as a disease biomarker, it is essential to understand precisely what the measurement of 
Hcys reflects about the disease of interest.  
 Chronic exposure to inorganic arsenic (InAs), a Class I human carcinogen (IARC 1987), 
has been linked to elevated risk for cancers of the skin, lung, bladder, liver, and kidney (Navarro 
Silvera and Rohan 2007).  Inorganic arsenic is metabolized through a series of methylation 
reactions to monomethyl (MMA) and dimethyl (DMA) arsenical species, with methyl groups 
donated by SAM via one-carbon metabolism (Lin et al. 2002).  Previously, our group identified 
that several factors associated with aberrant one-carbon metabolism—namely, global 
hypomethylation of blood cell DNA, folate deficiency, and HHcys— were risk factors for As-




population (Pilsner et al. 2009).   Interestingly, the association of HHcys with skin lesion risk 
was observed even after adjustment for folate deficiency, global DNA methylation, and As 
exposure (Pilsner et al. 2009). 
 
Figure 1.  Determinants of serum Hcys concentrations: one-carbon metabolism, 
transsulfuration pathway, and Hcys cellular efflux.  Genes with SNPs examined in the current 
study are displayed in orange. 
 
 
Plasma Hcys concentrations are influenced by single nucleotide polymorphisms (SNPs) 
in genes involved in one-carbon metabolism.  The most widely studied Hcys-associated gene 
variant is the nonsynonymous 677 CT polymorphism (rs1801133) in the 




methyltetrahydrofolate (5mTHF), a substrate for the remethylation of Hcys to methionine (Met), 
and the C677T variant is associated with reduced enzyme activity and elevated Hcys 
concentrations, particularly in populations with low folate intakes (Jacques et al. 1996).  Another 
common nonsynonymous MTHFR variant, 1298 AC (rs1801131), is also associated with 
reduced enzyme activity (Chango et al. 2000) and elevated Hcys concentrations (Castro et al. 
2003).  Importantly, genetic association studies can provide evidence about the causality of 
biomarker-disease relationships: gene variants are randomly distributed during gamete 
formation, and associations should not be subject to confounding or explained by reverse 
causation (Bochud et al. 2008).  Since the 677 CT variant is strongly associated with HHcys, it 
is commonly used as a genetic “proxy” for HHcys to examine the causal nature of HHcys-
disease associations (Clarke et al. 2012; Wald et al. 2002). 
 The prevalence of HHcys is particularly high among individuals of South Asian descent 
compared to other populations, which is believed to reflect folate and cobalamin deficiencies 
and/or genetic factors (Chandalia et al. 2003; Senaratne et al. 2001).  A cross-sectional survey of 
1,650 Bangladeshi adults found a high prevalence of HHcys, and plasma folate and cobalamin 
explained just 15% and 5% of the variance in plasma Hcys, respectively (Gamble et al. 2005).  It 
is unknown whether MTHFR 677 CT and 1298 AC are associated with Hcys concentrations 
in Bangladesh: these SNPs have variable effects on Hcys concentrations across populations 
(Wald et al. 2012), and the associations of these variants with Hcys concentrations has not been 
examined previously in a Bangladeshi population.   
 The objectives of the current study were to (1) identify gene variants that are associated 
with Hcys concentrations in Bangladesh; (2) confirm our group’s previous findings that HHcys 




(3) examine whether gene variants associated with HHcys are also associated with As-induced 
skin lesion incidence.  To address these objectives, we conducted a nested case-control study of 
As-induced skin lesions in the Health Effects of Arsenic Longitudinal Study (HEALS) cohort.  
We used two approaches to identify genetic variants associated with serum Hcys.  First, we 
examined a panel of SNPs in candidate genes involved one-carbon metabolism, with a particular 
focus on the two aforementioned nonsynonymous MTHFR SNPs, 677 CT and 1298 AC.  
Second, in a subset of 507 subjects with available GWAS data, we conducted an exploratory 
GWAS of serum Hcys to identify genetic loci using an “unbiased” approach.   







SUBJECTS AND METHODS 
Eligibility criteria and study design 
The Gene-Environment-Nutrition Interactions (GENI) study is a case-control study of 
incident As-induced skin lesions nested within a parent cohort, the Health Effects of Arsenic 
Longitudinal Study (HEALS) cohort, an ongoing prospective cohort study of As-exposed adults 
in Araihazar, Bangladesh (Ahsan et al. 2006).  GENI cases and controls were identified from the 
original cohort of 11,746 married men and women between 18 and 65 years, of which 9,727 
participants completed the baseline physical examination, provided urine and blood samples, and 
were free of skin lesions.  Initial HEALS recruitment was completed from October 2000 to May 
2002, and active follow-up of the cohort was done every 2 years: the first follow-up was 
completed from September 2002 to May 2004; second follow-up from June 2004 to August 
2006; and third follow-up from January 2007 to February 2009.  At baseline and at every follow-
up visit, trained physicians conducted comprehensive examinations to identify arsenicosis skin 
lesions (melanosis, leukomelanosis, and keratosis) across the entire body; the details of the 
structured examination protocol have been reported previously (Ahsan et al. 2006).  Melanosis is 
characterized by skin hyperpigmentation over a wide surface area; leukomelanosis is 
characterized by both skin hyperpigmentation and skin hypopigmentation over a wide surface 
area; and keratosis is characterized by bilateral skin thickening of the palms and soles (Ahsan et 
al. 2006b). 
The GENI study includes 876 incident skin lesion cases identified through the end of the 
third follow-up period in HEALS (February 2009).  The 876 skin lesion cases were individually 
matched to controls on gender, age (± 3 years), and follow-up time in the study (± 500 days).  




and/or DNA samples from the baseline recruitment visit for analysis, we devised a matching 
scheme to maximize the number of controls with biological samples.  Up to 3 possible controls 
were identified for each case, without prior knowledge of whether these controls had biological 
samples available.  Sample availability (serum and/or DNA) was then determined for each 
possible control, and the control with the greatest number of biological samples in the freezers 
(serum and/or DNA) was preferentially selected for each case.   
We had 703 cases and 705 controls with serum samples, and 701 matched pairs where 
both the case and control had a serum sample available.  There were 732 successfully matched 
pairs in which a control was identified with a DNA and/or serum sample, and 608 matched pairs 
in which both the case and control have both DNA and serum samples.  There were 144 skin 
lesion cases for which none of the three possible controls had either a serum or DNA sample in 
the freezers; for these cases, a control match was randomly selected from the three identified 
controls.   
Oral informed consent was obtained by our Bangladeshi field staff physicians, who read 
an approved consent form to the study participants. This study was approved by the Institutional 
Review Boards of Columbia University Medical Center and the Bangladesh Medical Research 
Council. 
Analytic techniques 
Methods for analysis of water As, urinary As, and urinary Cr are described in detail in 
Chapter 3.  Analytic methods for serum Hcys, DNA extraction, and genotyping are outlined here. 
Serum Hcys 
 Serum Hcys was measured using HPLC, as described in Chapter 3.  Serum samples in 




duplicate; samples were repeated if the coefficient of variation (CV) within the duplicates was 
>10%.  Samples were randomized in a two-step process such that the run order of the case-
control pairs was randomized, as well as the run order of the case and control samples within 
each matched pair.  The intra- and inter-day CVs were 3 and 8%, respectively. 
DNA extraction 
 DNA was extracted from blood clots using the Flexigene DNA kit (Qiagen), and the 
DNA concentration and quality (260/280 and 260/230 ratios) was determined using Nanodrop 
1000.  DNA samples were shipped to Columbia University on dry ice and stored at −80°C. 
TaqMan OpenArray SNP genotyping 
125 ng of DNA was processed with the TaqMan OpenArray Genotyping System (Life 
Technologies, Carlsbad, California, USA) according to the manufacturer’s protocol using 
custom-designed chips with 64 SNPs in candidate genes involved in one-carbon metabolism and 
folate transport (full list of SNPs in Appendix Table E1).   DNA samples in case-control pairs 
were processed on the same array chip, and the run order was determined using the same two-
step randomization process as for serum Hcys, but with different sample randomization orders.  
Genotype calls were generated using the OpenArray SNP Genotyping analysis software 1.0.3. 
Of the original 64 SNPs on the array, 11 SNP assays had call rates < 90% and were 
excluded, and of the remaining 53 SNPs, 21 SNPs had minor allele frequencies (MAF) < 1% in 
our sample and were additionally excluded.  The final dataset contained 32 SNPs with a mean 
call rate of 97.1%.   
Illumina Infinium HD SNP array 
A subset of GENI subjects had GWAS data available from the Illumina Infinium HD 




v2.1 chips according to manufacturer’s protocol and read on the BeadArray Reader, and 
genotype calls were generated using BeadStudio software.  The 299,140 measured genotypes 
were used to impute for 1,211,988 SNPs using HapMap 2 data with the Gujarati Indians in 
Houston, Texas (GIH) reference panel.   
Statistical methods 
Descriptive statistics (mean ± standard deviation [SD] for continuous variables, N [%] for 
categorical variables) were calculated separately for the cases and control groups.  Differences 
between case and control groups were examined using Wilcoxon test (continuous variables) and 
chi-square test (categorical variables), and differences in matched case-control pairs were 
examined using Wilcoxon signed-rank test (continuous variables), McNemar’s test (dichotomous 
variables), and Bowker’s test (categorical variables).   
 We examined whether genotype distributions were in accordance with Hardy-Weinberg 
equilibrium by comparing the expected vs. observed genotype frequencies in controls using Chi-
square tests.  Differences in genotype distributions between case and control groups were also 
examined using Chi-square tests.  Linkage disequilibrium parameters (pairwise D’ and R
2
) 
among MTHFR SNPs were calculated using Haploview version 4.2 (Barrett et al. 2005), and 
haplotype pairs (diplotypes) for each subject were constructed using PHASE version 2.1.1 
(Stephens et al. 2001; Stephens and Scheet 2005) for all subjects with complete data for 
rs1801133, rs1801131, and rs1476413.  Associations between SNP genotypes/haplotypes and 
serum Hcys were examined in the overall sample and separately in the cases and controls using 
general linear models.  Associations between serum Hcys and SNPs with risk of skin lesions 
were examined using conditional logistic regression with matched case-control pairs, with and 




using a linear mixed model adjusted for age, sex, genotype batch, and cryptic relatedness using 
Genome-wide Efficient Mixed Model Association (GEMMA) software (Zhou and Stephens 
2012, 2013).   
 Unless specified, statistical tests were conducted using SAS software, version 9.3 (SAS 





Characteristics of GENI study participants 
Demographic and clinical characteristics of the GENI skin lesion cases and controls are 
presented in Table 1.  Controls were matched to skin lesion cases on gender, age (± 3 years), and 
study follow-up time (± 60 days).  At baseline, skin lesion cases were more likely to report use of 
betelnut (P = 0.07), were less likely to own a television (P = 0.009), and had higher As 
concentrations in well water (P < 0.0001) and urine (P < 0.0001).  Serum Hcys concentrations 
were higher in skin lesion cases (P = 0.003), as well as the proportion of individuals who were 
classified as having HHcys, defined here as serum Hcys > 15 uM (P = 0.02).  The demographic 
and clinical data did not differ between GENI subjects with and without serum and/or DNA 
samples (data not shown).  The breakdown of the skin lesion types (melanosis, keratosis, and/or 
leukomelanosis) among the total 876 incident skin lesions cases is in Appendix Table E2. 
 Genotype frequencies of the three MTHFR SNPs on the OpenArray panel are shown in 
Table 2.   In addition to 677 CT (rs1801133) and 1298 AC (rs1801131), we measured 
rs1476413, a GA variant in intron 10 that is 2,176 bp away from 1298 AC.  The MAF for 
677 CT was 0.12 in both cases and controls, and approximately 20% and 1.6% of the total 
sample were CT heterozygous and TT homozygous, respectively.  The MAFs for 1298 AC 
and Intron 10 GA were higher than the MAF for 677 CT (overall sample, 0.38 and 0.43, 
respectively).  Genotype frequencies were in accordance with Hardy-Weinberg equilibrium for 
all three MTHFR SNPs (P > 0.05), and genotype distributions did not differ between cases and 






Table 1. Baseline descriptive and clinical characteristics for GENI participants with serum. 










Demographic    
Gender (male) 497 (70.5)
a
 495 (70.4) 1.0 
Age (years) 44.3 ± 9.5 (20 to 65)
b
 44.3 ± 9.5 (20 to 65) 0.03 
BMI (kg/m
2
) 19.8 ± 3.3 (13.0 to 32.3) 19.5 ± 2.8 (14.0 to 31.4) 0.05 
Cigarette smoking 
(ever) 
400 (56.7) 420 (59.7) 0.15 
Betelnut use (ever) 351 (49.8) 381 (54.2) 0.07 
Education   0.004 
0 years 297 (42.1) 341 (48.5)  
1-5 years 101 (14.3) 115 (16.4)  
> 5 years 307 (43.6) 247 (35.1)  
Television ownership 
(yes) 
270 (38.3) 222 (31.6) 0.009 
Arsenic exposure     
Well water As (µg/L) 85 ± 97 (0.1 to 571) 138 ± 134 (0.1 to 790) <0.0001 
Well water As category   <0.0001 
< 10 µg/L 178 (25.3) 106 (15.1)  
10-50 µg/L 166 (23.6) 116 (16.5)  
50-100 µg/L 128 (18.2) 121 (17.2)  
100-200 µg/L 147 (20.9) 172 (24.5)  
>200 µg/L 86 (12.2) 188 (26.7)  
Urinary As (µg/L)
c
 124 ± 125 (4 to 1228) 167 ± 177 (1 to 1278) <0.0001 
Urinary Cr (mg/dL)
c
 63 ± 46 (4 to 290) 61 ± 47 (3 to 376) 0.29 
Homocysteine    
Serum Hcys (µM) 15.3 ± 9.6 (3.1 to 108.2) 16.2 ± 9.1 (3.5 to 119.0) 0.003 
HHcys (Hcys > 15 µM) 272 (38.6) 309 (44.0) 0.02 
Serum Hcys category   0.10 
< 10 µM 169 (19.3) 133 (15.2)  
10-15 µM 264 (30.1) 261 (29.8)  
15-25 µM 217 (24.8) 235 (26.8)  




Table 2.  Genotype frequencies for MTHFR SNPs, overall and by skin lesion case status. 





     
 CC 501 (77.2)
a
 563 (77.9) 1064 (77.6) 1008 (78.1) 
 CT 136 (21.0) 147 (20.3) 283 (20.6) 262 (20.3) 
 TT 12 (1.8) 13 (1.8) 25 (1.8) 21 (1.6) 
 MAF 0.12 0.12 0.12 0.12 
1298 AC 
rs1801131 
     
 AA 255 (40.0) 278 (39.3) 533 (39.6) 505 (39.8) 
 AC 287 (45.0) 315 (44.5) 602 (44.7) 566 (44.6) 
 CC 96 (15.0) 115 (16.2) 211 (15.7) 198 (15.6) 
 MAF 0.38 0.38 0.38 0.38 
Intron 10 GA 
rs1476413 
     
 GG 226 (34.8) 239 (33.0) 465 (33.8) 436 (33.7) 
 GA 301 (46.4) 338 (46.6) 639 (46.5) 604 (46.6) 
 AA 122 (18.8) 148 (20.4) 270 (19.7) 255 (19.7) 
 MAF 0.42 0.44 0.43 0.43 
a.  N (%) (all such values), b. mean ± SD (all such values)  
 
 
Elevated serum Hcys is a risk factor for arsenic-induced skin lesions 
To confirm our group’s previous finding that HHcys was a risk factor for As-induced 
skin lesions (Pilsner et al 2009), we used conditional logistic regression to examine the 
unadjusted and adjusted odds ratios (ORs) for serum Hcys and other study covariates, shown in   
Table 3.  Consistent with Pilsner et al. 2009, serum Hcys at baseline was associated with a dose-




Table 3.  Unadjusted and adjusted ORs (95% CIs) for serum homocysteine and 










Serum Hcys     
 < 10 µM ref. ref. 
 10-15 µM 1.34 (0.99 to 1.80) 1.29 (0.94 to 1.79) 
 15-25 µM 1.53 (1.10 to 2.13) 1.60 (1.12 to 2.27) 
 > 25 µM 1.98 (1.25 to 3.14) 1.83 (1.12 to 3.01) 
Age    
 1-year 1.38 (1.04 to 1.83) 1.37 (1.01 to 1.79) 
Betelnut use    
 Never ref. ref. 
 Ever 1.21 (0.97 to 1.52) 1.17 (0.91 to 1.49) 
Television ownership     
 No ref. ref. 
 Yes 0.74 (0.59 to 0.92) 0.86 (0.67 to 1.11) 
Education    
 0 years ref. ref. 
 1-5 years 0.84 (0.65 to 1.09) 0.83 (0.63 to 1.09) 
 > 5 years 0.67 (0.51 to 0.87) 0.70 (0.52 to 0.94) 
Well water As    
 < 10 µg/L ref. ref. 
 10-50 µg/L 1.32 (0.91 to 1.91) 1.38 (0.95 to 2.01) 
 50-100 µg/L 1.81 (1.22 to 2.66) 1.90 (1.28 to 2.84) 
 100-200 µg/L 2.16 (1.51 to 3.10) 2.15 (1.49 to 3.11) 
 >200 µg/L 4.12 (2.78 to 6.11) 4.16 (2.78 to 6.21) 
 






MTHFR 677 CT is associated with elevated serum Hcys 
We next examined associations of MTHFR SNPs with serum Hcys concentrations.  The 
677 CT variant was strongly associated with serum Hcys concentrations in both cases and 
controls (P < 0.0001, Appendix Table E3).  Boxplots displaying serum Hcys concentrations by 
677 CT genotype for the overall sample are shown in Figure 2.  In the overall sample, 
compared to CC wildtype, geometric mean serum Hcys concentrations were approximately 3 µM 
higher in CT heterozygotes (P < 0.0001) and approximately 19 µM higher in TT homozygotes (P 
< 0.0001).  The 677 CT genotype explained 15.8% of the variance in log-transformed serum 
Hcys in controls and 7.4% in cases (Appendix Table E3).  The 1298 AC and Intron 10 GA 
variants were not associated with serum Hcys in cases or controls after conditioning on 677 
CT (Appendix Table E3). 
Figure 2.  Boxplots of serum Hcys by MTHFR 677 CT genotype for all subjects.  
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MTHFR Intron 10 GA is marginally associated with increased odds for skin lesions 
 Next, we examined associations of MTHFR SNPs with incident skin lesions in matched 
case-control pairs (Table 4).  Although 677 CT was strongly associated with serum Hcys in 
our sample, there was no association of the 677 CT variant with skin lesion risk (Table 4).  
Conversely, although Intron 10 GA was not associated with serum Hcys, those who were 
homozygous for the risk allele of Intron 10 GA had an OR for skin lesions of 1.29 (95% CI, 
0.96 to 1.75) in adjusted models, although this did not reach statistical significance (Table 4). 
MTHFR SNPs are in linkage disequilibrium 
 The three MTHFR SNPs are in linkage disequilibrium (LD):  In the HapMap GIH 
population, the pairwise D’ values for 677 CT with 1298 AC and Intron 10 G A are 1.0 
and 0.93, respectively, and the pairwise  D’ between 1298 AC and Intron 10 G A is 0.90.  
Using Haploview, we examined LD parameters in our sample and observed similar pairwise D’ 
values (Figure 3), indicating that the three SNPs were nearly in complete LD.  The R
2
 values 
were smaller than the D’ values (Figure 1) since the MAF for 677 CT was considerably lower 
than the MAFs for 1298 AC and Intron 10 G A. 
We constructed MTHFR haplotypes for all subjects with complete data for the three 
SNPs (Table 5).  The most common haplotype was wildtype CAG (677 C-1298 A-Intron 10 G).  
The C allele of 1298 AC was most commonly in phase with the A allele of Intron 10 GA, 
and the T allele of 677 CT was almost always in phase with 1298 A and Intron 10 G.   
Haplotypes containing both 677 T and 1298 C variant alleles were rare and occurred mainly in 
the case group.  Diplotype (haplotype pair) frequencies are listed in Appendix Table E4.  





Table 4.  Unadjusted and adjusted ORs (95% CIs) for MTHFR SNPs as independent 
predictors of arsenic-induced skin lesions in conditional logistic regression models. 







677 CT     
N=606 pairs General CC ref. ref. 
  CT 0.95 (0.71 to 1.27) 0.87 (0.64 to 1.19) 
  TT 0.91 (0.41 to 2.07) 0.84 (0.36 to 1.97) 
 Dominant CC ref. ref. 
  CT+TT 0.95 (0.72 to 1.24) 0.87 (0.65 to 1.16) 
 Recessive CC+CT ref. ref. 
  TT 0.92 (0.40 to 2.08) 0.84 (0.36 to 1.98) 
1298 AC     
N=585 pairs General AA ref. ref. 
  AC 0.98 (0.77 to 1.25) 0.97 (0.75 to 1.26) 
  CC 1.11 (0.79 to 1.57) 1.21 (0.84 to 1.74) 
 Dominant AA ref. ref. 
  AC+CC 1.01 (0.81 to 1.27) 1.03 (0.81 to 1.31) 
 Recessive AA+AC ref. ref. 
  CC 1.13 (0.82 to 1.55) 1.22 (0.87 to 1.73) 
Intron 10 GA     
N=608 pairs General GG ref. ref. 
  GA 1.05 (0.82 to 1.35) 1.04 (0.80 to 1.36) 
  AA 1.16 (0.85 to 1.58) 1.32 (0.95 to 1.84) 
 Dominant GG ref. ref. 
  GA+AA 1.09 (0.86 to 1.37) 1.12 (0.88 to 1.43) 
 Recessive GG+GA ref. ref. 
  AA 1.13 (0.85 to 1.49) 1.29 (0.96 to 1.75) 
 





Figure 3.  Linkage disequilibrium parameters for MTHFR SNPs.  Pairwise D’ and R
2
 values 
calculated using Haploview are shown for controls (A), cases (B), and the overall sample (C).  
 
Table 5.  Inferred haplotype counts and frequencies.  
 






   
C A G 552 (43.7) 588 (41.9) 1140 (42.8) 
C A A 84 (6.6) 114 (8.1) 198 (7.4) 
Total 677 C-1298 A 636 (50.3) 702 (50.1) 1338 (50.2) 
C C G 25 (2.0) 39 (2.8) 64 (2.4) 
C C A 448 (35.4) 496 (35.4) 944 (35.4) 
Total 677 C-1298 C 473 (37.4) 535 (38.2) 1008 (37.8) 
T A G 154 (12.2) 158 (11.3) 312 (11.7) 
T A A 0 (0.0) 1 (0.1) 1 (0.0) 
Total 677 T-1298 A 154 (12.2) 159 (11.3) 313 (11.7) 
T C G 1 (0.1) 3 (0.2) 4 (0.2) 
T C A 0 (0.0) 3 (0.2) 3 (0.1) 




MTHFR haplotypes are not significantly associated with increased odds for skin lesions 
 To attempt to tease apart the independent effects of each MTHFR SNP on skin lesion 
risk, we examined associations of MTHFR diplotypes with incident skin lesions (Table 6).  
Those with diplotypes containing a CAA haplotype (wildtype for 677 CT and 1298 AC, risk 
allele for Intron 10 GA) had an OR for skin lesions of 1.42 (95% CI, 0.92 to 2.19) compared to 
those with the wildtype diplotype (CAG/CAG).  Similarly, those with diplotypes containing the 
CCG haplotype (wildtype for 677 CT and Intron 10 GA, risk allele for 1298 AC)  had an 
OR for skin lesions of 1.48 (95% CI, 0.76 to 2.90) compared to wildtype (Table 6).  However, 
diplotypes containing the haplotype with risk alleles for both Intron 10 GA and 1298 AC 
(haplotype CCA) did not have an elevated risk for skin lesions compared to wildtype (OR 1.11, 
95% CI 0.80 to 1.53).  Diplotypes containing a TAG haplotype were also not significantly 
associated with skin lesion incidence (OR 0.82, 95% CI 0.61 to 1.12).   
MTHFR haplotypes and diplotypes are associated with serum Hcys 
 We also examined associations of MTHFR diplotypes with serum Hcys concentrations.  
Plots of geometric mean (± SD) serum Hcys concentrations by MTHFR diplotype in cases and 
controls are displayed in Figure 4.  The diplotype variable explained 19.6% of the variance in 
log-transformed serum Hcys in controls (Figure 4A), which is approximately 4% higher than the 
variance explained by 677 CT alone.  In cases, the MTHFR diplotype explained only 9.1% of 
the variance in serum Hcys (Figure 4B).  Compared to wildtype diplotype carriers, diplotypes 
containing the CAA haplotype had higher geometric mean serum Hcys concentrations (P < 
0.05), indicating that the Intron 10 GA risk allele is associated with increased serum Hcys.  




independently associated with Hcys in this population.  In agreement with the findings for 677 
CT, the TAG haplotype was strongly associated with serum Hcys (P < 0.0001).   
 
Table 6.  Unadjusted and adjusted ORs (95% CIs) for MTHFR diplotypes as predictors of 
skin lesions from conditional logistic regression models. 
 
 









   
 
Wildtype 1.29 (0.86 to 1.95) 1.42 (0.92 to 2.19) 
Wildtype + other 1.21 (0.86 to 1.70) 1.33 (0.93 to 1.91) 
Diplotypes containing 
CCG  
 . . 
 
Wildtype 1.36 (0.72 to 2.54) 1.48 (0.76 to 2.90) 
Wildtype + other 1.25 (0.69 to 2.25) 1.36 (0.73 to 2.55) 
Diplotypes containing 
CCA  
   
 
Wildtype 1.09 (0.80 to 1.47) 1.11 (0.80 to 1.53) 
Wildtype + other 0.97 (0.77 to 1.22) 0.98 (0.77 to 1.26) 
Diplotypes containing 
TAG  
   
 
Wildtype 0.99 (0.68 to 1.44) 0.95 (0.64 to 1.42) 




Figure 4.  Geometric mean Hcys concentrations by MTHFR diplotype.  Bars represent 
geometric mean (± SD) serum Hcys in controls (Figure 4A) and cases (Figure 4B).   
 




12.6 ± 1.4 µM 
 
CAA diplotypes 
14.6 ± 1.5 µM* 
 
CCG diplotypes 
10.4 ± 1.6 µM 
 
TAG (1 copy) 
15.9 ± 1.6 µM*** 
 
TAG (2 copies) 
45.2 ± 1.7 µM*** 
 





Figure 4.  Geometric mean Hcys concentrations by MTHFR diplotype.  Bars represent 
geometric mean (± SD) serum Hcys in controls (Figure 4A) and cases (Figure 4B).   
 




13.5 ± 1.5 µM 
 
CAA diplotypes 
15.1 ± 1.6 µM 
 
CCG diplotypes 
13.7 ± 1.6 µM 
 
TAG (1 copy) 
17.9 ± 1.6 µM*** 
 
TAG (2 copies) 
30.5 ± 2.1 µM*** 
 




MTHFR 677 CT is associated with urinary As metabolite percentages 
 Since MTHFR 677 CT genotypes had the strongest associations with serum Hcys, we 
also assessed the associations of 677 CT genotypes with urinary As metabolite percentages.  
The majority of skin lesion cases with genotype data also had urinary As metabolite data 
(657/723), but only a small proportion of controls had urinary As metabolite data (203/651).  As 
shown in Appendix Table E5, in cases, adjusted mean urinary %MMA was higher in 677 T allele 
carriers (adjusted mean ± SE, 13.9 ± 0.2% in CC wildtype, 14.9 ± 0.4% in T allele carriers, P = 
0.05), and urinary %DMA was lower  (adjusted mean ± SE, 71.4 ± 0.4% in CC wildtype, 69.7 ± 
0.7% in T allele carriers, P = 0.04).  In controls, 677 T allele carriers also had higher urinary 
%MMA and lower urinary %DMA (Appendix Table E5).  No significant associations between 
urinary As metabolites and 1298 AC or Intron 10 GA were observed (data not shown). 
Other one-carbon metabolism variants are not associated with serum Hcys or skin lesions 
 In addition to MTHFR gene variants, we examined the associations of the other 
OpenArray SNPs with both serum Hcys concentrations and skin lesion risk.  However, in 
preliminary analyses, we did not observe any significant associations (P < 0.05) between these 
SNPs with serum Hcys or skin lesion incidence (data not shown). 
GWAS of serum Hcys reveals novel genetic loci 
 The MTHFR diplotypes explained a smaller proportion of the variance in serum Hcys 
among skin lesion cases (9.1%) compared to controls (19.6%), indicating that there might be 
other important genetic determinants of serum Hcys concentrations in the skin lesion group.  To 
examine whether we could identify novel genetic loci associated with serum Hcys among skin 
lesion cases, we conducted an exploratory GWAS of serum Hcys in a subset of 507 subjects in 




presented in Figure 5, and the quantile-quantile (Q-Q) plot is shown in Figure 6.  We identified 
one SNP that was associated with serum Hcys at genome-wide significance (P < 5.0 x 10
-8
) 
(Figure 4).  This SNP (rs6438549, AG) is located in an intronic region of the NR1I2 gene on 
chromosome 3.  Another SNP in NR1I2 (rs2461818), in LD with rs6438549, was the 8
th
 most 
significant SNP genome-wide according to P-value (P = 9.81 x 10
-7
).   
The top gene-associated SNPs are listed in Table 7; when multiple SNPs were identified 
in an LD block at a gene locus, only the lead SNP was included in the table.  Since the GWAS 
was conducted in a convenience sample, we examined top hits that did not meet the genome-
wide P < 5.0 x 10
-8
 significance cutoff and explored the biologic significance of the identified 
genes (Appendix Table E6).  Among the top ranked SNPs in our analysis, there were hits in 
genes that had been identified in previous GWAS analyses.  Among our top 20 hits, there were 
two SNPs in PRICKLE2, which was a gene identified in a GWAS of serum folate concentrations 
in an Italian cohort (Tanaka et al. 2009).  Additionally, we identified an LD block of 8 SNPs in 
PTPRT; another member of the protein tyrosine phosphatase (PTP) family, PTPRD, was 
associated with plasma Hcys in a Spanish GWAS study (Malarstig et al. 2009). 
 Although 677 CT (rs1801133) was strongly associated with serum Hcys in our overall 
sample, in the GWAS of serum Hcys in the subset of 507 subjects, we did not identify 677 CT 
among the top 1,000 hits genome-wide (SNPs with P < 6.23 x 10
-4
).  However, 677 CT was in 
LD with the 43
rd
 most significant SNP (rs2639453, P = 1.17 x 10
-5
).  No candidate-gene SNPs 
included on the OpenArray platform, and no SNPs in any of the one-carbon metabolism genes 







Figure 5.  Manhattan plot from GWAS of serum Hcys.  Genomic coordinates for all GWAS 
SNPs are plotted on the x-axis, and the negative logarithm of the P-value for the association of 
each SNP with serum Hcys is plotted on the y-axis.  Datapoints above the red line represent 
SNPs with genome-wide significant P-values (P < 5.0 x 10
-8
) for associations with serum Hcys.  
Chromosomes are color-coded by the alternating black/gray color scheme (SNPs within 
















Figure 6.  Quantile-quantile (Q-Q) plot from GWAS of serum Hcys.  The figure displays the 
expected distribution of negative log-transformed P-values (x-axis) plotted against the observed 

























Table 7.  List of top gene-associated SNPs from GWAS of serum Hcys. 
 
 
RS# Gene Chr. 
Ref.  
allele 
B SE P 
rs6438549 NR1I2 3 A -7.53 1.36 4.69 x 10
-8
 
rs7611474 NLGN1 3 A -6.47 1.23 1.94 x 10
-7
 
rs17155012 FRMD4A 10 C -4.95 0.96 3.40 x 10
-7
 
rs6077536 PLCB4 20 T -4.13 0.81 4.60 x 10
-7
 
rs10916959 ECE1 1 A -2.86 0.57 8.98 x 10
-7
 
rs16927009 CD44 11 T -7.97 1.61 9.94 x 10
-7
 
rs6791571 PRICKLE2 3 G -3.03 0.63 2.04 x 10
-6
 
rs2425556 PTPRT 20 G -3.69 0.78 2.89 x 10
-6
 







In this nested case-control study of incident As-induced skin lesions in a cohort of 
Bangladeshi adults, we measured Hcys in baseline serum samples and SNPs in various one-
carbon metabolism genes to address three primary objectives: first, to confirm that HHcys was a 
risk factor for As-induced skin lesions; second, to identify genetic determinants of serum Hcys 
concentrations in this population; and third, to explore the causal nature of the association 
between HHcys and As-induced skin lesion incidence.  We focused on the nonsynonymous 
MTHFR variants 677 CT and 1298 AC, which are known to influence Hcys concentrations 
in other populations.  First, we confirmed our group’s previous finding (Pilsner et al. 2009) that 
serum HHcys was a risk factor for incident As-induced skin lesions.  Next, we found that 
MTHFR 677 CT was strongly associated with serum Hcys among both skin lesion cases and 
matched controls, and analysis of MTHFR diplotypes constructed from 677 CT, 1298 AC, 
and Intron 10 AG found that the Intron 10 GA variant had a modest association with Hcys 
concentrations independent of 677 CT.  MTHFR diplotypes explained approximately 20% of 
the variance in serum Hcys among controls, but only explained 9% of the variance in serum 
Hcys among skin lesion cases.  Despite the strong associations between MTHFR variants and 
serum Hcys, these gene variants were not significantly associated with skin lesion risk.  An 
exploratory GWAS of serum Hcys in a sample comprised predominately of skin lesion cases 
identified novel genetic loci associated with serum Hcys, which may provide information about 
the source of HHcys among individuals with As-induced skin lesions. 
Homocysteine—measured in serum samples from the baseline cohort, which were drawn 
prior to disease onset—was associated with a dose-dependent increase in risk for As-induced 




related to skin lesion incidence and/or (2) extracellular Hcys is correlated with endogenous or 
exogenous causal risk factor(s).  However, we did not find that the MTHFR SNPs and 
haplotypes that were associated with serum Hcys were associated with skin lesion incidence.  
Since MTHFR is causally related to Hcys, and MTHFR diplotypes explained a substantial 
proportion of the variance in serum Hcys in our population, we would expect to observe an 
association between MTHFR gene variants and skin lesion incidence if the serum Hcys 
association with skin lesions were indeed causal.  However, it is important to distinguish what 
the MTHFR finding does—and does not—imply about the causal nature of the HHcys-skin 
lesions association. 
First, many of the proposed mechanisms of HHcys-induced carcinogenesis involve 
intracellular Hcys, and serum Hcys might not perfectly reflect intracellular Hcys, particularly in 
relation to folate.  A small randomized controlled trial (RCT) of 50 subjects randomized to 500 
µg daily folic acid vs. placebo found only a moderate correlation between plasma Hcys and 
intracellular Hcys (measured in peripheral blood mononuclear cells [PBMCs]) at baseline (r = 
0.35, P = 0.01), and folic acid supplementation significantly reduced plasma Hcys but had no 
effect on intracellular Hcys concentrations (Smith et al. 2013).  The authors speculated that folate 
increases intracellular Hcys remethylation, resulting in reduced Hcys transport to the plasma, but 
homeostatic mechanisms keep intracellular Hcys concentrations within a tight range over a wide 
range of folate concentrations (Smith et al. 2013).  If intracellular Hcys is casually related to 
skin lesions, serum Hcys and skin lesion incidence would be associated, but since the folate-
related component of serum Hcys would not be associated with intracellular Hcys, we would not 




current study can only provide evidence that increased extracellular Hcys directly related to 
MTHFR variants is not associated with skin lesion risk. 
Second, although MTHFR SNPs are often used as proxies for HHcys in Mendelian 
randomization studies, MTHFR is involved in numerous biologic processes that could also 
influence As-induced skin lesion development.  For example, 5:10-methylenetetrahydrofolate 
(5:10 methylene-THF), the substrate used by MTHFR for 5mTHF synthesis, is involved in the de 
novo production of thymidines, and it has been hypothesized that 677 CT variants, while 
having negative impacts on methylation capacity, might also have protective health effects by 
increasing DNA repair capacity and minimizing uracil-induced DNA double strand breaks 
(DSBs) (Blount et al. 1997; Kennedy et al. 2012).  Given that a recent study found that As
III
 was 
a direct inducer of DSBs in Saccharomyces cerevisiae (Litwin et al. 2013), it is plausible that the 
different 677 CT genotypes might each have protective and deleterious effects on As-induced 
skin lesion risk.  At the very least, MTHFR SNPs are not likely to be appropriate proxies for 
HHcys in the study of As-induced skin lesion pathogenesis.   
Although we did not find that MTHFR variants were associated with risk of skin lesions, 
we observed significant associations of MTHFR variants with increased serum Hcys and 
decreased As methylation (increased urinary %MMA and decreased urinary %DMA), indicating 
that MTHFR variants, particularly 677 CT, explain a substantial proportion of the inter-
individual variation in these As toxicity markers.  A previous RCT of folic acid supplementation 
in folate-deficient Bangladeshis found that 400 µg folic acid significantly enhanced As 
methylation, decreased blood As, and decreased plasma Hcys compared to placebo, although the 
treatment response varied widely among individuals in the folic acid group (Gamble et al. 2006; 




with 677 CT or TT genotypes might not be as responsive to folic acid treatment as CC 
genotypes; for these individuals, additional supplementation with 5mTHF might enhance As 
methylation capacity and reduce serum Hcys. 
  Since the subset of GENI participants with GWAS data was predominantly comprised of 
skin lesion cases, the results of the GWAS of serum Hcys might provide insight into the source 
of HHcys among individuals who are predisposed to As toxicity.  The exploratory GWAS of 
serum Hcys identified a SNP in the NR1I2 gene, rs6438549, which was associated with serum 
Hcys at genome-wide significance.  In humans, the NR1I2 gene encodes the pregnane X receptor 
(PXR), a nuclear receptor (as a heterodimer with retinoid X receptor [RXR]) involved in 
CYP3A4-mediated xenobiotic detoxification (Luo et al. 2002).  PXR regulates the expression of 
Phase II enzymes (including glutathione S-transferases) and drug transporters (including 
multidrug resistance proteins [MRPs]) (Kakizaki et al. 2008), which are both involved in As 
detoxification and transport (Leslie et al. 2004; Liu et al. 2001).   Upregulation of PXR 
expression is found in a variety of human cancers (Qiao et al. 2013), and As
III
 exposure induces 
PXR expression in mouse models (Medina-Diaz et al. 2009).  Although there are not obvious 
biologic mechanisms linking PXR and serum Hcys, N-3 polyunsatured fatty acids (PUFAs) 
upregulate the expression of Hcys-metabolizing enzymes, including MTHFR, in a mechanism 
that might involve the binding of PXR to fatty acid-responsive elements in the promoters of 
MTHFR and other genes (Huang et al. 2012).   
Among the top 1,000 GWAS hits, we did not identify any SNPs in genes involved in 
Hcys-related metabolic pathways.  Instead, the top hits were in genes involved in a range of 
biological processes, including epithelial cell polarity establishment (FRMD4A, PRICKLE2), 




identified multiple genes that are associated with human squamous cell carcinomas: CD44 is a 
marker of tumor initiation in head and neck squamous cell carcinomas (HNSCCs) (Prince et al. 
2007), and FRMD4A expression is upregulated in primary HNSCCs (Goldie et al. 2012).  
Interestingly, a recent study of cultured human keratinocytes found that chronic exposure to 
environmentally-relevant concentrations of sodium arsenite (0.05 ppm) induced malignant 
transformation through NF-κB-mediated CD44 upregulation, suggesting that CD44 might be a 
molecular marker of As-induced neoplastic transformation in skin lesions (Huang et al. 2013).  
Possibly, the elevated serum Hcys that we observed among individuals who went on to develop 
skin lesions did not play a causal role in skin lesion pathogenesis, but instead reflected increased 
susceptibility to As-induced dysregulation of epithelial cell adhesion and polarity.   
 This study had several limitations.  First, we did not have As metabolite measures (InAs, 
MMA, and DMA) for all of our participants, and we were thus unable to fully examine the 
relationships among the As metabolites, Hcys, and one-carbon metabolism gene variants.  We 
plan to incorporate this data into the analysis once the As metabolite measures becomes available 
for our entire study sample.  Second, we did not have biologic samples (serum and/or DNA) for 
a small proportion of the cases and controls, which could bias our results.  Third, we did not have 
serum and/or plasma samples that had not undergone a freeze-thaw cycle, and thus, we were 
unable to measure plasma folate to assess folate nutritional status.   Fourth, we did not replicate 
the results of the GWAS of serum Hcys to verify our findings.  However, we plan to measure the 
top SNP hits in the entire GENI study sample to verify the associations of these SNPs with 
serum Hcys concentrations and additionally, to examine whether these SNPs are associated with 




 In conclusion, we observed that serum Hcys was a risk factor for As-induced skin lesions, 
in accordance with previous findings from our group (Pilsner et al. 2009), and that gene variants 
in MTHFR were associated with elevated serum Hcys concentrations in skin lesion cases and 
controls.  However, these MTHFR variants were not associated with skin lesion risk.  A GWAS 
of serum Hcys in a subset of GENI subjects identified mulitple genes involved in xenobiotic 
detoxification and epithelial cell polarity and adhesion, providing new information regarding the 
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Table E1.  List of SNPs on OpenArray platform. 
 
SNP assays with call rates < 90% (N=11)  
Symbol(s) Gene Name(s) RS# 
AS3MT arsenic (+3 oxidation state) methyltransferase rs3740400 
AS3MT arsenic (+3 oxidation state) methyltransferase rs11191439 
AS3MT arsenic (+3 oxidation state) methyltransferase rs11191453 
FOLR1 folate receptor 1 (adult) rs1801932 
FOLR1 folate receptor 1 (adult) rs9282688 
FOLR3 folate receptor 3 (gamma) rs2229185 
SLC19A1 solute carrier family 19 (folate transporter), member 1 rs12659 
SLC19A1 solute carrier family 19 (folate transporter), member 1 rs1051266 
SLC19A1 solute carrier family 19 (folate transporter), member 1 rs56822323 
SLC19A1 solute carrier family 19 (folate transporter), member 1 rs79091853 
SLC19A1 solute carrier family 19 (folate transporter), member 1 rs113642554 
SNP assays with MAF < 0.01 (N=21) 
Symbol(s) Gene Name(s) RS# 
AS3MT arsenic (+3 oxidation state) methyltransferase rs34556438 
AS3MT arsenic (+3 oxidation state) methyltransferase rs35232887 
CBS cystathionine-β-synthase rs34040148 
FOLR1 folate receptor 1 (adult) rs112062510 
FOLR1 folate receptor 1 (adult) rs121918405 
FOLR1 folate receptor 1 (adult) rs121918406 
FOLR1 folate receptor 1 (adult) rs35179028 
FOLR1 folate receptor 1 (adult) rs61735636 
FOLR1 folate receptor 1 (adult) rs76191655 




FOLR1 folate receptor 1 (adult) rs77771906 
FOLR1 folate receptor 1 (adult) rs7928649 
FOLR2 folate receptor 2 (fetal) rs13908 
FOLR3 folate receptor 3 (gamma) rs34970007 
FOLR3 folate receptor 3 (gamma) rs61746271 
FOLR3 folate receptor 3 (gamma) rs7925545 
FOLR3 folate receptor 3 (gamma) rs7926875 
FOLR3 folate receptor 3 (gamma) rs7926987 
MTHFD1 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1 
rs1803951 
SLC19A1 solute carrier family 19 (folate transporter), member 1 rs35786590 
-- -- rs117782026 
SNP assays included in current study (N=32) 
Symbol(s) Gene Name(s) RS# 
AS3MT arsenic (+3 oxidation state) methyltransferase  rs10748835 
AS3MT arsenic (+3 oxidation state) methyltransferase rs12416687 
AS3MT arsenic (+3 oxidation state) methyltransferase rs3740393 
AS3MT arsenic (+3 oxidation state) methyltransferase rs7085104 
BHMT betaine-homocysteine S-methyltransferase rs3733890 
FOLR1 folate receptor 1 (adult)   rs1540087 
FOLR1 folate receptor 1 (adult) rs2071010 
FOLR1 folate receptor 1 (adult) rs7109250 
FOLR2 folate receptor 2 (fetal) rs2298444 
FOLR2 folate receptor 2 (fetal) rs514933 
FOLR2 folate receptor 2 (fetal) rs651646 
FOLR2 folate receptor 1 (adult) rs651933 
FOLR3 folate receptor 3 (gamma) rs1802608 
FOLR3 folate receptor 3 (gamma) rs61734430 
MTHFD1 
methylenetetrahydrofolate dehydrogenase (NADP+ 































methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1 
rs2236225 
MTHFR methylenetetrahydrofolate reductase (NAD(P)H) rs1476413 
MTHFR methylenetetrahydrofolate reductase (NAD(P)H) rs1801131 









SHMT1 serine hydroxymethyltransferase 1 (soluble) rs1979277 
SLC19A1 solute carrier family 19 (folate transporter), member 1 rs1888530 
SLC19A1 solute carrier family 19 (folate transporter), member 1 rs3788200 
SLC46A1 solute carrier family 46 (folate transporter), member 1 rs1128162 
TCN2 transcobalamin II rs1801198 
TYMS thymidylate synthetase rs1001761 
TYMS thymidylate synthetase rs2847149 
TYMS thymidylate synthetase rs502396 




Table E2.  Skin lesion types among N=876 incident skin lesion cases. 
 
Skin lesion type N 




Lesion types among all cases     
Melanosis 655 74.8 -- 
Leukomelanosis 358 40.9 -- 
Keratosis 199 22.7  
Cases with 1 lesion type     
Melanosis only 392 44.7 67.0 
Leukomelanosis only 193 22.0 33.0 
Keratosis only 0 0.0 0.0 
Total cases with 1 lesion type 585 66.9 100.0 
Cases with 2 lesion types    
Melanosis + keratosis 126 14.4 51.2 
Melanosis + leukomelanosis 92 10.5 37.4 
Leukomelanosis + keratosis 28 3.2 11.4 
Total cases with 2 lesion types 246 28.1 100.0 
Cases with 3 lesion types    

























Table E3.  Regression coefficients for MTHFR genotypes predicting log-transformed 







SNP Model  
B (95% CI) B (95% CI) 
     
677 CT Unadjusted CC Ref. Ref. 
  CT 0.23 (0.14 to 0.31)*** 0.26 (0.18 to 0.35)*** 
  TT 1.28 (1.02 to 1.54)*** 0.61 (0.33 to 0.88)*** 
  P <0.0001 <0.0001 
  R
2
 (%) 15.8 7.4 
1298 AC Unadjusted AA Ref. Ref. 
  AC -0.09 (-0.17 to -0.01)* -0.06 (-0.14 to 0.02) 
  CC -0.10 (-0.22 to 0.01) -0.14 (-0.24 to -0.03)* 
  P 0.06 0.04 
  R
2
 (%) 0.9 1.0 
 Conditioned   AA Ref. Ref. 
 on  677 CT AC -0.02 (-0.10 to 0.05) -0.01 (-0.08 to 0.07) 
  CC 0.01 (-0.10 to 0.12) -0.05 (-0.16 to 0.05) 
  P 0.77 0.59 
  R
2
 (%) 16.0 7.7 
Intron 10 CT Unadjusted CC Ref. Ref. 
  CT -0.03 (-0.11 to 0.06) -0.04 (-0.12 to 0.04) 
  TT -0.03 (-0.14 to 0.07) -0.09 (-0.19 to 0.01) 
  P 0.76 0.21 
  R
2
 (%) 0.0 0.0 
 Conditioned   CC Ref. Ref. 
 on 677 CT CT 0.05 (-0.03 to 0.13) 0.02 (-0.06 to 0.09) 
  TT 0.10 (0.00 to 0.20) 0.02 (-0.08 to 0.12) 
  P 0.15 0.91 
  R
2
 (%) 16.2 7.4 
 




Table E4.  MTHFR diplotype counts and frequencies. 
677 CT/ 1298 AC/ Int. 10 GA 
Diplotype 
 
N overall/  
N with serum 
N (%) cases 
N (%) 
controls 
677-1298 CA/CA     
CAG CAG 259/249 126 (18.0) 133 (21.0) 
CAG CAA 86/82 49 (7.0) 37 (5.9) 
CAA CAA 7/7 5 (0.7) 2 (0.3) 
 Total 352/338 180 (25.7) 172 (27.2) 
677-1298 CA/CC     
CAG CCG 33/30 21 (3.0) 12 (1.9) 
CAG CCA 374/354 196 (28.0) 178 (28.2) 
CAA CCA 75/72 41 (5.8) 34 (5.4) 
 Total 482/456 258 (36.8) 224 (35.4) 
677-1298 CC/CC     
CCA CCG 23/22 13 (1.9) 10 (1.6) 
CCA CCA 180/168 97 (13.8) 83 (13.1) 
 Total 203/190 110 (15.7) 93 (14.7) 
677-1298 CA/TA     
CAG TAG 129/120 70 (10.0) 59 (9.3) 
CAA TAG 23/22 14 (2.0) 9 (1.4) 
 Total 152/142 84 (12.0) 68 (10.8) 
677-1298 CC/TA     
CCG TAG 7/5 5 (0.7) 2 (0.3) 
CCA TAG 108/101 48 (6.8) 60 (9.5) 
 Total  115/106 53 (7.6) 62 (9.8) 
677-1298 TA/TA     
TAG TAG 22/18 10 (1.4) 12 (1.9) 
TAA TAG 1/1 1 (0.1) 0 (0.0) 
 Total 23/19 11 (1.6) 12 (1.9) 
677-1298 CC/TC or TC/TC     
CCG TCG 1/1 0 (0.0) 1 (0.2) 
CCA TCG 3/3 3 (0.4) 0 (0.0) 
CCA TCA 1/1 1 (0.1) 0 (0.0) 
TCA TCA 1/1 1 (0.1) 0 (0.0) 




Table E5.  Least squares mean (± SE) urinary %InAs, %MMA, and %DMA by MTHFR 
















      
677 CT CC 13.9 ± 0.2 71.4 ± 0.4 14.2 ± 0.4 72.2 ± 0.6 
 CT 14.8 ± 0.5 69.9 ± 0.7
†
 15.4 ± 0.7 69.3 ± 1.0* 
 TT 16.5 ± 1.6 67.5 ± 2.5 17.3 ± 2.2 61.0 ± 3.3* 
 P 0.09 0.07 0.16 0.0006 
 CC 13.9 ± 0.2 71.4 ± 0.4 14.2 ± 0.4 72.2 ± 0.6 
 CT+TT 14.9 ± 0.4* 69.7 ± 0.7* 15.6 ± 0.7 68.6 ± 1.0* 
 P 0.05 0.04 0.08 0.002 
 
a. Cases:  CC, N=514; CT, N=132; TT, N=11;  b. Controls: CC, N=148; CT, N=50; TT, 
N=5; 
† 




Table E6.  Description of genes identified in GWAS of serum Hcys. 
 
 
Symbol Gene Name Process Function 
Known associations of genes with Hcys 







drug, metal, protein, zinc ion, 
sequence-specific DNA 










metabolic process and 
transport 
 
NLGN1 Neuroligin 1 
calcium-dependent cell-cell 
adhesion; positive regulation 
of intracellular protein kinase 
cascade 
cell adhesion molecule 
binding; receptor 
activity 
Identified in GWAS of autism (Glessner et 







establishment of epithelial 
cell polarity 
protein binding, bridging 
Identified in GWAS of Alzheimer's 
(Lambert et al. 2013), nicotine dependence 
(Yoon et al. 2012) 
 
Upregulation of FRMD4A in squamous cell 
carcinoma (Goldie et al. 2012) 
PLCB4 
phospholipa
se C, beta 4 
intracellular signal 
transduction; negative 
regulation of potassium ion 




activated protein kinase 




phospholipase C activity 
Identified in GWAS of neutrophil count 




apoptotic process; hormone 
catabolic process; peptide 
endopeptidase activity; 
metalloendopeptidase 
Gene variants associated with CHD (Wang 








enzyme 1 hormone processing; 
regulation of systemic 




activity; metal ion, 
peptide hormone binding 






Wnt receptor signaling 
pathway; cell-cell, cell-
matrix adhesion; monocyte 
aggregation 
collagen, hyaluronic 




Associated with esophageal squamous cell 
carcinoma in Indians exposed to tobacco 
and betel (Chattopadhyay et al. 2010) 
 
Biomarker of arsenic-induced neoplastic 
transformation in human keratinocytes 





maintenance of epithelial cell 
apical/basal polarity; neuron 
projection development 
metal and zinc ion 
binding: zinc-finger 
transcription factor 









cell adhesion; protein 
dephosphorylation; 
transmembrane receptor 




binding; protein tyrosine 
phosphatase activity 
PTPRD (PTP family) identified in  GWAS 
of plasma Hcys (Malarstig et al. 2009) 
 
Interacts with cadherin 2 (CDH2): SNP in 
CDH2, rs1108325, was 78
th
 top hit, P = 2.4 
x 10
-5
; SNP in another cadherin gene, 
CDH1, (rs347694), was 36
th
 top hit,  








Wnt receptor signaling 
pathway; activation of JNKK 
activity; cytoskeleton 
organization; intracellular 
protein kinase cascade; 
protein phosphorylation; 
response to stress 
ATP, protein binding; 
protein serine/threonine 













Chapter 8:  Conclusions and future directions 
Summary of major findings 
 The five epidemiologic studies contained in this dissertation were designed to address the 
overarching hypothesis that one-carbon metabolism and the transsulfuration pathway interact to 
influence susceptibility to As toxicity in humans.  We addressed this overall hypothesis by 
testing three working hypotheses, as outlined below:   
 
Hypothesis 1: 
We hypothesize that chronic As exposure is associated with alterations of global DNA 
methylation and hydroxymethylation. 
Principle findings from Specific Aim 1: 
 In Chapter 3, we observed that chronic As exposure was associated with increased 
global methylation of peripheral blood mononuclear cell (PBMC) DNA, as measured by [
3
H]-
methyl incorporation, in support of previous epidemiologic findings (Lambrou et al. 2012; 
Majumdar et al. 2010; Pilsner et al. 2007, 2009).  Additionally, our findings suggest that this 
positive association is linear over a wide range of environmentally-relevant As doses.   In 
Chapter 4, we found that the association between As exposure and global percent 5-
hydroxymethylcytosine (%hmC) of blood cell DNA was modified by gender, with a positive 
association in males and negative association in females.  The mechanism underlying this 
gender-specific observation is unclear.  We also found that age was negatively associated with 
global %hmC.  To our knowledge, this is the first study to examine global DNA 
hydroxymethylation in an epidemiologic study in a non-diseased population, and the first to 




mechanisms through which As exposure might influence 5hmC—aberrant Krebs cycle 
regulation via inhibition of pyruvate dehydrogenase (PDH), disruption of base excision repair 
(BER) pathways, and so forth—which should be explored experimentally.   
 
Hypothesis 2: 
We hypothesize that an oxidized intracellular GSH redox state is associated with a 
reduced capacity to methylate DNA and As. 
Principle findings from Specific Aim 2: 
In Chapter 5, consistent with our hypothesis, we observed that an oxidized plasma GSH 
redox state was associated with decreased As methylation capacity and increased blood As 
concentrations, but only among folate-deficient individuals.  We speculated that this association 
might be explained by S-glutathionylation of critical redox-sensitive cysteine (Cys) residues 
within the arsenic(III)-methyltransferase (AS3MT) active site (Fomenko et al. 2007) and that S-
glutathionylation might be a regulatory mechanism to prevent consumption of methyl groups 
during conditions of folate deficiency, when methyl groups are limiting.  Alternatively, our 
observations might simply indicate that under folate-sufficient conditions, AS3MT kinetics are 
not measurably influenced by the reducing environment.  Given this uncertainty, to avoid any 
“unintended consequences,” we would not advise a redox-based intervention to improve As 
methylation capacity among the folate deficient. 
Also consistent with our hypothesis, in Chapter 6, we found that an oxidized blood GSH 
redox state was associated with decreased global methylation of PBMC DNA.   Since it had been 
postulated by others that oxidative stress might lead to DNA hypomethylation by increasing 




Domann 2007), we examined whether there was evidence that blood SAM mediated this 
association in our study.  We observed that an oxidized blood GSH redox state was correlated 
with decreased plasma homocysteine (Hcys) and blood S-adenosylhomocysteine (SAH), 
providing evidence that intracellular oxidative stress increases Hcys flux through the 
transsulfuration pathway (Hultberg and Hultberg 2007; Rogers et al. 2007).   However, we did 
not find evidence that blood SAM was a mediator of the association between blood GSH redox 
state and global DNA methylation, suggesting that this relationship is explained by another 
mechanism.  We propose that this association might be explained by direct redox regulation of 
DNA methyltransferases (DNMTs) or histone deacetylases (HDACs), which should be explored 
in experimental models. 
 Moreover, these two studies highlight the importance of selecting biologically-relevant 
biomarkers to address mechanistic hypotheses and fully understanding the biochemistry 
underlying each mechanism.  In both studies, we were interested in examining “intracellular” 
GSH redox status and SAM concentrations.  However, we used plasma biomarkers of GSH 
redox and folate in Chapter 5—which are predicted by mathematical models to reflect hepatic 
GSH redox and hepatic SAM, respectively (Duncan et al. 2013; Reed et al. 2008)—and used 
whole blood biomarkers of GSH redox and SAM in Chapter 6, which should better reflect 
intracellular concentrations within PBMCs.  These two analyses were dependent upon separate 
measurements of GSH and glutathione disulfide (GSSG), which requires careful planning and 
sample preparation since GSH rapidly oxidizes to GSSG upon sample collection (Winters et al. 
1995).  In Chapter 5, if we had used total plasma GSH (plasma GSH+GSSG), as is common in 
many epidemiological studies, we would not have observed significant associations.  In addition, 




upon the availability of its methyl group substrate and thus, had not stratified by folate nutritional 
status, we would have concluded that plasma GSH redox was not associated with As 
methylation—even though the plasma GSH/GSSG ratio explained a substantial proportion of the 
variance in the urinary As metabolite percentages in the folate-deficient group.  
 
Hypothesis 3: 
We predict that aberrant regulation of one-carbon metabolism contributes to increased 
susceptibility to As-induced skin lesions.   Specifically, we predict that nonsynonymous variants 
in one-carbon metabolism genes, specifically variants that are known to influence enzymatic 
activities, and elevated serum Hcys are risk factors for As-induced skin lesion incidence.    
Principle findings from Specific Aim 3: 
In Chapter 7, we confirmed our group’s previous findings (Pilsner et al. 2009) that 
hyperhomocystenemia (HHcys) at baseline was a risk factor for As-induced skin lesion 
development.  We found that MTHFR haplotypes explained a large proportion of the variance in 
serum Hcys concentrations among both cases and controls.  Of the single nucleotide 
polymorphisms (SNPs) that we examined, the MTHFR 677 CT variant had the strongest 
association with serum Hcys concentrations: mean serum Hcys concentrations in CT 
heterozygotes and TT homozygotes were 3.6 and 21.3 µM higher than wildtype, respectively.  
Across human populations, the MTHFR 677 CT genotype is not consistently associated with 
elevated Hcys concentrations (Wald et al. 2012), but our findings indicate that in Bangladesh, 
MTHFR 677 CT heterozygotes, in addition to TT homozygotes, have elevated Hcys and 
impaired MTHFR enzymatic activity.  Over one-fifth of our study population were CT 




metabolism regulation on the population level.  We predict that in the Bangladeshi population, 
supplementation with 5mTHF, as opposed to folic acid, might be more effective to reduce Hcys 
and improve methylation capacity. 
However, we did not find that one-carbon metabolism gene variants were risk factors for 
As-induced skin lesions.  Specifically, even though HHcys was a risk factor for skin lesions and 
MTHFR 677 CT was strongly associated with serum Hcys, we found no association between 
MTHFR 677 CT variants and skin lesion risk.  Although it would be easy to conclude that 
HHcys does not have a causal role in As-induced skin lesion development, MTHFR could 
influence skin lesion risk through pathways that are independent of HHcys.  Many Mendelian 
randomization studies use MTHFR to infer causal effects of HHcys; this approach operates 
under the assumption that the effects of MTFHR on disease would only occur through a HHcys 
intermediate, which is a gross oversimplification of the underlying biology. 
To examine genetic determinants of serum Hcys concentrations in our population using 
an “unbiased” approach, we conducted an exploratory GWAS of serum Hcys in a subset of 
participants, which was predominately comprised of skin lesion cases.  Interestingly, we did not 
identify any one-carbon metabolism genes, or other genes known to directly influence Hcys, 
among our top-ranked SNPs.   We identified one genome-wide significant SNP in the gene  
encoding the pregnane X receptor (PXR), along with other SNPs in genes involved in redox 
signaling (PTPRT) and the establishment of epithelial cell polarity (PRICKLE2) that have been 
identified in other GWAS analyses (Malarstig et al. 2009; Tanaka et al. 2009). 
 Using GWAS to identify genetic determinants of circulating disease biomarkers might 
provide novel insights into mechanisms of disease pathophysiology.  This approach has been 




(COPD):  Several genes identified in GWAS analyses of Clara cell secretory protein and 
surfactant protein D, two important biomarkers of COPD, were found to be associated with 
COPD risk (Kim et al. 2012).  This approach might be particularly useful to study the biological 
source of HHcys as a disease biomarker.  The determinants of blood Hcys concentrations are 
multifactorial: For example, in Chapter 6, we observed that an oxidized blood GSH redox state 
was significantly associated with decreased Hcys concentrations.  We plan to measure our top 
GWAS hits in the full GENI study sample to examine whether these gene variants are also 
associated with susceptibility for As-induced skin lesions. 
 
Future directions 
Systems biology and mathematical modeling 
Given the astounding level of complexity in redox regulation, it is nearly impossible to 
predict the effects of an “antioxidant intervention,” such as N-acetyl-L-cysteine (NAC) or L-
ascorbic acid (vitamin C) supplementation, without implementing a systems-based approach (de 
Graaf et al. 2009).  In our studies, information from mathematical models of human one-carbon 
metabolism and transsulfuration pathways (Duncan et al. 2013; Reed et al. 2008) aided our 
selection of biologically-relevant biomarkers, and members of our group have collaborated with 
mathematicians at Duke University to create models of As metabolism to predict the effects of 
folate supplementation on As methylation and detoxification (Lawley et al. 2011).  There are 
numerous instances in the literature in which randomized controlled trials of antioxidant 
supplementation for disease prevention have yielded unintended adverse effects (ATBC 1994; 
Michailidis et al. 2013; Omenn et al. 1996); mathematical models of cellular redox signaling 




supplemention, as well as the discovery of novel biomarkers of redox dysregulation (Vicini et al. 
2002). 
Substantial evidence from experimental studies indicates that As exposure induces 
oxidative stress and redox disturbances:  Arsenic generates ROS through upregulation of 
NAPDH oxidase (NOX) enzymes (Chou et al. 2004; Zhang et al. 2011), inhibits redox-sensitive 
protein tyrosine phosphatases (PTPs) (Rehman et al. 2012), and perturbs the Nrf2, AP-1, and 
NF-κB redox signaling pathways (Barchowsky et al. 1996; Hu et al. 2002; Lau et al. 2013a; Lau 
et al. 2013b; Simeonova et al. 2001).  However, evidence from human population studies is 
lacking, and the limited number of epidemiologic studies of As exposure and oxidative stress 
have overwhelmingly examined markers of oxidative damage (reviewed in De Vizcaya-Ruiz et 
al. 2009).  Just this year, our group was the first to report that As exposure was associated with 
decreased blood GSH and altered blood GSH/GSSG and plasma Cys/CySS redox states in a 
population-based study (Hall et al. 2013), providing evidence that in humans, As exposure might 
perturb redox homeostasis.  Metabolomic profiling has been used to study perturbations of redox 
pathways (Suh et al. 2012), and metabolomic profiles can be combined with genetic and 
epigenetic data to examine pathways and interactions in complex diseases (Liu et al. 2012); this 
approach might be useful to study the influences of As exposure on oxidative stress and redox 
regulation in humans.   
 
Conclusions 
 Taken together, our findings suggest that the complex metabolic interplay between one-
carbon metabolism and the transsulfuration pathway influences susceptibility to As toxicity in 




global DNA hydroxymethylation.  We observed evidence that the GSH redox state contributes to 
the interindividual variation in As methylation capacity in humans, in addition to evidence that 
the GSH redox state influences global DNA methylation.  We confirmed that HHcys is an 
important risk factor for As-induced skin lesion incidence, and the strong associations between 
MTHFR gene variants and serum Hcys suggest that in the Bangladeshi population, 
supplementation with 5mTHF might be more effective for Hcys lowering than folic acid.   In 
addition, we used GWAS to identify novel genetic determinants of serum Hcys concentrations, 
which must be confirmed in future studies.  Perhaps most importantly, we have emphasized the 
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